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1.1 Cognitively healthy centenarians
One important accomplishment of humankind is the extension of the average
life expectancy. Worldwide, this phenomenon has shown a remarkable
linear increase over the last two centuries,[1] and by 2050 there will be 3.2
million of centenarians in the world.[2] However, a consequence of an aged
population is the increased prevalence of age-related diseases.[3] Therefore,
an increasing fraction of individuals will spend part of their old age in
disability or dependence on others. A major contributor to poor health at
old age is cognitive decline and dementia, of which Alzheimer’s disease (AD)
is the most common type. [4, 5] However, dementia is not an inevitable
consequence of aging: in fact, a small proportion of the population (<0.1%)
reaches at least 100 years of age while maintaining a high level of cognitive
and physical functions, so-called cognitively healthy centenarians.[6, 7]
This raises questions as to what extent these centenarians have exceptional
features that protect or delay the onset of dementia and other age-related
diseases, and to what extent genetic factors are involved. To nd an answer
to these questions, the 100-plus Study was initiated: a prospective cohort
study that aims at unraveling the environmental and genetic factors that are
associated with becoming a cognitively healthy centenarian.[6]
1.2 Epidemiology and genetics of Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder char-
acterized by the loss of cognitive functions, ultimately leading to loss of
independence, and death.[5, 8] In the aged Western populations it is cur-
rently one of the most prevalent diseases and poses a huge burden on patients,
their families, and society.[5, 4] Currently, there is no eective treatment to
prevent or to slow AD progression.[5, 8] The prevalence of AD increases
exponentially with age: while the disease is rare before the age of 65 years
(early-onset AD, EOAD), the more common form of the disease, late onset
AD (LOAD, age at onset >65 years), reaches ∼40% per year at 100 years of
age.[9] Next to aging, genetic factors play an important role: in fact, twin
studies indicated that the heritability of the common form of AD ranges
between 60-80%.[10] The strongest genetic risk factor for AD is APOE geno-
type, which was identied in the early 1990s through linkage studies, and
in the Caucasian population determines up to 30% of the genetic risk of
AD.[11, 12, 13] The APOE genotype for each individual is determined by the
combination of two out of three alleles (ε2, ε3, and ε4), that make up the
six possible genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 and ε4/ε4). The
1
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ε3 allele is the most frequent in the population ( 77%), followed by the ε4
allele ( 15%) and lastly the ε2 allele ( 8%). In terms of AD risk, the ε4 allele
increases AD susceptibility, while the ε3 is neutral and the ε2 allele has a
protective eect against AD. Compared to carrying no ε4 allele, carrying one
copy of the ε4 allele (i.e. ε3/ε4 heterozygous genotype) increases AD-risk by
approximately 3-5 fold, while AD-risk is increased to 15-30 fold in individuals
who carry two copies of the ε4 allele (i.e. ε4/ε4 homozygous genotype).[11,
12, 13, 14] With the development of genotyping arrays in the early 2000s,
genome-wide association studies (GWAS) became possible, leading to the
identication of additional genetic risk variants for LOAD.[15] Typically,
in GWAS the frequency of genetic variants is compared between a group
of individuals that manifest the phenotype of interest (cases) and a group
of individuals in which the phenotype of interest is absent (controls).[15]
Unlike linkage and family studies, typically hypothesis-driven, GWAS do
not require any prior knowledge and thus have the potential to reveal new
genetic discriminants of a given phenotype.[16] Additionally, the continuous
development of reference panels comprising tens of thousands of individ-
uals and next-generation imputation strategies have drastically improved
the number of genetic variants that can be analyzed, whilst simultaneously
reducing genotyping costs.[17, 18] Successive waves of GWAS of AD with
an increasing number of individuals have been performed, and the number
of variants identied to inuence the genetic risk to develop AD has steeply
increased.[19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29] Today, about 70 genetic
variants in addition to the APOE variants have been associated with a slight
modication of the risk of AD from GWAS. [30] Besides being a powerful
instrument to delineate the genetic landscape of AD, GWAS studies have
been pivotal to understand the molecular events that are associated with AD
pathology (Figure 1.1). The amyloid hypothesis, which was proposed during
the rst years of AD research, is the commonly adopted theory to explain AD
development. According to this theory, the imbalance between β-amyloid
production and clearance (i.e. β-amyloid metabolism) is at the basis of the
molecular cascade that lead to neuronal loss and ultimately to cognitive
decline (Figure 1.1).[31] However, drugs targeting β-amyloid have as of yet
been insuciently eective, as the decrease in the amount of β-amyloid in
the brain did not reduce the rate of disease progression and cognitive decline.
This has led, together with a better understanding of the genetic factors that
are associated with AD, to an evolution of the traditional β-amyloid theory
to encompass more complex disease aspects.[32] For example, part of the
current view of the etiology of AD is that the dysregulation of the endo-
1
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lysosomal tracking system and the immune response is a major causal
pathway, and that AD is not just a consequence of β-amyloid metabolism
(Figure 1.1).[33, 34] However, the extent to which dierent pathways associ-
ated with AD overlap and contribute to the total risk to develop the disease
is mostly unknown.
1.3 Genetic factors underlying AD and longevity
Given the high prevalence of AD at old ages, and the importance of genetic
factors for AD, cognitively healthy centenarians are exceptional individuals
to study. Theoretically, it would be expected that genetic variants that are
associated with an increased risk to develop AD should have a negative
eect on longevity, as AD is associated with increased mortality. Therefore,
the frequency of these variants in extremely old and healthy individuals
is expected to be lower than in the general population. In fact, the largest
genetic risk factor for AD, APOE, is also the largest genetic factor known
to inuence human longevity.[35] Surprisingly, only the APOE genotype is
associated with both the genetics of AD and longevity, with the ε4 allele
that increases AD risk and is associated with reduced longevity, and the ε2
allele which decreases AD risk and promote longer lifespan.[36] Such a small
overlap between the genetics of AD and longevity may be attributable to
several reasons: rst, across dierent populations and cohorts the genetics
of AD may be more homogeneous than the genetics of longevity; second, the
case-control approach typically applied in studies investigating the genetics
of AD cannot be robustly applied in studies investigating the genetics of
longevity. For example, in studies of longevity it is unclear which individu-
als should be considered as cases and/or as controls while for AD aected
individuals may be compared to (age- and population-matched) non-aected
individuals; third, given that longevity is the result of resisting or delaying
all deadly diseases, the eect on longevity of genetic variants associated
with one specic disease may be relatively small, such that a large number
of individuals of extreme age need to be compared to identify associated
genetic variants, and that is not always feasible.[16] Despite great interest
in understanding the relationship between cognitive decline due to AD and
extreme longevity with retained cognitive health, the extent to which cog-
nitively healthy super-agers are genetically protected against AD is largely
unknown, and therefore object of our investigations.
1
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Figure 1.1: Genetics underlying Alzheimer’s disease. The genetics factors at the
basis of Alzheimer’s disease are typically studied through Genome-Wide Association
Studies (GWAS), where the frequency of genetic variants across the genome is
compared between a sample of individuals with AD and a sample of individuals
without AD. Genetic variants with a signicant dierence of frequency between AD
patients and controls modify the risk to develop AD. Each genetic variant is thought
to act at the gene level by regulating its expression or regulation. These genes, in
turnm play a role in the molecular events that lead to AD. The commonly accepted
theory explaining AD is based on the centrality of the β-amyloid metabolism.
Specically, the imbalance between β-amyloid production and clearence is thought
to initiate the molecular cascade that eventually lead to cognitive decline and
dementia.
1
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1.4 Genetics of human longevity
Human longevity is one of the most complex phenotypes to study and it is
inuenced by environmental and genetic variables (Figure 1.2).[3] Long-lived
individuals tend to cluster in families, which suggests that genetic factors
play a role in determining extreme human longevity. In fact, although the
heritability of lifespan up to ∼70 years of age ranges only 10-25%, the heri-
tability of becoming a centenarian raises up to ∼50%.[37, 38, 39] This means
that to reach higher ages we become increasingly dependent on the favor-
able genetic elements of our genomes. Ever since the GWAS-era started,
many GWAS of longevity have been performed, trying to unravel the genetic
architecture of extreme human aging and the relationship with age-related
diseases.[40, 41, 42, 43, 44, 45, 46] As a result, a constellation of genetic
variants has been associated with extended lifespan in independent studies.
However, apart from APOE and few other candidates (CDKN2B, ABO), the
replication of these genomic regions in independent studies has been chal-
lenging, in part due to heterogeneity in the study designs, methodologies, and
populations. While not fully replicated, the genetic variants discovered thus
far were known to associate with age-related diseases, including cardiovas-
cular diseases and cancer, and with immunological and metabolic signatures,
which are known hallmarks of aging (Figure 1.2).[42, 43, 46] Altogether,
this suggests that an extended human lifespan is associated with a lower
genetic risk of age-related diseases.[46][47][48] Given the uncertainties that
are associated with the genetic factors associated with extreme longevity, it
is of interest to determine the extent to which cognitively healthy agers are
genetically predisposed to live longer, and whether this information can be
used to predict overall survival.
1.5 GWAS limitations and alternative approaches
Despite the robustness of the GWAS approach to study complex polygenic
traits such as longevity and AD, there are some limitations to this strategy.
First, very large sample sizes are necessary to achieve sucient statistical
power: the power to detect signicant associations is indeed a function of the
sample size, the variant eect-size (how much the variant-frequency is dif-
ferent between cases and controls), and the signicance threshold used (the
evidence-level that there is a true dierence between the variant-frequency
in cases and controls).[16] Given that the eect-size of variants aecting
complex traits are mostly small, and that the burden of multiple test cor-
rection is massive due to the high number of variants that are tested, it
1
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Figure 1.2: Genetics underlying human longevity. The genetic factors that in-
uence human longevity are thought to resemble those inuencing the genetic risk
to develop age-related diseases, such as cardiovascular, autoimmune and neurode-
generative disorders, frailty, and cancer. Several GWAS have been performed on
longevity, and although the replication rate across multiple study is generally low,
multiple genomic regions across the genome have been linked to longevity. These
genetic factors, along with environmental variables, model the relationship between
longevity and age-related diseases, dening dierent aging trajectories. On the
one end, protective elements (both genetic- and environmental-based) may shift
towards older ages the onset of age-related diseases and compress disability periods,
increasing the odds of successful aging. On the other, genetic predisposition to
diseases and environmental risk-factors may accelerate the onset of age-related
diseases, increasing late-life disability and shorthening lifespan.
1
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comes that the more individuals are compared, the higher the chance to nd
signicant associations.[16] However, an alternative strategy to increase
statistical power may be to compare individuals that carry extreme pheno-
types, as the eect-size should be maximal when comparing individuals that
represent the extreme ends of a disease spectrum.[48, 49, 50] For AD and
other age-related diseases, extreme cases may be dened by sporadic AD
cases (i.e. cases with no familial AD) with a relatively early age at disease-
onset. Extreme controls are represented by individuals who reach extreme
ages without the disease. [48, 49, 50] Alternatively, instead of testing each
variant independently, which is typically done in GWAS, one could test the
combined eect of multiple variants that are associated with a certain dis-
ease. One of the most commonly used methods to test the combined eect
of multiple common variants is the construction of polygenic risk scores
(PRS).[51, 52] A PRS is a weighted score that quanties the individual risk to
a certain phenotype and therefore can be used to stratify patients according
to their genetic risk for a given trait or to identify individuals at the highest
genetic risk. Normally, PRS are constructed using genetic variants that are
identied through GWAS, and under the assumption that genetic variants
do not change over time (i.e. the eect of a genetic variant does not change
at increasing ages), the PRS represents a powerful diagnostic and prognostic
tool.[52]
Another drawback of GWAS relates to the interpretation of signicant associ-
ations. The large majority of variants that are tested in GWAS are non-coding
variants, for which the downstream eects on gene and protein function
are unknown.[16] A trivial procedure is to associate the variant with the
closest gene, assuming a linear organization of the DNA, which underes-
timates the complexities of our genome. Given the amount of data that
is currently generated, multiple sources of variant annotation should be
taken into consideration, such as expression-quantitative-trait-loci (eQTLs,
i.e. associations between genetic variants and RNA expression), chromatin
structure, or structural variations. Finally, to better understand how genetic
factors aect dierent traits, it can be informative to explore the extent of
association of a genomic region on dierent phenotypes. Altogether, it may
be of interest to explore the added value of using extreme phenotypes in a
case-control genetic analysis of AD, and to provide an innovative framework
to perform gene-set enrichment analysis from set of SNPs.
1
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1.6 Aim of this thesis and outline
The overall objective of this thesis is to investigate the genetic factors un-
derlying extreme human longevity and the escape of Alzheimer’s disease,
for which we explore the genetic architecture of the cognitively healthy
centenarians from the 100-plus Study (Figure 1.3). The thesis is subdivided
into two sections: rstly, we focus on the comparison of the cognitively
healthy agers with young AD cases and population controls in context of
Alzheimer’s disease and human longevity (chapter 2, chapter 3, chapter 4,
and chapter 5). Secondly, we focus on the collaborative eorts in which
our cohort participated in terms of large GWAS of AD and longevity, and is
accompanied by the development of tools to integrate, visualize and analyze
results from GWAS (chapter 6, chapter 7, and chapter 8).
We rst explore the added value of analyzing extreme phenotypes in the ge-
netic research of AD by comparing extreme controls, i.e. cognitively healthy
centenarians, and extreme AD cases, i.e. relatively young AD cases, in a
case-control study of AD (chapter 2). We report that cognitively healthy
centenarians have a lower frequency of genetic variants associated with in-
creased AD risk compared to the general population, and a higher frequency
of protective variants. This led to a 2-fold enrichment in the variant eect-
size when comparing AD cases with cognitively healthy agers, showing
that the use of extreme phenotypes in genetic studies of complex traits is
protable.
We then investigate the molecular pathways that are known to play a
role in AD pathogenesis and their association with resilience against AD, by
combining the eect of multiple variants into polygenic risk scores (PRSs)
and pathway-specic PRSs (chapter 3). We report that cognitively healthy
centenarians have the lowest PRS and pathway-specic PRS for all major
AD-associated pathways. Moreover, while the risk of AD was signicantly
associated with a higher pathway-specic PRS of all pathways, only the
immune system response and endocytosis pathways signicantly inuenced
the resilience against AD, even after excluding APOE variants.
In chapter 4, we challenge to disentangle the eect on healthy aging from the
eect on AD risk of genetic variants that are associated with AD. Under the
hypothesis that genetic variants increasing the risk of AD should negatively
aect longevity, we found that most alleles that increase the risk of AD neg-
atively inuence healthy longevity, with the eect on AD that explained, for
the majority of variants, the negative eect on healthy longevity. However,
a subset of variants preferentially involved in immune-related processes
1
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Figure 1.3: Roadmap to understand theGenetics of CognitivelyHealthyCen-
tenarians. All chapters in this thesis present analyses that are based on three
distinct population: (i), a sample of Alzheimer’s disease (AD) patients from the
Amsterdam Dementia Cohort and other cohorts, (ii) a sample of healthy individuals
from the dierent studies, and (iii) a sample of cognitively healthy centenarians
from the 100-plus Study cohort. We will rst focus on genetic variants associated
with AD (chapter 2, chapter 3, chapter 4 and chapter 6), and then we will focus on
the genetics of longevity (chapter 5, chapter 7 and chapter 8).
1
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seemed to aect more strongly longevity than AD, suggesting a benecial
eect not only against AD, but also against other age-related diseases, or a
general neuroprotective eect.
Then (chapter 5), we focus on human longevity and attempt to construct
a polygenic risk score that associates with cognitively healthy aging and
survival. Using the results from a study on parental longevity, we show that a
polygenic risk score of 330 variants was signicantly associated with becom-
ing a cognitively healthy centenarian. Furthermore, this PRS signicantly
predicted survival in an independent cohort and was functionally enriched
for biological pathways resembling the hallmarks of longevity, such as slow
cell dierentiation and replacement, and oxidative stress.
In the second part of the thesis, we present the contribution of the cogni-
tively healthy centenarians from the 100-plus Study to large, collaborative
GWAS of AD (chapter 6) and longevity (chapter 7). In chapter 6, we combined
clinical studies and by-proxy studies in the largest GWAS of AD (at the time
of publication), leading to the discovery of six additional genetic variants
associated with AD. In addition to a better understanding of the genetic
landscape of AD, our ndings enforced the role of β-amyloid processing
and immune response as central biological pathways in AD pathogenesis.
Furthermore, we showed the applicability and predictability of the PRS for
stratifying patients based on their genetic background and identifying those
at the highest risk for the disease.
In chapter 7, we collaborated on, to date, the largest GWAS of longevity. We
introduced an unbiased method to identify cases (i.e. long-lived individuals)
and controls on country-based survival percentiles. In addition to APOE
variants, we propose an additional variant near the GPR78 gene to aect
longevity, and through genetic correlation and gene expression analyses,
we showed overlap between the genetics of diseases and the genetics of
longevity.
Finally, (chapter 8) we developed snpXplorer, a tool that is freely available to
the scientic community to explore summary statistics of genetic studies,
compare levels of association between dierent traits, and functionally an-
notate sets of genetic variants. This tool may be useful to explore the extent
of overlap between traits, which has applications in the diagnostic eld.
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The detection of genetic loci associated with Alzheimer’s disease
(AD) requires large numbers of cases and controls because variant
eect sizes are mostly small. We hypothesized that variant eect sizes
should increase when individuals who represent the extreme ends of
a disease spectrum are considered, as their genomes are assumed to
be maximally enriched or depleted with disease-associated genetic
variants. We used 1,073 extensively phenotyped AD cases with rel-
atively young age at onset as extreme cases (66.3 ± 7.9 years), 1,664
age-matched controls (66.0 ± 6.5 years) and 255 cognitively healthy
centenarians as extreme controls (101.4 ± 1.3 years). We estimated
the eect size of 29 variants that were previously associated with
AD in genome-wide association studies. Comparing extreme AD
cases with centenarian controls increased the variant eect size rela-
tive to published eect sizes by on average 1.90-fold (SE = 0.29, p =
0.0009). The eect size increase was largest for the rare high-impact
TREM2(R74H) variant (6.5-fold), and signicant for variants in/near
ECHDC3 (4.6-fold), SLC24A4−RIN3 (4.5-fold), NME8 (3.8-fold),
PLCG2 (3.3-fold), APOE− ε2 (2.2-fold), and APOE− ε4 (twofold).
Comparing extreme phenotypes enabled us to replicate the AD as-
sociation for 10 variants (p < 0.05) in relatively small samples. The
increase in eect sizes depended mainly on using centenarians as
extreme controls: the average variant eect size was not increased in
a comparison of extreme AD cases and age-matched controls (0.94-
fold, p=0.68), suggesting that on average the tested genetic variants
did not explain the extremity of the AD cases. Concluding, using
centenarians as extreme controls in AD case–control studies boosts
the variant eect size by on average twofold, allowing the replication
of disease-association in relatively small samples.
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2.1 Introduction
Alzheimer’s disease (AD) is often characterized by a slow but progressive
loss of cognitive functions, leading to loss of autonomy.[1] AD is rare at the
age of 65 years, but its incidence increases exponentially to 40% at the age of
100 years.[2] It is currently the most prevalent cause of death at old age and
one of the major health threats of the 21
st
century.[1] Better understanding
of the etiological factors that determine AD is warranted as no treatment
is currently available. Heritability plays an important role, as genetic fac-
tors are estimated to deter- mine 60–80% of the risk of AD. [3] About 30%
of the genetic risk is attributable to the ε4 allele of APOE gene, and large
collaborative eorts have identied over two dozen additional genetic loci
that are associated with a slight modication of the risk of AD.[4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17] The design of these association studies
relies on the comparison of very large numbers of cases with age-matched
controls, such that detected associations can be attributed specically to the
disease.[18] However, given the prevalence of AD in the aging population, it
is likely that a signicant fraction of the controls will develop the disease
at a later age. Therefore, as the AD risk for future cases likely involves
the same genetic variants, using age-matched controls may quench variant
association signals. This may, in part, explain the mostly small variant eect
sizes associated with common variants. Also, GWAS studies mostly compare
common genetic variants that are widely propagated in the population; as a
consequence, these have mostly small eects on AD risk.[19] Rare genetic
variants often have larger eect sizes than com- mon variants, but as there are
fewer carriers available in the population, the requirement for large sample
sizes stands.[20] The power of genetic analyses is determined by the variant
frequency, the eect size of the variant, the sample size, and signicance
threshold set to be obtained.[21] Therefore, instead of increasing sample
sizes of genetic studies to detect novel disease-associated genetic loci, an
alternative strategy is to increase variant eect sizes by sampling individuals
with extreme phenotypes.[20, 22, 23] For AD and other age-related diseases,
extreme cases may be dened by having a relatively early age at disease
onset, and having the phenotypic features characteristic for the disease, as
dened by diagnostic assessment. Extreme controls are represented by indi-
viduals who reach extreme ages without the disease.[22, 24, 25] Indeed, in a
case–control study of type 2 diabetes, the eect sizes for variants that were
previously associated with the disease were increased when using centenari-
ans as extreme controls.[24] The eect of using extreme phenotypes in other
2
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age-related diseases has not been studied. Here, we explored the potential
of using extreme phenotypes for genetic studies of AD by investigating
the change in eect size of known AD-associated variants. Furthermore,
using an age- and population-matched reference group, we investigated the
contribution of each extreme phenotype.
2
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Table 2.1: Population characteristics
Extreme AD (EA) Centenarian controls (EC) Normal controls (NC)
Individuals 1,073 255 1,664
Females (%) 564 (52.6%) 191 (74.9%) 893 (53.7%)
Age (SD)
a
66.4 (7.8) 101.4 (1.3) 66.0 (6.5)
APOE ε4 (%) 981 (42.7) 44 (8.6) 533 (16.0)
APOE ε2 (%) 76 (3.5) 78 (15.3) 304 (9.1)
a
Age at onset for extreme Alzheimer’s disease cases, age at study inclusion for extreme
controls and normal controls; SD, standard deviation; ApoE, Apolipoprotein E allele count for
ε4 and ε2, respectively. Reference to the cohorts reported in this table are: [18, 19, 20]
2.2 Methods
2.2.1 Cohort description
As extreme AD cases group (denoted by EA), we used 1,149 AD cases from
the Amsterdam Dementia Cohort (ADC). The ADC comprises patients who
visit the memory clinic of the VU University Medical Center, The Nether-
lands.[21, 18] This cohort of AD patients is extensively characterized and
comprises 503 early-onset cases (denoted by eEA) with an age at onset <65
years, and 646 late-onset cases (denoted by lEA). Of the 503 early-onset cases,
255 had an age at onset <60 years (i.e., young early onset, denoted by yEA).
The diagnosis of probable AD was based on the clinical criteria formulated
by the National Institute of Neurological and Communicative Disorders and
Stroke-Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) and based on National Institute of Aging-Alzheimer association
(NIA-AA).[22, 23] At baseline, all subjects underwent a standard clinical di-
agnostic assessment including neurological examination and standard blood
tests. In addition, all subjects underwent magnetic resonance imaging, an
electroencephalogram, and cerebrospinal uid (CSF) was analyzed for most
patients.[24] Clinical diagnosis is made in consensus-based, multidisciplinary
meetings. Together, this elaborate diagnostic procedure reduces the chance
of misdiagnosis. The extensive phenotyping in combination with the early
disease onset generates an AD cohort that can be regarded extreme. As ex-
treme control group (denoted by EC), we used 268 self-reported cognitively
healthy centenarians from the 100-plus Study cohort.[20] This study includes
Dutch-speaking individuals who (i) can provide ocial evidence for being
aged 100 years or older, (ii) self-report to be cognitively healthy, which is
conrmed by a proxy, (iii) consent to donation of a blood sample, (iv) consent
2
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to (at least) two home visits from a researcher, and (v) consent to undergo an
interview and neuropsychological test battery. As normal controls (denoted
by NC) we used 1,717 middle-aged (55–85 year-old) individuals from a repre-
sentative sample of Dutch individuals from the Longitudinal Aging Study
Amsterdam (LASA) cohort.[19, 25] LASA is an ongoing longitudinal study of
older adults initiated in 1991, with the main objective to determine predictors
and consequences of aging. The Medical Ethics Committee of the VU Uni-
versity Medical Center (METC) approved the ADC cohort, the LASA study
and the 100-plus Study. All participants and/or their legal guardians gave
written informed consent for participation in clinical and genetic studies.
2.2.2 Genotyping and imputation methods
We selected 29 single-nucleotide variants for which evidence for a genome-
wide signicant association with AD was found in previous studies (Table
S1, Table S2).[4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17] Genetic vari-
ants were determined by standard genotyping or imputation methods. In
brief, we genotyped all individuals using the Illumina Global Screening
Array (GSAsharedCUSTOM_20018389_A2) and applied established quality
control methods.[26] We used high-quality genotyping in all individuals
(individual call rate > 98%, variant call rate > 98%), individuals with sex
mismatches were excluded and Hardy-Weinberg equilibrium-departure was
considered signicant at p < 1x10−6. Genotypes were prepared for impu-
tation using provided scripts (HRC-1000G-check-bim.pl).[27] This script
compares variant ID, strand and allele frequencies to the haplotype reference
panel (HRC v1.1, April 2016).[26] Finally, all autosomal variants were sub-
mitted to the Michigan imputation server (https://imputationserver.
sph.umich.edu).[26] The server uses SHAPEIT2 (v2.r790) to phase data and
imputation to the reference panel (v1.1) was performed with Minimac3.[26,
28] A total of 1,149 extreme AD cases, 1,717 normal controls and 268 extreme
(centenarian) controls passed quality control. Prior to analysis, we excluded
individuals of non-European ancestry (NEA = 67, based on 1000Genomes [29]
clustering) and individuals with a family relation (NEA=9,NEC=13,NNC=53,
identity-by-descent ≥0.3), [30] leaving 1,073 extreme AD cases (NeEA=464
and NlEA=609), 1,664 normal controls and 255 centenarian controls for the
analysis.
2

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































For each AD-associated variant, we explored the change in eect size (E)
relative to reported eect sizes when (1) comparing extreme AD cases with
extreme (centenarian) controls (EA vs. EC); (2) comparing extreme AD cases
with normal controls (EA vs. NC); and (3) comparing normal AD cases with
extreme (centenarian) controls (NA vs. EC). To calculate variant eect sizes,
we used logistic regression models correcting for population stratication
(principal components 1–6).[31, 32] We calculated odds ratios relative to the
Haplotype Reference Consortium (HRC) alternative allele assuming additive
genetic eects, and estimated 95% condence intervals (CIs). We estimated





where Ek1−2 indicates the eect size change for variant k in a comparison of
cohort 1 and cohort 2, e.g, EAPOEε4EA−EC indicates the eect size change for the
APOE ε4 variant when extreme AD cases (EA) are compared with cognitive
healthy centenarians (EC). The logORk1−2 denotes the eect size of variant k
when comparing cohort 1 and cohort 2. The eect size of variant k reported
in literature (Table S1) is denoted by logORkl . We estimated the added value
of using extreme (centenarian) controls rather than normal age-matched
controls in a case-control analysis. For this, we wanted to compute the
change in eect size when comparing non-extreme AD cases with extreme
controls (NA vs. EC). As we do not have direct access to normal AD cases,
we estimated the eect size for the NA-EC comparison by summing (1) the
eect size from the comparison of normal AD cases and normal controls, as
reported in literature (logORkl ), and (2) the eect size from the comparison





NC−EC . The added value of using extreme







To assess whether age at disease onset had an impact on the change in eect
size due to the extreme cases (EEA−NC), we estimated the logOR
k
eEA−NC
(early-onset extreme AD cases vs. normal controls), logORklEA−NC (late-
onset extreme AD cases vs. normal controls) and the logORkyEA−NC (younger
2
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early-onset AD cases vs. normal controls), and their 95% CI. Then, we
computed the probability that the eect size changes EkeEA−NC and E
k
lEA−NC
diered using a two-samples z-test (two-tailed p-value).
2.2.4 Determining significance of change in eect size
For each variant, we estimated Ek1−2 and a 95% CI by sampling (S=10,000)
from the logORk1−2 and logOR
k
l based on their respective standard errors.
The probability of divergence between the distributions of the logORk1−2 and
the logORkl was determined using a two-sample z-test (two-tailed p-value).
The probability of observing Ek1−2 > 1, i.e, an increased eect size for variant
k, is considered to be a Bernoulli variable with p=0.5 (equal chance of having
an increased/decreased eect). The number of variants that show an increase
in eect (Ek1−2) then follows a binomial distribution. The average change in







Condence intervals and probability of divergence between Ē1−2 and previ-
ously reported eect sizes were estimated by sampling (S=10,000, two-tailed
p-value). Quality control of genotype data, population stratication analysis,
and relatedness analyses were performed with PLINK (v1.90b4.6), whereas




Figure 2.1: Comparison of age at disease-onset and age at inclusion for cases
and controls in previously reported case-control comparisons, and in our
extreme phenotypes comparison. Weighted mean and (combined) standard de-
viation of the age at onset for AD cases and age at inclusion for controls. As weights,
we used the sample sizes of each GWA study. Note that previous case-control stud-
ies of AD included samples from multiple cohorts, sometimes overlapping across
studies. References to the cohorts reported in this gure are: [7, 8, 13]
2.3 Results
After quality control of the genetic data, we included 1,073 extreme AD
cases (with mean age at onset 66.4 ± 7.8 and 52.7% females), 1,664 normal
(age-matched) controls (mean age at inclusion 66.0 ± 6.5, 53.7% females),
and 255 cognitive healthy centenarians as extreme controls (mean age at
inclusion 101.4 ± 1.3, 74.7% females) (Table 2.1). Within the extreme AD
cases group, there were 464 early- onset cases (mean age at onset 59.1 ±
4.1, 54% females), and 609 late-onset cases (mean age at onset 72.1 ± 4.8,
51% females). The age at onset of the extreme AD cases was on average 8.2
years earlier compared with previous GWA studies; the age at disease onset
was on average 15.4 years earlier in early-onset cases and 2.5 years earlier
in late-onset cases, whereas the age at study inclusion of our centenarian
controls was on average 29.5 years higher than for previously published
2
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controls (Figure 2.1).
2.3.1 Eect of comparing extreme cases and centenarian controls
In a genetic comparison of extreme AD cases and centenarian controls
(EA–EC comparison) the average eect size over all 29 genetic variants
was 1.90-fold increased relative to the eect sizes reported in published stud-
ies (ĒEA−EC=1.90 ± 0.29; p=0.0009) (Figure 2.3). For 21 out of 29 variants,
we observed an increased eect size (EkEA−EC>1),which is signicantly more
than expected by chance (p=0.012) (Figure 2.2 and Table 2.2). The increase in
eect size ranged from 1.06 (variant near CASS4) to 6.46 (variant in TREM2
[R47H]) and was observed both in common variants (MAF>1%, n = 19) and
rare variants (MAF<1%; TREM2 [R47H] and ABI3) (Table 2.2). For variants
near or in the genes TREM2 (R47H), SLC24A4-RIN3, and ECHDC3, the increase
was more than fourfold compared with previously reported eect sizes. For
nine variants the eect size increase was two- to fourfold (in or near the
genes NME8, PLCG2, HLA-DRB1, CD2AP, ZCWPW1, ABCA7 [A > G], APOE
ε2, HS3ST1, and ABI3, in order from high to low eect size increases). For
nine variants the increase was between one- and twofold (in or near genes,
APOE ε4, EPHA1, CELF1, PTK2B, MS4A6A, SORL1, BIN1, PICALM, and CASS4)
(Figure 2.2). The eect sizes of six genetic variants were not increased in
our extreme phenotype analysis compared with previously reported eect
sizes (ĒEA−EC between 0 and 1): in or near TREM2 (R62H), KANSL1, CR1,
ABCA7 (G > C), CLU, and INPP5D. At last, the eect sizes of two variants were
in the opposite direction compared to previously reported eects(EkEA−EC ).
Specically, for the variant in FERMT2 we found an inverted direction of
eect size and a lower magnitude of eect as compared with previous studies
(EFERMT 2EA−EC between 0 and -1). For the variant near MEF2C we observed a
larger eect size as compared with those previously published, but in the
opposite direction (EMEF2CEA−EC <1).
Overall, for seven common variants (MAF> 1%), the eect size was signi-
cantly increased relatively to the previously reported eect sizes (Table 2.2), in
or near genes APOE ε2 (2.2-fold, p=1.4x10−7), APOE ε4 (2.0-fold, p=1.5x10−9),
SLC24A4-RIN3 (4.5-fold, p=2.8x10−3), ECHDC3 (4.6-fold, p=0.018), PLCG2
(3.3-fold p=0.028), NME8 (3.9-fold, p=0.033), and MEF2C (-1.9-fold, p=0.033).
Variants with signicant eect size changes were also more likely to be
associated with AD in a comparison of extreme cases and centenarians.
The association with AD reached nominal signicance (p<0.05) in 10 out
of 21 variants with a changed eect size >1 (Table 2.2). Next to APOE ε4
2
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Figure 2.2: Change in variant eect-size using extreme cases and centenar-
ian controls relative to published eect-sizes, for 29 AD associated genetic
variants. Dashed red line at EkEA−EC = 1 indicates same eect- size as reported
in literature. Orange bars indicate nominal statistical signicance for the associa-
tion with AD (p<0.05). Stars indicate signicant changes of eect-size relative to
previously reported eect sizes (p<0.05, two-sample z-test)
(logORAPOEε4EA−EC =2.1, SE=0.17, p=1.3x10
−33
) and APOE ε2 (logORAPOEε2EA−EC =-
1.8, p=3.2x10−21), variants in or near these genes were signicantly associated
with AD: SCL24A4-RIN3, PLCG2, ECHDC3, NME8, BIN1, ZCWPW1, ABCA7
(A > G), and HLA-DRB1 (Table 2.2).
2.3.2 Eect of using extreme AD cases
The average eect size in a comparison of extreme AD cases with normal
controls (EA vs. NC) did not signicantly change relative to the previously
reported eect sizes (ĒEA−EC=0.94 ± 0.12, p=0.68) (Figure 2.3). The eect
size was signicantly increased for APOE ε4 variant (1.3-fold, p=1.4x10−5),
and nominally signicant for APOE ε2 (1.4-fold, p=0.017). For 14 individual
variants, we observed an increased eect size, but this was not more than
what could be expected by chance (p=0.5, Figure 2.4 and Table S3). We then
separated AD cases into early-onset extreme AD cases (NeEA=464, age at
onset <65 years) and late-onset extreme AD cases (NlEA=609), and estimated
the change in eect sizes. Unexpectedly, the average eect size in the early-
onset cases was lower relative to previously published eect sizes (ĒeEA−NC
was 0.86 ± 0.16, p=0.79), whereas for late-onset cases the eect size was
2
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similar to published eect sizes (ĒlEA−NC was 1.01 ± 0.14, p=0.46) (Figure 2.6
and Table S4). We found signicant dierences between the eect sizes
in early-onset and late-onset AD cases (logORkeEA−NC and logOR
k
lEA−NC ,
respectively) for the variants in or near APOE ε2 (-0.41 vs. -0.89; p=0.05),
ZCWPW1 (0.01 vs. 0.24: p=0.016) and MS4A6A (0.12 vs. -0.13; p=0.0079).
When we extended the comparison with only the youngest early-onset AD
cases (NyEA=255, age at onset <60 years) and normal controls, the average
eect size was still lower than previously published eect sizes (ĒyEA−NC
was 0.87 ± 0.20, p=0.74) (Table S4).
2.3.3 Eect of extreme controls
In a comparison of normal AD cases and extreme (centenarian) controls
(NA vs. EC), the eect size was on average 1.88-fold higher relative to
previously reported eect sizes (ĒNA−EC = 1.88 ± 0.24, p=0.0001) (Figure 2.3
and Figure 2.5). This was almost identical to the average increase in eect size
when we compared the extreme cases with centenarian controls (ĒEA−EC =
1.90 ± 0.29; p=0.0009) (Figure 2.3). At the variant level, the change in eect
sizes was similar in both analyses (Figure 2.7A). In fact, in a comparison of
normal AD cases with extreme controls, we observed an increased eect
size for 24/29 variants relative to published variant eect sizes (EkNA−EC> 1),
which is more than expected by chance (p=0.00027) (Figure 2.5 and Table
S3). As in the comparison of the extremes, we found a signicant increase
in eect size for variants in or near APOE ε2 (1.7-fold, p<5x10−5), APOE
ε4 (1.7-fold, p<5x10−5), NME8 (4.5-fold, p=0.0035), SLC24A4-RIN3 (3.9-fold,
p=0.0045) and PLCG2 (2.9-fold, p=0.019). The main exception to this was the
increased eect size of the rare TREM2 (R47H) variant (allele frequency =
0.001), which was increased more when using extreme AD cases than when
using normal AD cases in a comparison with extreme controls (6.46-fold vs.
3.42-fold) (Figure 2.7A). For this rare variant we identied seven carriers in
1,073 extreme cases, and none in 255 centenarian controls. The eect size
increase did not reach signicance as CIs were large, which is according to
expectations for very rare variants in small sample sizes. However, overall,
the extreme controls contributed more to the eect size change than the




In this study, we found that the eect sizes of 29 variants previously identied
in genetic case control analyses for AD were increased in a case–control
analysis of extreme phenotypes. The use of extreme AD cases and cognitively
healthy centenarians as extreme controls increased eect sizes for association
with AD up to sixfold, relative to previously published eect sizes. On
average, the use of extreme phenotypes almost doubled the variant eect
size. Although changes in eect size were dierent per variant, the eect
size increase was driven mainly by the centenarian controls. This profound
increase enabled us to replicate the association with AD of 10 common
variants in relatively small samples. In a comparison of AD cases (either
normal or extreme) with centenarian controls, we observed signicant eect
size increases for variants in or near PLCG2, NME8, ECHDC3, SLC24A4-RIN3,
APOE ε2, and APOE ε4. We also found a large eect size increase for the rare
TREM2 (R47H) risk variant, which did not reach signicance owing to variant
rareness. This suggests that the tested variants or loci might (positively
or negatively) contribute to the long-term preservation of cognitive health
and/or to longevity in general. PLCG2, NME8, and TREM2 are implicated in
immunological processes,[8, 35] whereas SLC24A4, ECHDC3, and APOE are
involved in lipid and cholesterol metabolism (Table S5).[17, 36, 37] Both these
processes were previously associated with longevity,[38, 39] such that an
overlapping etiology of maintained cognitive health and maintained overall
health may contribute to the observed increase in eect size. However, with
the exception of the APOE locus, these loci were thus far not associated with
longevity in GWA studies.[40, 41, 42, 43] We speculate that the association
might be dependent on the maintained cognitive health in the centenarians
of the 100-plus Study cohort.[20] Alternatively, longevity studies may have
been underpowered to detect the association of these loci with extreme
survival. Future studies will have to establish the mechanism behind the
association of these genes with preserved cognitive health.
Next to APOE, the HLA-DRB1 locus has been associated with both AD
[13] and longevity.[40] However, its most informative variants, rs9271192
for AD and rs34831921 for longevity, are not in linkage disequilibrium (r2
= 0.04), suggesting that these are independent signals. Interestingly, the
variants for which the eect size did not signicantly increase when using ex-
treme cases and centenarian controls are also involved in immunity (variants
in/near TREM2, CR1, ABCA7, CLU, INPP5D, and MEF2C) and lipid/cholesterol
metabolism (variants in/near ABCA7 and CLU ) (Table S5). We speculate
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Figure 2.3: Average increase in eect-size for the dierent comparisons. Av-
erage increase in eect sizes for: Extreme AD cases (NEA = 1,073), of which early
onset cases (NeEA = 464), late onset cases (NlEA = 609); centenarian controls (NEC
= 255); normal controls (NNC = 1,664). 95% condence intervals were estimated by
random sampling (S = 10,000)
2
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that the variants with an increased eect size might inuence changes in
cognitive health during aging while variants with no increased eect size
do not inuence these processes. Using extreme cases did not increase the
variant eect sizes relative to published eect sizes, even though most of
the extreme cases were biomarker conrmed and their mean age at onset
was 8.2 years younger than the mean age at onset in other studies.[7, 8,
13] The only exception to this was the (non-signicant) eect size increase
for the rare TREM2 (R47H) risk variant, which was driven in part by using
extreme AD cases. This suggests that based on the tested genetic variants,
the phenotypically extreme cases presented in this study are not genetically
more extreme than cases presented in other studies. In fact, the variant eect
sizes of early-onset AD cases were on average lower than the variant eect
size of late-onset AD cases, and this persisted even when selecting only the
youngest early-onset cases. One explanation for this observation may be
that an early age at onset may be driven by rare, high-impact variants,[44]
whereas the disease onset at later ages may depend to a greater extent on
more common risk variants. Furthermore, we found signicant dierences at
the variant level, between the eect sizes in early-onset and late-onset cases
for common variants in/near ZCWPW1 and APOE ε2, and also in -opposite
directions- for the variant in MS4A6A. These results are a rst indication
that these variants may dierentially inuence age of disease onset, however,
future experiments will have to conrm this nding. Our main nding is
that, in a genetic case-control study of extreme phenotypes, the majority of
the observed increase in eect size is attributable to the extreme controls,
implicating that collecting cohorts of extreme controls is protable. We note
that the centenarians used in this study were selected for their preserved
cognitive health, which might have further enlarged the eect size increase
for genetic variants that were previously identied for their AD association.
We acknowledge that using centenarians as controls in genetic studies of AD
could result in the detection of variants associated with extreme longevity,
such that newly detected AD-associations need to be veried in an age-
matched AD case-control setting. Nevertheless, the eect sizes for all but
two variants are in the same direction as previously reported, which suggests
that the tested AD variants do not have signicant pleiotropic activities that
counteract their AD-related survival eects. Notably, the two variants with
an opposite eect, in or near MEF2C and FERMT2, also did not associate
with AD in our age-matched case-control analysis. This suggests that the
AD association of these variants is not consistent across studies. This is in
line with results from unpublished GWASs of AD in which AD-associations
2
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of variants near the MEF2C and FERMT2 genes were not replicated [45, 46]
(p=0.053,[45] p=0.0003 for MEF2C [46] and p=1.6x10−5 for FERMT2 [46]
variant, with 5.0x10
−8
being the genome-wide signicance threshold). A
strength of our study is that our cohorts of AD patients and controls, were
not previously used in the discovery of any of the known AD-associated
variants; we thus provide independent replication in a genetically homoge-
neous group of individuals, as they all came from one specic population
(Dutch). Concluding, in our comparison of cases and controls with extreme
phenotypes we found that on average, the eect of AD-related variants in
genetic association studies almost doubled, whereas at the variant level eect
sizes increased up to sixfold. The observed increment in eect size was
driven by the centenarians as extreme controls, identifying centenarians as
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2.7 Supplementary Figures
Figure 2.4: Extreme AD cases vs. normal controls: EkEA−NC . The eect-size
change was signicant for 4 variants (p<0.05, two-sample z-test; bars annotated with
a star [*]). Orange bars indicate nominal statistical signicance for the association
with AD (p<0.05). Dashed red line (EkEA−NC = 1) indicates same eect-size as
reported in literature.
Figure 2.5: Normal ADs vs. Extreme (centenarian) controls: EkNA−EC . Eect-
size change (EkNA−EC ) was signicant for 5 variants (p<0.05, two-sample z-test; bars
annotated with a star [*]). Orange bars indicate nominal statistical signicance
for the association with AD (p<0.05). Dashed red line indicates same eect-size as
reported in literature.
2
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Figure 2.6: Early onset AD vs normal controls and late onset AD vs nor-
mal controls. Eect-sizes and 95% condence intervals of a comparison of
early onset AD cases (logORkeEA−NC , age at onset ≤ 65 years) and late-onset AD
(logORklEA−NC , age at onset > 65 years) with normal controls. For all the variants,
the 95% condence intervals overlapped. [*]: dierence between logORkeEA−NC
and logORklEA−NC was signicant (p<0.05, two-sample z-test).
2
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Figure 2.7: Comparison of eect size changes at the variant level. A: Eect
of using extreme AD cases vs. normal AD cases: x-axis: EkEA−EC : Eect size
changes from a comparison of the extreme cases and extreme (centenarian) controls
relative to published eect sizes. Dashed line x-axis average eect-size increase
EkEA−EC at 1.90 ± 0.29; y-axis: E
k
NA−EC : eect-size changes from a comparison
normal AD cases with extreme (centenarian) controls relative to published eect
sizes. Dashed line y-axis: average eect-size increase EkNA−EC at 1.88 ± 0.24. See
Table 2.2 for EkEA−NC and Table S3 for E
k
EA−NC values. B. Eect of using extreme
cases vs. using extreme controls: x-axis: eect-size changes of extreme AD cases
vs. normal controls relative to published eect-sizes. Dashed line x-axis: average
eect-size increase EkEA−NC at 0.94 ± 0.12. Y-axis: Variant eect-size change of
normal AD cases vs. extreme controls relative to published eect-sizes. Dashed line
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Developing Alzheimer’s disease (AD) is inuenced by multiple genetic
variants that are involved in ve major AD-pathways. Per individual,
these pathways may dierentially contribute to the modication of
the AD-risk. The pathways involved in the resilience against AD
have thus far been poorly addressed. Here, we investigated to what
extent each molecular mechanism associates with (i) the increased
risk of AD and (ii) the resilience against AD until extreme old age, by
comparing pathway-specic polygenic risk scores (pathway-PRS). We
used 29 genetic variants associated with AD to develop pathway-PRS
for ve major pathways involved in AD. We developed an integrative
framework that allows multiple genes to associate with a variant, and
multiple pathways to associate with a gene. We studied pathway-PRS
in the Amsterdam Dementia Cohort of well-phenotyped AD patients
(N=1,895), Dutch population controls from the Longitudinal Aging
Study Amsterdam (N=1,654) and our unique 100-plus Study cohort of
cognitively healthy centenarians who avoided AD (N=293). Last, we
estimated the contribution of each pathway to the genetic risk of AD
in the general population. All pathway-PRS signicantly associated
with increased AD-risk and (in the opposite direction) with resilience
against AD (except for angiogenesis, p<0.05). The pathway that con-
tributed most to the overall modulation of AD-risk was β-amyloid
metabolism (29.6%), which was driven mainly byAPOE-variants. After
excluding APOE variants, all pathway-PRS associated with increased
AD-risk (except for angiogenesis, p<0.05), while specically immune
response (p=0.003) and endocytosis (p=0.0003) associated with re-
silience against AD. Indeed, the variants in these latter two pathways
became the main contributors to the overall modulation of genetic risk
of AD (45.5% and 19.2%, respectively). The genetic variants associated
with the resilience against AD indicate which pathways are involved
with maintained cognitive functioning until extreme ages. Our work
suggests that a favorable immune response and a maintained endocy-
tosis pathway might be involved in general neuro-protection, which
highlight the need to investigate these pathways, next to β-amyloid
metabolism.
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3.1 Introduction
Owing changes in lifestyle and advances in healthcare, life expectancy has
greatly increased during the last century.[1] A consequence of an increased
fraction of aged individuals in the population is the increased prevalence of
age-related diseases. A major contribution to poor health and disability at old
age is cognitive decline due to Alzheimer’s disease (AD).[2] The incidence
of AD increases exponentially with age and reaches ∼40% per year at 100
years, making it one of the most prevalent diseases in the elderly.[3] Yet,
a small proportion of the population (<0.1%) avoids the disease, reaching
at least 100 years while maintaining a high level of cognitive health.[4]
Both the development and the resilience against AD are determined by a
combination of benecial and harmful environmental and genetic factors that
is unique for each individual.[1, 5, 6] Thus far, large collaborative genome-
wide association studies (GWAS) have discovered common genetic variants
associated with a small modication of the risk of AD.[7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20] Of these, the alleles that encompass the APOE gene
explain the largest proportion of the risk to develop or the chance to escape
AD. We previously showed that those who avoided cognitive decline until
extreme ages (cognitively healthy centenarians) were relatively depleted
with genetic variants associated with an increased risk of AD.[21] However,
the degree of depletion of these variants in the genomes of cognitively
healthy centenarians relative to the middle-aged healthy individuals was
not constant, which might point towards a dierential impact of associated
biological pathways on either avoiding or developing AD. This led us to
hypothesize that an individuals’ chance to develop AD or to being resilient
against AD may be determined by pathway-specic risk. Previous studies
indicated that ve specic biological pathways associate strongly with AD
risk: immune response, β-amyloid metabolism, cholesterol/lipid dysfunction,
endocytosis and angiogenesis.[22, 23, 24, 25, 26, 27] However, the extent to
which dierent pathways contribute to the polygenic risk of AD is unknown.
The degree to which a pathway contributes to the individual risk can be
studied with pathway-specic polygenic risk scores (PRS).[28, 29] In a typical
polygenic risk score, the eect-sizes of all genetic variants that signicantly
associate with a trait are combined.[30] In a pathway-specic PRS, additional
information is necessary: (i) the association of genetic variants to genes,
and (ii) the association of genes to pathways. Previous studies of pathway-
PRS in AD approached these challenges using the closest gene for variant
mapping. For this, a 1:1 relationship between variants and genes is assumed,
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however, as AD-associated variants are mostly intronic or intergenic, the
closest gene is not necessarily the gene aected by the variant. Additionally,
dierent databases often have dierent functional annotations of genes, and
this uncertainty was previously not taken into account when constructing
pathway-PRS.[28, 29]
An accurate mapping of the genetic risk of AD conferred by specic
molecular pathways may lead to a greater comprehension of individual AD
subtypes and might represent a rst important step for the development of
targeted intervention strategies and personalized medicine.[31] Here, we
propose a novel integrative framework to construct pathway-PRS for the
ve major pathways suggested to be involved in AD. We then tested whether
specic pathways dierentially contributed to the risk of AD as well as to
the chance of avoiding AD until extreme old ages. Finally, we estimated
the contribution of each pathway to the polygenic risk of AD in the general
(healthy middle-aged) population.
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3.2 Methods
3.2.1 Populations
Population subjects are denoted by P : they consist of a representative Dutch
sample of 1,779 individuals aged 55-85 years from the Longitudinal Aging
Study Amsterdam (LASA).[32, 33] Patients diagnosed with AD are denoted
by A. The patients are either clinically diagnosed probable AD patients from
the Amsterdam Dementia Cohort (N=1,630) or pathologically conrmed
AD patients from the Netherlands Brain Bank (N=436).[34, 35, 36] Escapers
of AD are denoted by C: these are 302 cognitively healthy centenarians
from the 100-plus Study cohort. This study includes individuals who can
provide ocial evidence for being aged 100 years or older and self-report to
be cognitively healthy, which is conrmed by a proxy.[4] All participants
and/or their legal representatives provided written informed consent for
participation in clinical and genetic studies. The Medical Ethics Committee
of the Amsterdam UMC (METC) approved all studies.
3.2.2 Genotyping and imputation
We selected 29 common genetic variants (minor allele frequency >1%) for
which a genome-wide signicant association with clinically identied AD
cases was found (Table S1).[7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
37, 38, 39] We genotyped all individuals using Illumina Global Screening
Array (GSAsharedCUSTOM_20018389_A2) and applied established qual-
ity control measures.[40] Briey, we used high-quality genotyping in all
individuals (individual call rate >98%, variant call rate >98%) and Hardy-
Weinberg equilibrium-departure was considered signicant at p <1x10−6.
Genotypes were prepared for imputation using provided scripts (HRC-1000G-
check-bim.pl).[41] This script compares variant ID, strand and allele fre-
quencies to the haplotype reference panel (HRC v1.1, April 2016).[41] Fi-
nally, all autosomal variants were submitted to the Michigan imputation
server (https://imputationserver.sph.umich.edu). The server uses
SHAPEIT2 (v2.r790) to phase data and imputation to the reference panel
(v1.1) was performed with Minimac3. Variant-genotypes of total of 1,779
population subjects, 302 centenarians and 2,052 AD cases passed quality
control. Prior to analysis, we excluded individuals of non-European ancestry
(NC = 2, NP = 63 and NA = 94 based on 1000Genomes clustering)[42] and
individuals with a family relation (NC = 7, NP = 62 and NA = 63, identity-
by-descent >0.3), leaving 1,654 population subjects, 293 cognitively healthy
centenarians and 1,895 AD cases for the analyses.
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3.2.3 Polygenic risk score
To calculate the personal polygenic risk scores, or the genetic risk of AD
that aects a single individual, the eect-sizes of all genetic variants that
signicantly associate with AD are combined. Formally, a PRS is dened as
the sum of trait-associated alleles carried by an individual across a dened
set of genetic loci, weighted by eect-sizes estimated from a GWAS.[30]
We constructed a polygenic risk score (PRS) using 29 variants that were
previously associated with AD. As weights for the PRS, we used the variant
eect-sizes (log of odds ratio) as published in large GWAS of AD (Table S1).




(dossk ∗ βk) (3.1)
whereK is the full set of variants, dossk is the allele dosage from the (imputed)
genotype of variant k in subject s and βk is the eect size as determined in
the largest published AD case-control GWAS (Table S1).
3.2.4 Mapping variants to pathways
We studied the ve pathways implicated in AD: immune response, β-amyloid
metabolism, cholesterol/lipid dysfunction, endocytosis and angiogenesis.[22,
23, 24, 25, 43, 44] For these pathways we developed the variant-pathway
mapping Mkp , which represents the degree of involvement of a given vari-
ant in the pre-selected pathways. To generate this value, we (i) associated
genetic variants to genes (variant-gene mapping), (ii) associated genes to
pathways (gene-pathway mapping) and (iii) combined these mappings in
the variant-pathway mapping.
Variant-gene mapping
The association of a variant with a specic gene is not straight-forward as the
closest gene is not necessarily the gene aected by the variant. The two most
recent and largest GWAS of AD addressed the relationship between genetic
variants and associated genes applying two independent methods.[20, 19]
Briey, one study used (i) gene-based annotation, (ii) expression-quantitative
trait loci (eQTL) analyses, (iii) gene cluster/pathway analyses, and (iv) dier-
ential gene expression analysis between AD cases and healthy controls.[19]
The other study integrated (i) positional mapping, (ii) eQTL gene-mapping,
and (iii) chromatin interaction as implemented in the tool Functional Map-
ping and Annotation of Genome-Wide Association Studies (FUMA).[20, 45]
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The list of genes most likely aected by each variant was obtained from both
studies and used to derive a weighted mapping for each genetic variant k
to one or more genes g , mkg , denoted as the variant-gene mapping weight.
This weight was calculated by counting the number of times a variant k
was associated with gene g across the two studies and dividing this by the
total number of genes associated with the variant (Table S2). For variants
in/near CR1, PILRA, PLCG2, ABCA7 and APOE, we assumed the culprit gene
as known, and we assigned a 1:1 relationship between the variant and the
gene (Table S2).
Gene-pathway mapping
Each gene from the variant-gene mapping was classied into the pre-dened
set of pathways integrating four sources of information:
• Gene-sets from the unsupervised pathway enrichment analysis within
MAGMA statistical framework from Kunkle et al.,[19] in which the
authors identied 9 signicant pathways (coupled with the genes
involved in each pathway), which we mapped to 3 of the 5 pathways
of interest (Table S3);
• Associated genes from Gene-ontology (GO, from AmiGO 2 version
2.5.12, released on 2018-04) terms resembling the 5 pathways of interest
within the biological processes tree (including all child-terms) (Table
S4);[46, 47]
• Gene-sets derived from an unsupervised functional clustering analysis
within DAVID (v6.8, released on 2016-10):[48, 49] the gene-set from
the variant-gene mapping was used to obtain 12 functional clusters
which were then mapped to the 5 pre-selected pathways using a set of
keywords (Table S5 and Table S6);
• Gene-pathway associations from a recent review concerning the ge-
netic landscape of AD (Table S7);
By counting the number of times each gene was associated to each pathway
according to these sources, and dividing by the total number of associations
per gene, we obtained a weighted mapping of each gene g to one or more
pathways p, w
g
p , denoted as the gene-pathway mapping weight (Table S8
and Table S9). In case the gene-pathway mapping could not be calculated (i.e.
there was no mapping to any of the pathways of consideration), we excluded
the gene from further analyses (Table S8 and Table S9).
Variant-pathway mapping
To associate variants with pathways, we combined the variant-gene mapping
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and the gene-pathway mapping. Given a variant k, mapping to a set of genes








wheremkg is the variant-gene mapping weight of variant k to gene g , and w
g
p
is the gene-pathway mapping weight of gene g to pathway p. In this way,
for each variant, we calculated a score indicative of the involvement of the
variant in each of the ve pathways (variant-pathway mapping, Table S10).
For some variants no variant-pathway mapping was possible. We marked
these variants as unmapped (Table S10).
3.2.5 Pathway-specific polygenic risk score
For the pathway-specic polygenic risk score (pPRS), we extended the def-
inition of the PRS by adding as multiplicative factor the variant-pathway
mapping weight of each variant. Given a sample s and a pathway p, we









k is the variant-pathway mapping of variant k to pathway p.
3.2.6 Association of PRSs in the three cohorts
We calculated the polygenic risk score (PRS) and pathway-PRS (pPRS) for the
population subjects, the AD cases and the cognitively healthy centenarians
(P, A and C, respectively). Prior to analyses, the PRSs of all three populations
were combined together and were scaled (µ=0, σ=1). We then investigated
the inuence of APOE, gender and age on the risk scores: we calculated the
PRSs and pPRSs with and without the two APOE variants and we correlated
the resulting (p)PRSs with sex, age (age at inclusion for controls, age at
onset for cases) and population substructure components. To inspect the
dierential contributions of the risk scores to AD development or resilience
against AD, we calculated (i) the association of the risk scores (PRS and
pPRS) with AD status by comparing AD cases and population subjects (A
vs. P), and (ii) the association of the risk scores with resilience against AD
by comparing cognitively healthy centenarians and population subjects (C
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vs. P comparison). For the associations, we used logistic regression models
with the PRS and pPRS as predictors, adjusting for population substructure
(principal components 1-5). Resulting eect-sizes (log of odds ratio) can
be interpreted as the odds ratio dierence per one standard deviation (SD)
increase in the PRS, with a corresponding estimated 95% condence intervals
(95% CI). Association analyses of the (p)PRS in the three population were
also stratied by sex. Last, we veried the classication performances of the
single variants as well as the (p)PRS by calculating the area under the ROC
curve for classication of AD and resilience against AD.
3.2.7 Resilience against AD vs. increased AD-risk
To further investigate the relationship between the eect of each pathway
on AD and on resilience against AD, we calculated the change in eect-size.
This corresponds to the ratio between the eect-size of the association with
resilience against AD (log of odds ratios of C vs. P comparison) and the eect-
size of the association with AD (log of odds ratios of A vs. P comparison).
We calculated the change in eect-size for the pPRS including and excluding
APOE variants. We estimated 95% condence intervals for the eect-size
ratios by sampling, and we tested for signicant dierence between the
change in eect-size including and excluding APOE variants (respectively for
each of pPRS) using t-test. A value for the change in eect-size of 1 indicates
a similar eect on increased risk of AD and resilience against AD. Although
a value for the change in eect size is unknown a priori, since all variants
considered are selected to be associated with AD, a value <1 is expected (i.e.
a larger eect on AD than on resilience against AD).
3.2.8 Contribution of each pathway to polygenic risk of AD
We estimated the contribution of each pathway to the genetic risk of AD
in the general population: this equals to the variance explained by each of
the pre-selected pathways to the genetic risk of AD. Mathematically, this is
the ratio between the variance of each pathway-PRS and the variance of the
combined PRS as calculated in the individuals of the general population. As
such, it is a function of the variant-pathway mapping, the eect-size (log of
odds ratio) of the variants, and the variant frequencies. Given a variant k
and the relative variant-pathway mapping Mkp , we dened the percentage P
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where βk is the variant eect-size from literature, and MAFk ∗ (1−MAFk)
is the variance of a Bernoulli random variable that occurs with probability
MAFk , i.e. the minor allele frequency of each variant k in our cohort of
population subjects. Here, Mkp is interpreted as the probability that variant k




p = 1, so that each
variant contributes equally, yet dierentially at the level of each pathway.
This means that the variance of a variant is only counted once, even if the
variant contributes to multiple pathways. When calculating the contributions
of each pathway, we also considered variants with missing variant-pathway
mapping. For these variants, the variant-pathway mapping was set to 1 for
an unmapped pathway. Together, the pathway PRS variances sum to the
total PRS variance.
3.2.9 Implementation
We performed quality control of genotype data as well as population stratica-
tion analysis and relatedness analysis with PLINK (v2.0). All subsequent anal-
yses were performed with R (v3.5.2), Bash and Python (v2.7.14) scripts. We
provide a R script to construct pPRS and PRS using our variant-pathway anno-
tation and user’s genotypes. In addition, all the scripts we used to perform the
analyses can be found at https://github.com/TesiNicco/pathway-PRS.
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Figure 3.1: Boxplots of PRS and pPRS in the dierent settings. A. The PRS
including all the 29 known AD-associated variants, with and without APOE variants.
As weight for the PRS, we used published variant eect-sizes (Table S1). B. and C.
The pPRS for each of the selected molecular pathways, including and excluding
APOE variants, respectively. For all plots, risk scores were calculated for AD cases,
population subjects and cognitively healthy centenarians. Then, risk scores were
compared between (i) AD cases and population subjects (A vs. P comparison) and
(ii) cognitively healthy centenarians and population subjects (C vs. P comparison).
For representation, we scaled all PRS and pathway-PRS to be µ=0 and σ=1. For
the comparison, we used logistic regression models with risk scores as predictors.
Annotation: ***, p-value of association <5x10−6; **, p-value of association <0.0005; *,




After quality control of the genetic data, we included 1,654 population sub-
jects (with mean age at inclusion 62.7 ± 6.4, 53.2% females), 1,895 AD cases
(with mean age at onset 69.2 ± 9.9, 56.4% females), and 293 cognitively healthy
centenarians (with mean age at inclusion 101.4 ± 1.3, 72.6% females) (P, A
and C respectively).
3.3.1 Polygenic risk scores associate with AD and escape from AD
To each subject, we assigned a PRS representative of all 29 AD-associated
variants, including and excluding APOE variants. We found that the PRS,
when including APOE variants, signicantly associated with an increased
risk of AD and, in the opposite direction, with increased chance of resilience
against AD (A vs. P : OR=2.61, 95% CI=[2.40-2.83], p=8.4x10−113 and C vs. P :
OR=0.54, 95% CI=[0.45-0.65], p=1.1x10−10 (Figure 3.1 and Table S11). When
excluding APOE variants, the PRS was still signicantly associated with an
increased risk of AD and, in the opposite direction, with increased risk of
resilience against AD (A vs. P : OR=1.30, 95% CI=[1.22-1.40], p=3.1x10−14 and
C vs. P : OR=0.78, 95% CI=[0.69-0.89], p=2.4x10−4) (Figure 3.1, and Table S11).
3.3.2 Pathway-specific PRS associate with AD and escape from AD
We annotated the 29 AD-associated genetic variants to 5 selected pathways
(Figure 3.2). According to our variant-gene mapping, the 29 AD-associated
variants mapped to 110 genes (Table S8). The number of genes associated
with each variant ranged from 1 (e.g. for variants in/near CR1, PILRA, SORL1,
ABCA7, APOE or PLCG2, to 30 (a variant in the gene-dense region within
the HLA region) (Figure 3.2 and Table S8). We were able to calculate the
gene-pathway mapping weight for 69 genes (Table S9). The remaining 41
genes were not mapped to the 5 pathways. In total, we calculated the variant-
pathway mapping for 23 loci to at least one of the pre-selected biological
pathways (Figure 3.2 and Table S10).
We then calculated the pPRS for each pathway in population subjects,
AD cases and cognitively healthy centenarians including and excluding
APOE variants (Figure 3.1B and Figure 3.1C). The number of variants that
contributed to each pPRS was 19 for immune response, 11 for β-amyloid
metabolism, 19 for endocytosis, 8 for cholesterol/lipid dysfunction and 4
for angiogenesis pathways (Table S10 and Table S11). Overall, the pPRS
(including and excluding the APOE variants) positively and signicantly
correlated with each other and with the overall PRS (Figure 3.5), and did not
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Figure 3.2: Variant-pathways mapping. Locus: chromosome and position of the
AD-associated genetic variants (coordinates are with respect to GRCh37). N.genes:
total number of genes associated with each variant according to variant-gene map-
ping. Variant-gene mapping: Genes: all genes with at least one annotation to the 5
selected molecular pathways associated with AD. Weight: the weight of the variant-
gene mapping. Gene-pathway mapping: Immune response, Beta-amyloid, Endocytosis,
Cholesterol/lipid, Angiogenesis: the weight of each molecular pathway at the gene
level. Variant-pathway mapping: summarization of each variant’s eect after com-




correlate with gender and age (Figure 3.5).
When including APOE variants, the pPRSs of all pathways (except for
angiogenesis) signicantly associated with increased risk of AD, indepen-
dently from gender (A vs. P, immune response: OR=2.15, 95% CI=[1.99-
2.32], p=2.0x10−80; β-amyloid metabolism: OR=2.52, 95% CI=[2.32-2.73],
p=7.8x10−109; endocytosis: OR=2.55, 95% CI=[2.35-2.77], p=1.7x10−109; choles-
terol/lipid dysfunction: OR=2.55, 95% CI=[2.35-2.76], p=2.1x10−110; angiogen-
esis: OR=1.05, 95% CI=[0.98-1.12], p=0.134) (Figure 3.1B, Table S11, Figure 3.6
and Table S12). The association of pPRSs with increased chance of being
resilient against AD was in the opposite direction for all pathways, and the
association was signicant for all pathways except for angiogenesis (C vs.
P, immune response: OR=0.64, 95% CI=[0.54-0.74], p=1.4x10−8; β-amyloid
metabolism: OR=0.59, 95% CI=[0.49-0.71], p=2.7x10−8; endocytosis: OR=0.55,
95% CI=[0.46-0.66], p=1.3x10−10; cholesterol/lipid dysfunction: OR=0.58,
95% CI=[0.48-0.70], p=1.8x10−8; angiogenesis: OR=0.90, 95% CI=[0.79-1.01],
p=0.078) (Figure 3.1B, Table S11). Directions of eects were consistent in
both males and females, but the signicance of associations was reduced due
to stratication (Table S12 and Figure 3.5). When excluding APOE variants,
the pPRSs of all pathways (except for the angiogenesis) was still signicantly
associated with increased risk of AD without specic gender eects (A vs.
P, immune response: OR=1.19, 95% CI=[1.11-1.27], p=5.5x10−7; β-amyloid
metabolism: OR=1.19, 95% CI=[1.12-1.28], p=2.0x10−7; endocytosis: OR=1.27,
95% CI=[1.19-1.36], p=2.8x10−12; cholesterol/lipid dysfunction: OR=1.18,
95% CI=[1.11-1.27], p=7.5x10−7; angiogenesis: OR=1.05, 95% CI=[0.98-1.12],
p=0.134) (Figure 3.1C, Table S11, Figure 3.6 and Table S12). The association
of pPRSs with increased chance of being resilient against AD was in the op-
posite direction for all pathways, yet the association was signicant only for
the immune response and the endocytosis pPRS (C vs. P, immune response:
OR=0.82, 95% CI=[0.72-0.94], p=0.003; β-amyloid metabolism: OR=0.91, 95%
CI=[0.80-1.03], p=0.131; endocytosis: OR=0.79, 95% CI=[0.70-0.90], p=0.0003;
cholesterol/lipid dysfunction: OR=0.91, 95% CI=[0.80-1.03], p=0.145; angio-
genesis: OR=0.90, 95% CI=[0.79-1.01], p=0.078) (Figure 3.1C and Table S11).
In the sex-stratied analysis, females reported consistent direction of eects
and signicant associations of immune response and endocytosis pathways,
while in males the direction was consistent for immune response, endocytosis
and angiogenesis pathways, and it was opposite for β-amyloid metabolism
and cholesterol/lipid dysfunction (yet not signicant) (Figure 3.6 and Table
S12). We note that apart from APOE variants (for which we stratied the anal-
yses for), there was no major driver in the pPRS as well as the single-variant
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associations (Figure 3.7 and Figure 3.8).
3.3.3 Comparison of eect on AD and escaping AD
To further evaluate the association of the pPRSs with AD and with resilience
against AD, we compared, for each pPRS, the reciprocal eect size associated
with resilience against AD with the eect size associated with increased risk
of AD (change in eect size, Figure 3.3A). When including APOE variants,
the change in eect-size was <1 for all pathways (except for the angiogenesis
pathway) (Figure 3.3B). This is expected as the eect-size of APOE variants
on causing AD is much larger than its eect on resilience against AD (Fig-
ure 3.3A). When excluding APOE variants, the change in eect-size was still
<1 for β-amyloid metabolism and cholesterol/lipid metabolism (respectively
0.54 and 0.58), but it approximated 1 for endocytosis (0.96) and it was larger
than 1 for the immune response and angiogenesis (respectively 1.12 and
2.15) (Figure 3.3B). Interestingly, we found that the relative eect-size for
immune response and endocytosis excluding APOE variants was signicantly
higher than that including APOE variants (p<2.1x10−197 and p<8.9x10−180
respectively), suggesting a larger eect on resilience against AD compared
to AD-risk for these pathways, specically when excluding APOE variants
(Figure 3.3B).
3.3.4 Contributions of each pathway to the polygenic risk of AD
Finally, we estimated the relative contribution of each pathway to the poly-
genic risk of AD in the general population. This is indicative of the degree of
involvement of each pathway to the total polygenic risk of AD, and as such
it is based on out variant-pathway mapping. Including APOE variants, the
contribution of the pathways to the total polygenic risk of AD was 29.6% for
β-amyloid metabolism, 26.6% for immune response, 21.6% for endocytosis,
19.5% for cholesterol/lipid dysfunction, 0.3% for angiogenesis and 2.3% for
the unmapped variants (Figure 3.4A). When we excluded APOE variants, the
contribution of the pathways to the total polygenic risk of AD was 45.5% for
immune response, 19.2% for endocytosis, 13.7% for β-amyloid metabolism,
8% for cholesterol/lipid dysfunction, 1.4% for angiogenesis and 12.3% for the
unmapped variants (Figure 3.4B).
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Figure 3.3: Change in eect-size between association with escaping AD and
causing AD for the ve pPRSs. A The eect-sizes (log of odds ratio) and the
relative 95% condence intervals of the association of the (p)PRS with both AD-risk
and resilience against AD, grouped by pathway. B. Each bar represents the ratio
between the eect-size of the association with escaping AD (Resilience eect in A)
and with causing AD (Risk eect in A), respectively with and without APOE variants.
Ratios larger than 1 are then indicative of larger eect-size on resilience against AD
compared to AD-risk. We then compared the change in eect-size for each pathway
when including and excluding APOE variants using t-tests. Annotation: ***, p-value
of association <5x10
−6
; **, p-value of association < 0.0005; *, p-value of association
< 0.05.
3.4 Discussion
In this work, we studied 29 common genetic variants known to associate
with AD using polygenic risk scores and pathway-specic polygenic risk
scores. As expected, we found that a higher PRS for AD was associated with
a higher risk of AD. Previous studies showed that polygenic risk score of
AD not only associated with increased risk of AD, but also with neuropatho-
logical hallmarks of AD, lifetime risk and the age at onset in both APOE ε4
carriers and non-carriers.[28, 29, 50, 51, 52, 53, 54] We now add that, using
our unique cohort of cognitively healthy centenarians, the PRS for AD also
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associates with resilience against AD at extremely old ages. This adds further
importance to the potentiality of using PRS and APOE genotype in a clinical
setting.[51, 50, 53, 55] In addition, our analyses suggest that the long-term
preservation of cognitive health is associated with the selective survival of
individuals with the lowest burden of risk-increasing variants or, vice versa,
the highest burden of protective variants. Using an innovative approach,
we studied ve pathways previously found to be involved in AD as well as
the contribution of these pathways to the polygenic risk of AD. We showed
that all pathways-PRS except angiogenesis associate with increased AD risk,
both including and excluding APOE variants and independently from gender.
When we studied the association of pathways-PRS with resilience against AD
until extreme old ages, we found that, as expected, the enrichment of the pro-
tective APOE ε2 allele and the depletion of the risk-increasing APOE ε4 allele
represented a major factor in avoiding AD. However, when excluding the two
APOE variants, only immune response and endocytosis signicantly associ-
ated with an increased chance to be resilient against AD. Interestingly, both
pathways had a larger or similar eect on resilience against AD-resilience
compared to developing AD, suggesting that these pathways might be in-
volved in general neuro-protective functions. Based on the variant eect
size, variant frequency and our variant-pathway mapping, we found that the
β-amyloid metabolism (29.6%) followed by immune response (26.6%) were
the major contributors to general modication of AD-risk. After excluding
APOE variants, according to our analysis, immune response (45.5%) and
endocytosis (19.2%) contributed most to the modication of AD-risk.
Our approach to map variants to associated genes and to map genes to
pathways resulted in a weighted annotation of variants to pathways that
allowed for uncertainty in gene as well as pathway assignment, which was
not done previously. We note that considering uncertainty in variant-gene as
well as gene-pathway assignments is crucial because most genetic variants
are in non-coding regions, which makes the closest gene not necessarily the
culprit gene, and because dierent functional annotation-sources often do
not overlap. In our variant-pathway mapping, a larger number of annotations
(both variant-genes and gene-pathways), generally causes a dilution of the
"true" variant eect, reecting increasing uncertainty in the annotation
sources used. This depends on the specic regions, for example, the HLA
region carries many genes with large linkage signals, however, all genes
in this region are typically annotated with immune response. We point
out that the power of the PRSs does not only reect the eect-size of the
variants, but also the number and frequency of the variants that contribute
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to the PRSs: due to this, a larger number of very common variants with
relatively small eect-size can still have more power (yet small ORs) than a
small number of relatively rare variants with high eect-size. The pathway-
specic PRS that we proposed in this manuscript can be re-used for the
identication of subtypes of AD patients compromised in a specic AD-
associated pathway. This is of interest for clinical trials, in order to test
responsiveness to compounds in specic subsets of patients. For example,
monoclonal antibody targeting TREM2 receptors could work better in AD
patients who have an impaired immune response pathway. Recently, several
studies attempted to construct pathway-specic PRS to nd heterogeneity
in AD patients based on a genetic basis.[28, 29] In line with our ndings,
Ahmad et al. found that genes capturing endocytosis pathway signicantly
associated with AD and with the conversion to AD.[29] Other studies used
less variants [28] or less stringent selection for variants, and did not observe
a dierential involvement of pathways in AD etiology.[56]
The amyloid cascade hypothesis has been dominating AD-related re-
search in the last two decades. However, treatments targeting amyloid
have, so far, not been able to slow or stop disease progression. This has led
to an increased interest for the other pathways that are important in AD
pathogenesis.[22] Part of the current view of the etiology of AD is that the
dysregulation of the immune response is a major causal pathway, and that
AD is not only a consequence of β-amyloid metabolism.[57, 58] In addition,
previous studies showed that healthy immune and metabolic systems are
associated with longer and healthier lifespan.[1, 59] Our results indicate that,
excluding APOE variants, the eect of immune response and endocytosis
on escaping AD is stronger or comparable to the eect on causing AD. This
suggests that these pathways might be involved in the maintenance of gen-
eral cognitive health, as the cognitively healthy centenarians represent the
escape of all neurodegenerative diseases until extreme ages. We recently
found evidence for this hypothesis in the protective low frequency variant in
PLCG2, which is involved in the regulation of the immune response.[52] This
variant is enriched in cognitively healthy centenarians, and protects against
AD as well as frontotemporal dementia and dementia with Lewy bodies.
We included this variant in the total PRS as well as in the pathway-PRS for
the immune response (variant-pathway mapping was 60%) and endocytosis
(variant-pathway mapping was 40%). Regarding endocytosis, this pathway is
thought to play a role both in neurons, as part of the β-amyloid metabolism,
but also in glia cells, as part of the immune response. Thus, a dysregulation in
the interplay between these pathways might lead to an imbalance of immune
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Figure 3.4: Explained variance of each pathway-specic PRS to polygenic
risk of AD The pie charts represents the explained variance of each pathway-
specic PRS to the polygenic risk of AD, including and excluding APOE variants.
The contributions are calculated according to (i) our variant-pathway mapping,
(ii) the eect size (log of odds ratio) of each variant from literature (Table S1), and
(iii) variant’s frequency in our cohort of middle-aged healthy population subjects.
We also considered variants with missing variant-pathway mapping (unmapped
pathway).
signaling factors, favoring the engulfment of synapses and AD-associated
processes. This, in turn, may contribute to the accumulation of amyloid and
tau pathologies.[60, 61, 62, 63]
We assessed the eect of common and low frequency variants on the
development and the escape of AD. Therefore, the contributions of rare,
causative variants associated with increased AD risk, such as those in APP,
PSEN1, PSEN2, TREM2 and SORL1were not considered. Despite the large odds
ratios to develop AD associated with carrying such variants, the frequency
of these variants in the population is ultra-low, and therefore have a minor
eect on the total AD risk in the population.[11, 12] However, future versions
of the PRS will most likely include the eect of carrying disease-associated
rare variants. This will aect individual PRS scores and the necessity to
accordingly adapt the results generated with current PRSs. Compared to
the sizes of recent GWAS of AD, we included relatively small sample sizes,
particularly with respect to the cognitively healthy centenarians, a very rare
phenotype in the population (<0.1%).[4] These sample sizes are however
sucient to study PRSs. The cohorts that we used in this study were not
used in any GWAS of AD, therefore we provide independent replication of
AD PRS in a homogeneous group of (Dutch) individuals.
We note that, apart from APOE variants (for which we stratify the anal-
yses for), none of the other variants have been associated with longevity
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or well cognitive functioning in the largest and most recent GWAS.[64, 65]
We acknowledge that our variant-pathway mapping reects the current
state of imperfect knowledge at the level of AD-GWAS ndings, variant-
gene and gene-mechanism relationships. Thus, as new variants, pathways or
functional relationships will be identied, the contributions and the pathway-
specic PRSs will need to be recalculated. Of note: the study in which the
genome-wide signicant association with AD of the variant in/near KANSL1
was originally identied, reported a larger eect size compared to the eect
size used in our manuscript, (β=0.31 and β=0.07, respectively), possibly be-
cause the original analysis was stratied by APOE. We cannot exclude that we
underestimated the contribution of KANSL1 in the analyses. Moreover, since
theKANSL1 variant did not map into one of the analyzed pathways, it was not
included in any of the pathway-specic PRS calculations. A limitation, not
exclusive to our work, is the highly debated role of APOE gene. We mapped
the eect of APOE to four pathways and we are aware this assignment is
relatively arbitrary. We add that APOE has well-studied (cardio)vascular
properties that are included in our cholesterol and lipid metabolism pathway.
The combination of a large eect and unclear pathway assignment makes
that pathway-PRS including APOE challenging to use. Lastly, we point out
that the variance contributions might change in dierent populations, as it
depends on variant frequency and population heterogeneity.
Concluding, with the exclusion of APOE variants and based on our func-
tional annotation of variants, the aggregate contribution of the immune
response and endocytosis represents more than 60% of the currently known
polygenic risk of AD. This indicates that an intervention in these systems
may have large potential to prevent AD and potentially other related dis-
eases and highlights the critical need to study (neuro)immune response and
endocytosis, next to β-amyloid metabolism.
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3.7 Supplementary Figures
Figure 3.5: Correlation plot of the (p)PRS and covariates. The gure shows
the correlation between the pathway-PRS (respectively with and without APOE
variants), the full-PRS (respectively with and without APOE variants), ages (ages
at study inclusion for controls, ages at diagnosis for AD cases) and the 5 principal
components derived from the population stratication analysis. We used Pearson
correlation and p-values were adjusted with Holm-Bonferroni correction.
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Figure 3.6: Sex-stratied analysis of the (p)PRS. The gure shows the sex-
stratied analyses in the context of the overall analysis, respectively for the pathway-
PRS (including and excluding APOE variants) and the Full-PRS (including and ex-
cluding APOE variants). For each PRS (pathway-PRS or Full- PRS) we report both
the odds ratio for AD and those for AD-resilience.
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Figure 3.7: Area under ROC curve for classication of AD or AD-Resilience
status, for each variant. The gure shows the quality of the classication of AD
and AD-Resilience status using single-variants.
Figure 3.8: Area underROC curve for classication ofADandAD-Resilience
status, for each PRS and pPRS. The gure shows the quality of the classication
of AD and AD-Resilience status using PRS and pPRS.
3
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3.8 Supplementary Tables
Supplementary Tables can be accessed by scanning the following code or
accessing the journal’s website here.
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4. The Alzheimer-Longevity axis
The eect of Alzheimer’s disease-associated genetic
variants on longevity
Niccolo’ Tesi, Marc Hulsman, Sven J. van der Lee, Iris E. Jansen,
Najada Stringa, Natasja M. van Schoor, Martijn Huisman, Philip Schel-
tens, Wiesje M. van der Flier, Marcel J.T. Reinders, and Henne Holstege





Human longevity is inuenced by the genetic risk of age-related
diseases. As Alzheimer’s disease (AD) represents a common condi-
tion at old age, an interplay between genetic factors aecting AD
and longevity is expected. We explored this interplay by studying
the prevalence of AD-associated single-nucleotide-polymorphisms
(SNPs) in cognitively healthy centenarians, and replicated ndings in
a parental-longevity GWAS. We found that 28/38 SNPs that increased
AD-risk also associated with lower odds of longevity. For each SNP,
we express the imbalance between AD- and longevity-risk as an
eect-size distribution. Based on these distributions, we grouped the
SNPs in three groups: 17 SNPs increased AD-risk more than they de-
creased longevity-risk, and were enriched for β-amyloid metabolism
and immune signaling; 11 variants reported a larger longevity-eect
compared to their AD-eect, were enriched for endocytosis/immune-
signaling, and were previously associated with other age-related dis-
eases. Unexpectedly, 10 variants associated with an increased risk of
AD and higher odds of longevity. Altogether, we show that dierent
AD-associated SNPs have dierent eects on longevity, including
SNPs that may confer general neuro-protective functions against AD
and other age-related diseases.
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4.1 Introduction
The human lifespan is determined by a benecial combination of environ-
mental and genetic factors.[1, 2] Long-lived individuals tend to cluster in
families, suggesting that the role of the genetic factors is considerable,[3,
4] however, the research of genetic variants that inuence human lifespan
has yielded contrasting results: only the longevity-association of the APOE
alleles and few additional variants consistently replicated across studies
(CDKN2B, ABO).[5, 6] While the replication rate in independent studies is
low, a large collection of genetic variants has been associated with longevity
through genome-wide association studies (GWAS) in dierent studies and
populations.[5, 6] The majority of these variants was previously identied
to associate with other age-related conditions, including cardiovascular dis-
ease, autoimmune and neurological disorders, suggesting that the genetics
underlying human longevity depends on a lower risk for several age-related
diseases.[5, 6, 2] Of all age-related diseases, late-onset Alzheimer’s Disease
(AD) is the most common type of dementia and one of the most prevalent
causes of death at old age.[7] The largest risk factor for AD is aging: at 100
years of age, the disease’s incidence is about 40% per year.[8] Genetic factors
play a signicant role in AD as heritability was estimated to be 60-80%:[9]
the strongest common genetic risk factor for AD is the APOE ε4 allele, and
large collaborative GWAS have identied 41 additional common variants
associated with a slight modication of the risk of AD.[10, 11, 12, 13] De-
spite high incidence rates of AD at very old ages, AD is not an inevitable
consequence of aging, as demonstrated by individuals who surpass the age
of 100 years with high levels of cognitive functioning.[14] As AD-associated
variants increase the risk of AD, leading to earlier death, a negative eect
on longevity for these variants should be expected. However, apart from
APOE alleles, genetic variants that inuence the risk of AD were not found
to aect the human lifespan in previous GWAS. In fact, often we assume that
AD-associated variants aect AD only, but this may still not hold true. For
example, at the molecular level, there may be other age-related traits that
share (part of) the biological pathways underlying AD. Nevertheless, for an
AD-associated variant that aects AD only, the relative eect on longevity
should be proportional to the corresponding eect on AD, albeit in a dierent
direction. This means that if a variant increases the risk of AD 2-fold, then
carriers will have twice as much AD-related mortality as non-carriers, and as
a consequence, they will have twice as little chance to age into a cognitively
healthy centenarian. However, in case a genetic variant is protective against
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multiple conditions, it might be expected that the overall eect on longevity
results larger than the absolute eect on AD alone.
We have previously shown that cognitively healthy centenarians are
depleted with genetic variants that increased the risk of AD compared to
a general population. Yet, the extent of depletion was variant specic, sug-
gesting that a subset of AD-variants may be specically benecial to reach
extremely old ages in good cognitive health.[15, 16] In addition, the extent to
which these variants aect other age-related diseases is mostly unknown.[17]
Using the notion of eect-size proportionality, we set out to investigate the
relationship between AD- and longevity- risk for genetic variants associated
with AD.
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4.2 Methods
4.2.1 Populations and selection of genetic variants
We included N=358 centenarians from the 100-plus Study cohort, which com-
prises Dutch-speaking individuals aged 100 years or older who self-report
to be cognitively healthy, which is conrmed by a proxy.[14] As popula-
tion controls, we used population-matched, cognitively healthy individuals
from ve studies: (i) the Longitudinal Aging Study of Amsterdam (LASA,
N=1,779),[18, 19] (ii) the memory clinic of the Alzheimer center Amsterdam
and SCIENCe project (N=1,206),[20, 21] (iii) the Netherlands Brain Bank
(N=40),[22] (iv) the twin study of Amsterdam (N=201)[23] and (v) the 100-
plus Study (partners of centenarian’s children, N=86).[14] See Supplementary
Methods: Populations for a detailed description of these cohorts. Throughout
the manuscript, we will refer to the union of the individuals from these
ve studies as population subjects. The Medical Ethics Committee of the
Amsterdam UMC (METC) approved all studies. All participants and/or their
legal representatives provided written informed consent for participation
in clinical and genetic studies. Genetic variants in our populations were
determined by standard genotyping and imputation methods. All samples
were genotyped using the same commercial kit. After establishing quality
control of the genetic data (see Supplementary Methods: Quality control),
2,905 population subjects and 343 cognitively healthy centenarians were left
for the analyses (Table 4.1). We then selected 41 variants representing the
current genetic landscape of AD (Table S1).[13] We restricted our analysis
to high-quality variants with a minor allele frequency >1% in our cohorts,
which led to the exclusion of 3/41 variants (rare variants in the TREM2 gene
rs143332484 and rs75932628 and ABI3 gene rs616338), leaving 38 variants for
the analyses.
4.2.2 AD and longevity variant eect sizes
We rst retrieved the eect-size on AD (EkAD ) for each AD variant, k, from
one of the largestGWAS of AD.[13] To estimate a condence interval, we
sampled (S=10000) from the published eect-sizes (log of odds ratios) and
their respective standard errors. To calculate the eect-size on longevity
(EkLGV ) for the same variants, we used a logistic regression model with
cognitive healthy centenarians as cases and population subjects as controls
while adjusting for population stratication (PC 1-5). The number of principal
components to include as covariates was arbitrarily chosen; however, as all
individuals were population-matched, we expected these components to
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correct all major population eects. The resulting p-values were corrected
for multiple testing (False Discovery Rate, FDR). To calculate the condence
interval, we repeated this bootstrapping procedure (B=10,000) of the data.
For convenience, variant eect-sizes on AD and longevity were calculated
with respect to the allele that increases the risk of AD, such that EkAD > 0.
Given a variant k, with a relative eect-size on AD (EkAD ) and on longevity
(EkLGV ), we dened that the variant has an expected direction if the variant
increases the risk of AD, i.e. EkAD > 0, and at the same time decreases the risk
of longevity, i.e. EkLGV < 0. Inversely, we dene that the longevity eect has
an unexpected direction if the allele that increased AD risk also increased the
risk of longevity, i.e. EkAD > 0 and E
k
LGV > 0. The probability of observing
an expected direction was considered a Bernoulli variable with p=0.5 (i.e.
equal chance of having an expected/unexpected direction), thus the number
of variants with an expected direction follows a binomial distribution.
4.2.3 Imbalance of variant eect direction
We represented each variant as a data point whose coordinates were dened
by the variant’s eect on AD (EkAD , on the y-axis) and its eect on longevity
(EkLGV , on the x-axis). See Figure 4.4 for an example. For each variant, we
then calculated the normalized angle, αk , of the vector representing the data







where αk ∈ [−1;1]. This normalized angle relates to the imbalance between
the risk of AD and the risk of longevity. That is, for αk < 0 the variant
has an expected direction, while for αk > 0 the variant has an unexpected
direction. As the eect-sizes are sample estimates, we subsequently took their
condence interval into account to create, for each variant, a distribution of
the imbalance in the eect direction (IED). Hereto, we assumed a Gaussian
density for both EkAD and E
k





a variance equal to the estimated condence interval for both eect sizes,
respectively. We sampled 10,000 times from these distributions and calculated
the corresponding imbalance (αk), to get a (non-Gaussian) distribution of
the IED for that variant, IEDk . To group variants with similar patterns of
their IED distributions, we ordered the IED by their median value ( ˜IEDk),
and dened a group of variants in which the eect sizes were in the expected
direction (
˜IEDk ≤ 0), which we subsequently split in those that have (i) a
4
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larger eect on longevity as compared to the eect on AD (
˜IEDk ≤ −1/2,
longevity-group), and those that have (ii) a larger eect on AD as compared
to the eect on longevity (−1/2 < ˜IEDk ≤ 0, AD-group). We dened a third
group of variants that have an eect in the unexpected direction (
˜IEDk > 0,
Unex-group). These cut-o calues were not arbitrarily chosen, instead, they
represent the point at which the eect on AD equals the (negative) eect
on longevity (IEDk = −1/2) and the point at which no eect on longevity is
observed (IEDK = 0).
4.2.4 Replication of findings in large GWAS cohorts
To nd additional evidence for our ndings, we inspected the association
statistics of the 38 AD-associated variants in the largest GWAS on parental
longevity.[6] Briey, in this study ospring’s genotypes were used to model
parental age at death. In this dataset, we looked at the signicance of as-
sociation with longevity for the 38 variants (p-values were corrected with
FDR) and their direction of eect. Finally, we tested the consistency in
the expected/unexpected directions between our study and the GWAS on
parental longevity using binomial tests. We did not use a case-control GWAS
of longevity as the most recent included our cohort, thus the resulting asso-
ciations would be biased.[5]
4.2.5 Linking variants with functional clusters
To investigate each variant’s functional consequences, we calculated the
variant-pathway mapping, which indicates the degree of involvement of
each genetic variant in AD-associated pathways (Figure 4.5). See Supple-
mentary Methods: variant-pathway mapping, for a detailed explanation
of our approach. Briey, the variant-pathway mapping depends on (i) the
number of genes each variant was associated with and (ii) the biological
pathways each gene was associated with. We calculated the variant-pathway
mapping for all 38 AD-associated variants. Finally, we compared the variant-
pathway mapping within each group of variants dened based on the IEDs
(Longevity-, AD- and Unex-groups) using Wilcoxon sum rank tests and
correcting p-values using FDR: this was indicative of whether a group of
variants was enriched for a specic functional cluster (Figure 4.5).
4.2.6 Cell-type annotation at the level of each cluster
To further explore the biological basis of the dierent groups of variants
(Longevity-, AD- and Unex-groups), we calculated the degree of enrichment
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of each group for specic brain cell-types (see Supplementary Methods: cell-
type annotation, for a detailed description). This annotation depends on the
number of genes each variant was associated with, and the expression of
these genes in the dierent brain cell-types, i.e. astrocytes, oligodendrocytes,
microglia, endothelial cells, and neurons. We nally compared the cell-
specic annotations within each group of variants (Longevity-, AD- and
Unex-groups) using Wilcoxon sum rank tests and correcting p-values using
FDR, which indicated whether a group of variants was enriched for specic
brain cell-types (Figure 4.5).
4.2.7 Implementation
Quality control of genotype data, population stratication analysis and re-
latedness analysis were performed with PLINK (v2.0 and v1.9). All sub-
sequent analyses were performed with R (v3.6.3), Bash, and Python (v3.6)
scripts. All scripts are freely available at https://github.com/TesiNicco/
Disentangle_AD_Age.[24] Variant-gene annotation and gene-set enrich-
ment analyses were performed through the web-server that is freely accessi-
ble at https://snpxplorer.net.
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Table 4.1: Population characteristics
Population controls Cognitively Healthy Centenarians
Individuals 2,905 343
Females (%) 1400 (48.2%) 246 (71.7%)
Age (SD)
a
68.3 (11.5) 101.4 (1.8)
ApoE ε4 (%) 1012 (17.38) 48 (7.15)
ApoE ε2 (%) 523 (9.00) 91 (13.26)
a
, Age at study inclusion; SD, standard deviation; ApoE, Apolipoprotein E allele count for
the ε4 and ε2, and relative allele frequency in population controls and cognitively healthy
centenarians. References to the cohorts reported in this table are: [21, 19, 14, 22, 23, 20]
4.3 Results
4.3.1 AD-associated variants also associate with longevity
We explored the association with longevity of 38 genetic variants previously
associated with AD from GWAS (Table S1). We tested these variants in
343 centenarians who self-reported to be cognitively healthy (mean age at
inclusion 101.4±1.3, 74.7% females), as opposed to 2,905 population subjects
(mean age at inclusion 68.3±11.5, 50.7% females) (Table 4.1). We found a
signicant association with longevity for two variants after multiple testing
correction (FDR<5%, variants in the APOE gene; rs429358 and rs7412, Table
S2). We compared the direction of eect on longevity with that on AD
as found in literature: of the 38 variants, 28 showed an association in the
expected direction, i.e. alleles that increased AD risk were associated with
lower odds of longevity, and this was signicantly more than expected by
chance (p=0.005 including APOE variants, p=0.01 excluding APOE variants,
see section 4.2).
4.3.2 Distributions of the imbalance in the eect direction (IED)
To study the relationship between the eect on AD and longevity for all 38
AD-associated variants in more detail, we created distributions of the imbal-
ance in the variant eect direction (IED): Figure 4.1. The IED of a variant
indicates (i) whether the eects on AD and longevity are in the expected or
unexpected direction, and (ii) how the eetcs on AD and longevity relate
to each other. For example, the two variants rs7412 and rs429358 in APOE
gene signicantly associated with longevity in the expected direction and
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thus had tight condence intervals. The resulting IED relied completely in
the expected direction side (Figure 4.1). In addition, the eect on AD was
larger than that on longevity, causing the IED to slightly skew towards the
AD-side (Figure 4.1). However, as the association of a variant with longevity
became less strong (thus with larger condence intervals) or was in the
unexpected direction, the fraction of data points in the unexpected direction
increased. For example, for the intergenic variant rs6733839 close to BIN1
gene, we observed a larger eect on AD compared to cognitively healthy
aging (EBIN1AD = 0.17, SE = 0.01 and E
BIN1
LGV = −0.14, SE = 0.08, p = 0.09),
yet in the expected direction. The resulting IED is skewed towards the AD
side (Figure 4.1), and, due to large condence intervals on longevity, we
observed data points in the unexpected direction. Finally, variant rs593742
near ADAM10 gene (EADAM10AD = 0.08, SE = 0.01 and E
ADAM10
LGV = 0.06,
SE = 0.09, p = 0.49) associated with higher odds of both AD and longevity
(unexpected direction of eect), with a resulting IED largely on the unex-
pected side with fewer data points on the expected direction (due to large
condence intervals).
4.3.3 Grouping variants based on IED distributions
Based on the median value of each IED distributions, ˜IEDk , we grouped
the variants into (i) a Longevity-group (variants with a ˜IEDk skewed to-
wards the longevity-end of the spectrum), (ii) an AD-group (variants with a
˜IEDk skewed towards the AD-end of the spectrum), and (iii) an Unex-group
(variants with a
˜IEDk in the unexpected direction). The AD-group included
17 variants (in/near genes APOE (1), APOE (2), SCIMP, PLCG2 (1), MS4A6A,
BIN1, PILRA, APP, PLCG2 (2), CR1, SLC24A4, TREML2, ACE, APH1B, FERMT2,
PICALM, CD33) and the longevity-group included 11 variants (in or near
genes SHARPIN (1), SHARPIN (2), HS3ST1, EPAH1, IQCK, PRKD3, CD2AP,
PLCG2 (3), SPI1, HLA, EDHDC3), such that the eect of 28/38 (74%) of all
variants was in the expected direction. The eect of 10 variants was in
the unexpected direction, the Unex-group: (PTK2B, CLU, KANSL1, INPP5D,
ABCA7, CHRNE, SORL1, IL34, ADAM10, CASS4) (Figure 4.1).
4.3.4 AD-associated variants in large GWAS of longevity
To nd additional evidence for longevity associations, we inspected the AD-
associated variants’ eect in the largest GWAS on parental longevity.[6] Of
the 38 AD-associated variants, association statistics were available for 34 of
the variants (missing from Longevity-group: PLCG2 (3), SPI1; missing from
4
100 Chapter 4. The Alzheimer-Longevity axis
Figure 4.1: Overview of the 38 genetic variants associated with Alzheimer’s
disease. A. Genomic coordinates (with respect to GRCh37), variant identier, and
closest gene. B. The variant-pathway mapping score for the four functional clusters
(darker colors represent stronger associations). Variants reporting red crosses could
not be annotated as no biological processes were found to be associated with the
related genes. C. The eect size on AD (from literature) and the observed eect size
on longevity (LGV) for each variant (darker colors indicate stronger eect). The
same color indicates expected direction (i.e. increased risk of AD and decreased
chance of longevity), while dierent colors indicates unexpected direction. For
the longevity eects, we also annotate variants with a signicant association (*,
unadjusted p-value<0.05). D. The distribution of the imbalance direction of eect
(IED) of AD-risk and longevity (see section 4.2 for details). The Longevity-, AD- and
Unex-groups were derived based on the median value of the IED (blue vertical line).
E. Average expression of the genes associated with the variants in ve dierent
brain cell-types (the darker, the higher the expression).
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Unex-group: KANSL1, INPP5D). Overall, 21/26 (81%) of the variants in the
expected direction in our study (of which 6/9 variants in Longevity- and
15/17 variants in the AD-group), were also in the expected direction in the
independent parental longevity dataset. Variants in the expected direction in
the rst analysis are signicantly more likely to be in the expected direction
in the replication analysis than in the unexpected direction (p=0.01, based on
a binomial test, Figure 4.3). Six AD-associated variants reached signicance
in the parental-longevity GWAS after correcting for multiple comparisons
(FDR<5%): variants in the APOE gene (rs429358 and rs7412) and variants
in/near PRKD3 (rs8764613), CD2AP (rs9381564), APH1B (rs117618017 ) and
BIN1 (rs6733839). Of these, variants in/near PRKD3 and CD2AP belonged
to the Longevity-group in our analysis. Conversely, only 2/8 (25%) variants
that we observed in the unexpected direction in our study were also in
the unexpected direction in the parental-longevity GWAS, such that these
variants were not more likely to be in the unexpected direction (p=0.29, based
on a binomial test, Figure 4.2).
4.3.5 Functional characterization of variants
The 38 AD-associated variants included coding variants (N=10), intronic
variants (N=20), and intergenic variants (N=8) (Table S3). 12/28 of the in-
tronic/intergenic variants had eQTL associations. In total, the 38 variants
mapped to 68 unique genes, with most variants mapping to one gene (N=21)
and fewer mapping to 2 genes (N=10), 3 genes (N=2), 4 genes (N=1), 5 genes
(N=2), 6 and 7 genes (N=1, respectively) (Figure 4.6 and Table S3). We per-
formed gene-set enrichment analysis using a sampling-based approach to
explore the biological processes enriched in the 68 genes associated with
AD-variants (see section 4.2 and Figure 4.5). We found 115 signicantly
enriched biological processes after correction for multiple tests (FDR<5%,
Table S4). After clustering these terms based on their semantic similarity, we
found four main clusters of biological processes: (i) β-amyloid metabolism,
(ii) lipid/cholesterol metabolism, (iii) endocytosis/immune signaling and
(iv) synaptic plasticity (Figure 4.1, ?? and Table S5). Next, we calculated the
variant-pathway mapping score (see Methods and Figure 4.5), which indicates
how well a variant is associated with each of the 4 functional clusters. In total,
we calculated the variant-pathway mapping for 30 variants; we imputed the
annotation of 6 variants (Table S5), while 2 variants could not be annotated
(variants rs7185636 and rs1582763 in/near IQCK and MS4A6A genes), because
the associated genes were not annotated with any biological process function
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(Table S5). Finally, we tested whether the Longevity-, AD- and Unex-groups
were enriched for specic functional clusters by comparing the distribution
of variant-pathway mapping within each group (see section 4.2, Figure 4.3,
and Figure 4.5). The Longevity-group was signicantly (FDR<10%) enriched
for the endocytosis/immune signaling functional cluster; the AD-group for
the endocytosis/immune signaling, β-amyloid metabolism and to a smaller
extent for the synaptic plasticity functional clusters; the Unex-group was
mainly enriched for the endocytosis and β-amyloid metabolism functional
clusters.
4.3.6 Expression of AD-associated genes in brain cell-types
We explored whether specic brain cell types, i.e. astrocytes, oligodendro-
cytes, microglia, endothelial cells and neurons, were enriched within each
group of variants (see section 4.2 Table S5, and Table S6). Figure 4.1 shows
the collapsed cell-type expression for all 38 AD-associated variants. We
then tested the enrichment for cell-type expression within the Longevity-
, AD- and Unex-groups. The Longevity-group was signicantly enriched
for myeloid and endothelial cells, the AD-group for myeloid cells, while




Figure 4.2: Forest plot of association statistics of AD-variants in our study
and the largest GWAS of parental longevity. The plot shows the association of
AD-variants in our study and the largest by-proxy GWAS on parental longevity.[6]
The association statistics of 34/38 variants were available from publicly available
summary statistics of Timmers et al. study. [6] Plotted eect-sizes are with respect
to the AD-risk increasing allele. Thus, an expected direction of eect is shown
for variants with a negative estimate. Nominally signicant associations with AD
(p<0.05) are annotated with an asterisk (*), and signicant associations after FDR
correction are annotated with two asterisks (**).
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4.4 Discussion
4.4.1 Summary of the findings
We studied the eect on longevity of 38 genetic variants previously asso-
ciated with AD through GWAS.[13] We found that a majority of 74% of
the alleles that increase the risk of AD is associated with lower odds of
becoming a centenarian (expected direction). Overall, most variants (N=17)
had a larger eect on AD than on longevity: these variants were associated
with β-amyloid metabolism and endocytosis/immune signaling, and were
primarily expressed in microglia. A subset of variants (N=11) had a larger
eect on longevity than their eect on AD. These variants were associated
mostly with endocytosis and immune signaling, and they were expressed
in microglia and endothelial cells. These variant-eects were conrmed for
81% of the alleles in an independent dataset, the largest GWAS on parental
longevity. In contrast, 26% of the variants increased both the risk of develop-
ing AD and the risk of becoming a centenarian (N=10), (unexpected direction).
These unexpected eects could only be replicated for 2 of the variants in the
independent dataset, suggesting that the expected eects were more robust
across studies than the unexpected eects. Together, our ndings suggest
that a subset of variants associated with AD-risk may also aect longevity,
for example through their eect on other age-related diseases.
4.4.2 AD-associated variants and their eect on healthy aging
A single study previously explored the extent to which 10 AD-associated
variants aect longevity: apart from APOE locus, none of the other 10 tested
AD-associated variants signicantly associated with longevity.[25] In ad-
dition to APOE, four variants showed a negative eect on longevity while
increasing AD-risk (in/near ABCA7, EPHA1, CD2AP, and CLU ). In agreement
with these ndings, we also found that only the APOE variants signicantly
associated with longevity, and variants in/near EPHA1 and CD2AP belong
to the Longevity-group. However, in our study, we found that most alle-
les associated with an increased risk of AD associated with a decreased
chance of longevity. The inability to observe such an inverse relationship
between variant eects on AD and longevity in the previous study may be
explained by the relatively small sample sizes, combined with a low number
of (well-established) AD variants analyzed (N=10). In our study, groups sizes
were also relatively small, but the centenarians had a relatively high level of
cognitive health, which might have contributed to an increased eect size of
AD-associated genetic variants in our comparison.[15, 16]
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4.4.3 Dierent trajectories of eect of AD-associated variants on longevity
Variants with a larger eect on AD than longevity
For most variants with eects in the expected direction, the risk-increasing ef-
fect on AD was more extensive than the negative eect on survival/longevity.
These variants, which include both APOE alleles, might negatively aect
lifespan because carriers are removed from the population with increasing
age due to AD-associated mortality. For the APOE variants specically, the
distribution of the imbalance in the eect directions suggests a nearly similar
proportion of the increased risk of AD and decreased risk of longevity for
both APOE variants ˜IEDk ≈ 1/2. This explains why multiple previous studies
have associated APOE variants with longevity. In our cohort of centenarians,
the frequency of the deleterious ε4 allele is half of that of the population
controls (8% vs. 16%, respectively). In comparison, the frequency of the pro-
tective ε2 allele is nearly two-fold increased (16% vs. 9%).[15] Note, however,
that inclusion criteria of the centenarian cohort required them to self-report
to be cognitively healthy, which might have increased the observed longevity
eect. Apart from the APOE variants, the AD-group included 15 variants,
all of which were among the rst to be associated with AD through GWAS
(CR1, CD33, BIN1, MS4A6A, PICALM, and SLC24A4),[26, 27] eventually rep-
resenting variants with the strongest eect on AD.Functional annotation
showed signicant enrichment of β-amyloid metabolism, which aligns with
the importance of functional APP metabolism in maintaining brain health.
We also observed functional enrichment of endocytosis and immune signal-
ing, and a specic cell-type enrichment for microglia. This is in line with the
currently growing hypothesis of the involvement of immune dysfunctions
in the etiology underlying AD.[28, 29]
Variants with a larger eect on longevity than AD
The second-largest group of variants constituted a subset of 11 variants with
a larger eect on longevity than the eect on AD, which suggests that these
variants may be involved in other age-related diseases or general age-related
processes. The AD-association of most of these variants is relatively recent,
likely due to small eect sizes (ORs) or variants rareness (low minor allele
frequency, MAF); both features necessitate a very large number of samples to
identify these variants as signicantly associating with the disease. The vari-
ants within this group were specically enriched for immune response and
endocytosis, which are known hallmarks of longevity.[1, 30, 31] In addition
to the rare non-synonymous variant in the PLCG2 gene (rs72824905, MAF:
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0.6%), which was recently observed to be protective against AD, frontotem-
poral dementia (FTD) and dementia with Lewy bodies, other variants within
this group were previously linked with disease risk factors. One of the two
non-synonymous variants in the SHARPIN gene, variant rs34173062 (MAF:
5.7%), has been associated with respiratory system diseases in GWAS.[32, 33,
34] Variant rs7185636 (MAF: 17.1%), intronic of the IQCK gene, is in complete
linkage with a variant (rs7191155, R2=0.95), which was previously associated
with body-mass index (BMI).[35] The variant rs876461 (MAF: 13.0%) near the
PRKD3 gene is in linkage with variant rs13420463 (R2=0.42), which has been
associated with systolic blood pressure.[36] Further, the variant near CD2AP
gene associates with the development and maintenance of the blood-brain
barrier, a specialized vascular structure of the central nervous system which,
when disrupted, has been linked with epilepsy, stroke and AD.[37] Variant
rs9275152 (MAF: 10.4%) maps to the complex Human-Leukocyte-Antigen
(HLA) region, which codes for cell-surface proteins responsible for the reg-
ulation of the adaptive immune system. In numerous GWAS, variants in
the HLA region were associated with autoimmune diseases, cancer, and
longevity.[6, 38] The AD-associated variant in this region (rs9275152) is also
a risk variant for Parkinson’s disease.[39] Finally, the genomic region sur-
rounding the SPI1 gene (in which variant rs3740688 maps) has been previously
associated with cognitive traits (intelligence, depression)[40] and, with lower
evidence, with kidney disease and cancer.[41, 42] The remaining variants
rs56402156, rs7920721, and rs4351014 (in/near EPHA1, ECHDC3, and HS3ST1)
have not been directly associated with other traits, although their associated
genes were implicated in systemic lupus erythematosus (HS3ST1) and can-
cer (EPHA1, ECHDC3).[43, 44, 45] Together, these ndings suggest that the
counterpart of each risk-increasing allele, the AD-protective alleles, might
give a survival advantage that is not only specic to AD. Their functional
and cell-type annotations suggest that they contribute to the maintenance
of regulatory stimuli in the immune and endosomal systems, which may be
essential to maintain brain and overall physical health, necessary to reach
extremely old ages in good cognitive health.[16]
Variants associated with increased risk of AD and increased longevity risk
Unexpectedly, ten variants increased the risk of AD while at the same time
increasing the chance to reach ages over 100 in good cognitive health, which
is an unexpected balance. We note that the IED distributions of these variants
were broad, and in some cases even showed a bimodal behavior (in/near
KANSL1, IL34, CHRNE): this is attributable to the small eect-sizes (and
4
4.4 Discussion 107
Figure 4.3: Comparison of functional annotation and cell-type annotation
within the Longevity-, AD- and Unex-groups. A. The weights of the 4 func-
tional clusters within the Longevity-, AD- and Unex-groups. B. The weights of the
dierent cell-types in the brain, per group. Dierences in functional weights and
cell-type weights within each group were calculated using Wilcoxon sum rank tests.
The resulting p-values were FDR-corrected.
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large standard errors) on longevity for these variants, which caused data
points to easily ip between the expected and unexpected direction during
the sampling procedure. Replication of the direction of the variant eect in
an independent dataset of parental longevity indicated that the unexpected
direction was replicated in only the CLU and CHRNE variants, suggesting
that future studies will have to further explore (the robustness of) these
unexpected eects. One explanation for such counter-intuitive eects may be
a variant interaction with other variants, which was shown for the variant in
the KANSL1 and CLU gene with respect to the APOE genotype.[46] Therefore,
carrying the risk allele of such variants may specically aect the risk of AD
in APOE ε4 allele carriers, which are not prevalent among cognitively healthy
centenarians. An alternative explanation may be that these variants have
age-dependent eects: for example, high blood pressure at midlife increases
the risk of AD, but after the age of 85 a high blood pressure protects against
AD.[47] Similarly, a high body-mass-index (BMI) increases the risk of AD at
midlife, while being protective at older ages.[48] In line with this hypothesis,
the AD variant in/near IL34 gene codes for a cytokine that is crucial for
the dierentiation and the maintenance of microglia.[49] Although further
studies are needed, an excessive dierentiation in middle-age individuals may
increase brain-related inammation and AD-risk, while it might compensate
for the slower dierentiation and immune activity at very old ages. Indeed,
next to IL34, several genes that may be aected by these Unex-variants, such
as PTK2B and INPP5D, play a role in aging-associated processes, such as
cellular senescence or immunity.[50, 51]
4.4.4 Strengths and weaknesses
We acknowledge that our ndings are based on relatively small sample sizes,
especially for the cognitively healthy centenarian group. This phenotype
is rare, and individuals need to be individually approached for study inclu-
sion,[14] which is prohibitive for large sample collection. As population
subjects in our comparison, we used individuals from ve dierent cohorts:
all from the same (Dutch) population, all tested cognitively intact, and did
not convert to dementia at the time of analyses. It is known that the analysis
of genetic variants with small eect-sizes in relatively small sample sizes
leads to large condence intervals: we took this uncertainty into account by
bootstrapping eect sizes, causing the IED of several variants to be widely
spread. By focusing our analysis on SNPs that were genome-wide signif-
icantly associated with AD (thus habving tight condence intervals), we
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limited this dispersion to the eects-sizes on longevity only. For this reason,
we anticipate that using a random set of SNPs (e.g. to investigate the basic
properties of the IED), would increase further more the dispersion of data
points along the longevity-AD-unexpected spectrum, as condence intervals
on both longevity and AD would likely be larger. Although our work repre-
sents a rst step towards understanding the eect of AD-associated variants
on longevity, a replication analysis in larger cohorts of centenarians and/or
long-lived individuals is warranted to further support our ndings. Secondly,
in the functional annotation analysis, we had to deal with the problem that
the downstream eect of AD-associated variants is often unclear. To accom-
modate this uncertainty, we allower multiple genes to be associated with
each variant. However, it is likely that our variant-pathways annotation will
change as we gain more understanding about these variant-gene-eects, the
likely aected genes, and their functions. When we inspected the parental-
longevity GWAS, most of the variants that were in the expected direction in
our study were also in the same direction in the GWAS; however, this was not
true for all variants. The variant that deviated the most between our study
and the parental-longevity GWAS was rs9275152 in the HLA region: while
we clustered this variant in the longevity-group, in the parental-longevity
GWAS the direction of eect was opposite (i.e. unexpected), suggesting that
the variant increased the risk of AD and at the same time the chance of a
long lifespan. The genomic region to which HLA maps is biologically known
to be aected by many recombination events and may be population- and
environment-dependent, which may explain this divergence.[52] In addi-
tion to HLA-variant, variant rs34674752 in the SHARPIN gene reported the
second-largest eect-size in our study (after APOE ε4), while the eect-size
of this variant in the GWAS was very small, yet in the expected direction.
To this end, we note that the individuals used in the parental-longevity
GWAS were themselves not extremely old individuals, such that possible
pleiotropic eects at very old ages, as described earlier, may not be observable
in this GWAS. However, while we observed overall consistency in eect-size
direction for variants in the expected direction, 6/8 of the variants in the
unexpected direction were in the expected direction in the GWAS, with vari-
ants near SORL1, IL34, and ADAM10 having the most noticeable dierences.
We speculate that the relatively young ages of the GWAS samples, together
with the small sample size of our centenarian cohort may be the cause of
such discrepancy.
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4.4.5 Conclusions
Most AD-associated variants that increase the risk of the disease are associ-
ated with lower odds of longevity. We identied a subset of variants with
a larger eect on longevity than on AD, that were previously associated as
risk-factors for other age-related diseases, and that are selectively enriched
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4.7 Supplementary Methods
4.7.1 Populations
The 100-plus Study focuses on the biomolecular aspect of preserved cogni-
tive health until extremely old ages. This study includes (1) Dutch-speaking
centenarians who can (2) provide ocial evidence for being aged 100 years
or older, (3) self-report to be cognitively healthy, which is conrmed by an
informant (i.e. a child or close relation), (4) consent to donation of a blood
sample and (5) consent to (at least) two home-visits from a researcher, which
includes an interview and neuropsychological testing.[14] This study also
includes (1) siblings or children from centenarians who participate in the
100-plus Study, or partners thereof who (2) agree to donate a blood sample, (3)
agree to ll in a family history, lifestyle history, and disease history question-
naire. The Longitudinal Aging Study of Amsterdam (LASA) is an ongoing
longitudinal study of older adults initiated in 1991, with the main objective
to determine predictors and consequences of aging.[18, 19] The SCIENCe is
a prospective cohort study of subjective cognitive decline (SCD) patients.[20,
53] Participants undergo extensive assessment, including cerebrospinal uid
collection (CSF) and optional amyloid positron emission tomography scan
(PET), with annual follow-up. The primary outcome measure is clinical
progression. All individuals were labeled cognitively intact. The Netherlands
Brain Bank (NBB) cohort is a prospective donor program for psychiatric
diseases. All subjects were labeled cognitively intact after neuropathological
examination.[22] The Netherland Twin Registry study (NTR) was established
in 2004 to collect biological and environmental data in twin families to create
a resource for genetic studies on health, lifestyle, and personality.[23]
4.7.2 Genotyping and imputation
Genetic variants in our populations were determined by standard genotyp-
ing and imputation methods, and we applied established quality control
methods: we genotyped all individuals with the Illumina Global Screening
Array (GSAsharedCUSTOM-20018389-A2) and excluded individuals with low-
quality genotypes (individual call rate <98%, variant call rate <98%), individ-
uals with sex mismatches and variants deviating from Hardy-Weinberg equi-
librium (p < 1x10−6). Genotypes were prepared for imputation comparing
variants identiers, strand and allele frequencies to the Haplotype Reference
Panel (HRC v1.1, April 2016), and all remaining variants were submitted to
the Sanger imputation server (https://imputation.sanger.ac.uk).[54]
The server uses EAGLE2 (v2.0.5) to phase the data, and imputation to the ref-
4
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erence panel was performed with PBWT.[55, 56] Before analysis, we excluded
individuals of non-European ancestry and individuals with a family relation,




We annotated each variant to the likely aected gene(s), so-called variant-
gene mapping, combining annotation from Combined Annotation Dependent
Depletion (CADD, v1.3), expression-quantitative-trait-loci in the blood (eQTL
from GTEx v8), and positional mapping (from RefSeq build 98).[57, 58, 59]
In the case of coding variants, we condently associated the variant with
the corresponding gene. Alternatively, we rst considered possible eQTL
associations. When these were not available, we included all genes at increas-
ing distance d from the variant (starting with d ≤ 50kb, up to d ≤ 500kb,
increasing by 50kb until at least 1 gene was found). Our procedure allows
the association of each variant with one or multiple genes (Figure 4.5).
Gene-pathway mapping
The resulting list of genes was used to nd the molecular pathways enriched
in the AD variants. See Figure 4.5 for a schematic representation of our
annotation framework. We realized that allowing multiple genes to associate
with each variant could result in an enrichment bias, as neighboring genes
are often functionally related. To control this, we implemented a sampling
technique: at each iteration, we (i) sampled one gene from the pool of genes
associated with each variant, and (ii) performed a gene-set enrichment anal-
ysis with the resulting list of genes. The gene-set enrichment analysis was
performed considering biological processes (BP) and implemented with the
enrichGO function of the R package clusterProler, with all genes as back-
ground and correcting p-values controlling the False Discovery Rate (FDR).
Finally, we averaged p-values for each enriched term over the iterations
(N=1,000). To facilitate interpretation, we merged signicantly enriched
biological processes. First, we calculated the semantic similarity between all
signicant biological processes (i.e. FDR<5%) using Lin as a distance mea-
sure.[60] We then applied hierarchical clustering on the resulting distance
matrix and selected the number of functional clusters using the dynamic tree-
cut method as implemented in cutreeDynamic function from the R package
WGCNA, specifying 15 as the minimum number of terms per cluster (using
the default value of 20 resulted in 2 functional clusters only). To provide
4
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an interpretation of each functional cluster, we selected the most frequent
words describing the biological processes underlying each cluster, and show
this as word-clouds as implemented in R package wordcloud2. Finally, by
counting how often a functional cluster was associated with a gene, we could
calculate a weighted annotation of each gene to the 4 functional clusters,
so-called gene-pathway mapping (Figure 4.5). The variant-gene mapping as
well as the gene-pathway mapping procedures were performed using the
web-server application available at https://snpxplorer.net. [61] Due to
the initial selection of signicantly enriched BP, not every gene in the list
of variant-associated genes is annotated with (at least one of) these terms.
Consequently, these genes could not be related to the nal functional clusters.
To overcome this, we connect these genes to the functional clusters using a
k-nearest neighbor (k-NN ) imputation. The k-NN model was initially trained
using the functional clusters as classes and the semantic similarity matrix
between the enriched biological processes as features (feature terms). Then,
for each gene with missing annotation, we (i) extracted all the biological pro-
cesses the gene is involved in (input biological processes), and (ii) calculated
the semantic similarity matrix between these terms and the feature terms,
which denes the similarity between the input biological processes and the
feature terms. Finally, we (iii) predicted the probability of classication of
the similarity matrix to the classes (functional clusters), and used this as
weight for the gene-pathway mapping (Figure 4.5).
Variant-pathway mapping
The variant-pathway mapping represents the combined annotation of each
variant to the dierent functional clusters. As such, it depends on the variant-
gene mapping and the gene-pathways mapping. Briey, given a variant k,
we (i) retrieved all the genes that were associated with the variant in the
variant-gene mapping, Gk , and (ii) retrieved all the biological processes
(gene ontology term identiers) that were associated with these genes, GOG.
Because we clustered biological processes into functional clusters, by looking
at which functional clusters the GOG belonged to, we could assign a weight
of association for variant k to each of the functional clusters.
4.7.4 Variant-cell-type mapping
To study brain-specic cell-types and their relationship with AD-associated
variants, we used the publicly available gene expression dataset GSE73721:
this dataset includes gene expression values of 6 fetal astrocyte samples, 12
adult astrocyte samples, 8 sclerotic hippocampal samples, 4 whole human
4
116 Chapter 4. The Alzheimer-Longevity axis
cortex samples, 4 adult mouse astrocyte samples, and 11 human samples
of other puried central-nervous-system (CNS) cell-types. We restricted
to the gene expression of 12 astrocyte samples and 11 samples of puried
CNS cell-types from the cortex of adult humans (total N=23, mean age of
41.5±19.6 years). To calculate the variant-cell-type mapping, we averaged
the gene expression of the genes mapping to the same variant.
4
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4.8 Supplementary Figures
Figure 4.4: Explanation of the distribution of imbalance variant eect direc-
tion (IED). The gure shows the sequential steps for constructing the distribution
of the expected direction of variant eect for AD-risk compared to longevity for
two toy variants (SNP1 and SNP2). A. Axes denition, with the y-axis being the
eect-size for AD-risk (log of odds ratio) of a variant, derived from literature and set
positive by denition. The x-axis identies the eect-size of a variant on longevity.
This can be either positive or negative depending on the variant’s association in
cognitively healthy centenarians as opposed to population subjects. The blue area
represents that the two eects are in the expected direction with respect to each
other, i.e. a variant increases the risk of AD and at the same time decreases the
chance of longevity. Oppositely, the grey area refers to the unexpected direction
of eect. B. Two toy variants (SNP1 and SNP2) are shown as data points. α(1−2)
represents the angle of the data point vector with the x-axis. C. Normalization of
the α(1−2) value into an arbitrary space. Here, we used [−1;1]. D. Repeating this
procedure for each bootstrap iteration of each variant, we obtained the distribution
of imbalance eect direction for each variant (IED). Values smaller than 0 indicate
the expected direction of eect, whereas values larger than 0 refer to the unexpected
direction of eects. Additionally, values close to 0 indicate a larger AD eect than
longevity eect, and values close to -1 suggest that the variant’s longevity eect is
larger than the AD eect.
4
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Figure 4.5: Schematic representation of the variant-pathway and variant-
cell-typemapping. The gure shows a schematic representation of the annotation
framework used to functionally annotate AD-associated variants and perform cell-
type enrichment. Outputs are represented as blue squares, while methods are
represented in orange. In the variant-gene mapping, showed in the grey box,
we start from a list of variants and, through the integration of predicted variant
consequences (CADD), eQTL and position, we obtain a list of genes. Note that here
multiple genes may be associated with each variant. The yellow box shows the
gene-pathway mapping: briey, we perform gene-set enrichment analysis followed
by clustering of the signicantly enriched pathways to obtain functional clusters.
We then calculate the gene-pathway mapping by looking at the (enriched) pathways
associated with each gene and their associated functional clusters to get a weight
for each gene-functional cluster association. Finally, we average the gene-pathway
mapping of each gene associated with the same variant. Imputation methods (k-NN )
are implemented for genes with missing annotation to obtain the gene-pathway
mapping. Together, the grey box and the yellow box form the variant-pathway
mapping. At the bottom, the green box shows the gene-cell-type enrichment using
the public dataset GSE73721 of gene expression in dierent brain cell-types. Similar
to the gene-pathway mapping, we calculate a weight of association of each gene to
each cell-type, and we average these weights in case multiple genes mapped to the
same variant (variant-cell-type mapping).
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Figure 4.6: Variant-gene mapping for the 38 AD-associated variants. A. The
sources used to annotate each variant to the likely aected genes. Coding: variants
located in the coding region of a gene (e.g. synonymous or non-synonymous
variants). eQTL: variants associated with RNA expression changes in blood from
the GTEx consortium. Position: variants intronic or intergenic without evidence of
eQTL associations that were annotated based on neighboring genes. B. Barplot of
the number of genes associated with each variant. C. Distribution of genes across
the chromosomes. D. Distribution of the previously identied variants along the
genome together with each variant’s minor allele frequency and annotation.
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4.9 Supplementary Material
Supplementary Tables can be accessed by scanning the following code or
accessing the journal’s website here.
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5. Genetic predisposition to longevity
Polygenic risk score of longevity predicts longer sur-
vival across an age-continuum
Niccolo’ Tesi, Sven J. van der Lee, Marc Hulsman, Iris E. Jansen,
Najada Stringa, Natasja M. van Schoor, Martijn Huisman, Philip Schel-
tens, Wiesje M. van der Flier, Marcel J.T. Reinders, and Henne Holstege





Studying the genome of centenarians may give insights into the molec-
ular mechanisms underlying extreme human longevity and the escape
of age-related diseases. Here, we set out to construct polygenic-
risk-scores (PRS) for longevity and to investigate the functions of
longevity-associated variants. Using a cohort of centenarians with
maintained cognitive health (N=343), a population-matched cohort of
older-adults from ve cohorts (N=2,905), and summary statistics data
from a GWAS on parental longevity, we constructed a PRS including
330 variants that signicantly discriminated between centenarians
and older-adults. This PRS was also associated with longer survival in
an independent sample of younger individuals, (p=0.02), leading up to
a 4-year dierence in survival based on common genetic factors only.
We show that this PRS was, in part, able to compensate for the delete-
rious eect of the APOE-ε4 allele. Using an integrative framework,
we annotated the 330 variants included in this PRS by the genes they
associate with. We nd that they are enriched with genes associated
with cellular dierentiation, developmental processes, and cellular
response to stress. Together, our results indicate that an extended
human lifespan is, in part, the result of a constellation of variants
each exerting small advantageous eects on aging-related biological
mechanisms that maintain overall health and decrease the risk of
age-related diseases.
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5.1 Introduction
The human aging process is inuenced by genetic and environmental factors,
which makes it one of the most complex traits to study.[1, 2] Previous studies
estimated that the heritability of lifespan up to ∼70 years of age ranges 10-
25%.[3, 4] However, to reach higher ages we become increasingly dependent
on the favorable genetic elements of our genomes. In fact, the heritability of
becoming a centenarian has been estimated to be 60%.[5] Interestingly, cen-
tenarian genomes are depleted of single-nucleotide-polymorphisms (SNPs)
associated with age-related diseases, while they are enriched with protective
SNPs.[6, 7] Therefore, studying the genetic variants enriched in centenarians
may give insights into the underlying etiology of extreme human longevity.[6,
7]
The research of SNPs that inuence the human lifespan has focused
mainly on the replication of candidate genes discovered in model organ-
isms.[8, 9] Recently, genome-wide association studies (GWAS) have been per-
formed to identify genetic loci associated with longevity. GWAS of longevity,
in which the frequency of genetic variants is compared between long-lived
persons and the average population, do not require prior knowledge and
have the potential to discover new genetic determinants.[10] These studies
have identied a constellation of SNPs associated with a longer lifespan
across a wide range of populations.[11, 12, 13, 14, 15, 16] However, the associ-
ation of the identied genetic loci has typically a low replication rate across
independent studies, with only the APOE-ε4 allele (variant rs429358) and
genetic variants in CDKN2A/B gene consistently associated with reduced
lifespan.[11, 14, 15, 17] The diculty in replicating longevity-associated SNPs
may be attributable to dierent measures of survival and longevity, dierent
statistical methods, and population dynamics.[8, 15, 18] For example, some
studies used a dichotomous longevity phenotype based on the survival to
ages above 90 or 100 years, others used the top 10% or 1% of survivors in a
population,[12, 14] while other studies modeled age at death as a continuous
variable and yet others used more sophisticated statistical models.[13, 15]
On top of methodological and phenotypical divergencies between studies,
population dynamics including gene-environmental interactions and popu-
lation biases may potentially have a large eect on longevity,[18] and might
explain the poor replication rate in independent cohorts. Lastly, the genetic
variants identied thus far carry small eects, such that large sample sizes
are required for an association with longevity to reach statistical signicance
in a GWAS setting.[8] Although poorly replicated, 29 genomic regions have
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been associated with a longer lifespan in the most recent GWAS studies.[11,
12, 14, 15, 16, 18] The genes that harbor these variants have been implicated
in age-related diseases including cardiovascular diseases (APOE, ANRIL),
type I diabetes (FOXO3, LPA), cancer (CDKN2B, BEND4), and neurological
diseases (APOE, GPR78, GRIK2).[13, 15] Together, this suggests that an ex-
tended human lifespan is associated with a lower genetic risk of age-related
diseases.[8, 15, 19] Indeed, centenarians across populations have been shown
to compress their disability period to the very end of their lives, escaping or
delaying age-related diseases until extreme ages.[5, 20, 21, 22]
We hypothesize that variants associated with longevity are maximally
enriched in cognitively healthy centenarians because, in addition to reaching
at least 100 years ( 1% of the population), these centenarians are cognitively
healthy, and represent an even smaller percentage of the general population
(∼0.1%).[20] We previously found that the selection for cognitive health next
to being 100 years or older is associated with prolonged longevity in this
cohort compared to centenarians from the general population.[20, 21, 22,
23] Therefore, the centenarians in this cohort represent the ideal group to
construct and test polygenic risk scores for longevity. A polygenic risk score
(PRS) is a weighted score of independent variants representative of the risk to
develop a phenotypic trait and can be used to study the combined inuence
of genetic factors on a certain trait. Although a PRS of parental longevity was
previously associated with survival, validation in a cohort of extremely old
individuals is missing. Besides, to prioritize SNPs to include in the PRS using
a cohort of cognitively healthy agers may improve association statistics of the
PRS. In this study, we started from 29 genomic regions previously associated
with longevity: we annotated SNPs to likely aected genes and sought to
detect signicant associations using gene-based tests as opposed to single
variant associations. Importantly, we constructed polygenic risk scores (PRS)
combining the eect of multiple variants and tested the association of the
risk scores (i) with becoming a cognitively healthy centenarian, and (ii) with
survival in a subset of controls with follow-up data. We further explore the
relationship between the PRS and the deleterious eect of APOE-ε4 allele,
and using an innovative framework, we functionally annotate the variants
included in the best PRS model.
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5.2 Results
5.2.1 Study population
We studied the genetics underlying extreme human longevity in a case-
control setting using as cases individuals that reached at least 100 years
of age and who self-reported as cognitively healthy. As controls, we used
a sample of population-matched, older-adults drawn from ve dierent
studies (see section 5.4). After establishing quality control of the genotyping
data, 343 cognitively healthy centenarians (mean age at inclusion 101.4±1.8,
71.7% females) and 2,905 controls (mean age 68.3±11.5, 48.2 % females) were
included in the analyses (Table S1).
5.2.2 Linking genetic variants with genes
We linked genetic variants previously associated with longevity (Table S2)
to their likely aected genes. However, for non-coding variants, the closest
gene is not necessarily the aected gene. Of the 29 investigated variants,
only a few are coding (N=5), while most are intronic (N=16) or intergenic
(N=8), for which variant consequences are unclear. To investigate the variant-
eect on gene function, we combined variant consequences as predicted
by the Combined Annotation Dependent Depletion (CADD),[24] expression
quantitative-trait-loci (eQTL) in blood from the Genotype-Tissue Expression
(GTEx) consortium,[25] and positional information to associate each variant
to the gene(s) it likely aects. This allows each genetic variant to associate
with one or more genes, depending on annotation certainties. With this
procedure, the 29 genetic variants mapped to 65 unique genes: 16 SNPs
mapped to 1 gene, while 6 mapped to 2 genes, 4 to 3 genes, 1 to 6 genes, 1 to
8 genes, and 1 to 12 genes (Figure 5.5 and Table S3). This annotation tool is
freely accessible to the community at https://snpxplorer.eu.ngrok.io.
5.2.3 Combined association of multiple variants at the gene level
While single variant associations represent the standard procedure for GWAS,
we hypothesized that testing the aggregated association of multiple variants
across a gene might improve association statistics. In total, we tested the joint-
association of variants at the gene-level for 53/65 genes using the MAGMA
statistical framework (see section 5.4).[26] After correction for multiple tests
(False Discovery Rate, FDR), the association of APOE and CDKN2B genes
remained signicant at FDR<10% (p=3.14x10−12 and p=0.002, respectively,




































































Figure 5.1: Association of the PRSs with becoming a cognitively healthy cen-
tenarian and the eect of inclusion of sub-signicant variants. The top panel
shows the number of variants (in log10 scale) included in each PRS (including APOE
variants). The bottom panel shows the p-value of the dierence in PRS score between
the cognitively healthy centenarians and controls. Circles denote PRSs including the
APOE variants and triangles PRSs without the APOE variants. Red points refer to the
most signicant models including and excluding APOE, respectively. Known refers
to the PRS including the 29 previously identied variants associated with longevity.
PRS-x refers to the PRS including additional sub-signicant variants depending on
the p-value of association of the variants in the by-proxy GWAS on longevity: PRS-8
for variants with p<5x10−8; PRS-7 for variants with p<5x10−7; PRS-6 for variants
with p<5x10−6, etc.
5.2.4 Polygenic Risk Scores
A polygenic risk score (PRS) is a weighted score of independent variants
that quanties the genetic risk to develop a certain trait. As weights for the
PRS, we used eect-sizes as found in the summary statistics of the largest
GWAS on parental longevity.[15] First, we constructed a PRS using the pre-
viously identied longevity variants and tested the association of the PRS
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with becoming a cognitively healthy centenarian. We found a signicant
association of the PRS (OR=1.42, 95% CI=[1.26-1.60], p=6.59x10−9), mainly
driven by APOE variants (when excluding the APOE variants: OR=1.07, 95%
CI=[0.96-1.20] and p=0.22) (Figure 5.1 and Table S5). Single-variant associa-
tion of these variants is available in Table S6. Next, we investigated whether
the addition of sub-signicant, independent longevity variants increased the
association of the PRS with becoming a cognitively healthy centenarian (see
section 5.4). The number of additionally included variants to the PRS was
based on the association p-value as found in the summary statistics provided
by Timmers et al.: PRS-8 (p<5x10−8, 19 variants in total), PRS-7 (p<5x10−7,
42 variants in total), PRS-6 (p<5x10−6, 94 variants), PRS-5 (p<5x10−5, 332
variants), PRS-4 (p<0.0005, 1,216 variants), PRS-3 (p<0.005, 3,620 variants),
PRS-2 (p<0.05, 8,339 variants) and PRS-1 (p<0.5, 16,926 variants) (Figure 5.1,
Table S5, Table S7). For all these PRSs, we tested the dierence between
cognitively healthy centenarians and population controls. We observed a
consistent direction of the eect for all PRSs, with centenarians having on
average a higher score than population controls. Including APOE variants,
we found that the most predictive PRS was the PRS-6, which comprised 96
independent variants (OR=1.44, 95% CI=[1.28-1.61], p=8.39x10−10). Exclud-
ing APOE variants, the most predictive PRS was the PRS-5, comprising 330
independent variants (OR=1.27, 95% CI=[1.13-1.42], p=4.05x10−5, Figure 5.1,
Figure 5.7 and Table S5, Table S7). Single-variant association for all variants
is available in Table S8. A more stringent correction for population eects,
including 5 additional PCs as covariates, did not change our ndings (Table
S9). Of note: while controls were a combination of dierent cohorts, we did
not observe cohort-specic associations (Table S10 and Figure 5.11).
5.2.5 Survival analysis
We investigated whether the PRS could predict survival in a subset of the
population controls for which follow-up data were available. To investigate
the association of the PRS with survival considering APOE variants, we
performed a survival analysis using the PRS without APOE variants with the
highest evidence of association in our cohort, i.e. PRS-5. We performed a mul-
tivariate Cox regression to estimate the association of the PRS-5 with survival
while adjusting for age at inclusion, gender, population substructure, and
APOE-ε4 carriership. The PRS-5 was signicantly associated with survival
in the expected direction (hazard ratio, HR=0.89, 95% CI=[0.80-0.98], p=0.02),
i.e. having a higher PRS corresponded to reduced mortality. At 50% survival
5
5.2 Results 135




























































Figure 5.2: Association of the PRS-5 model without APOE on survival, strat-
ied by APOE-ε4 status. The top panel shows the survival curves for individuals
with high-PRS and low-PRS, stratied by APOE-ε4 status (dichotomized in “carriers”
of APOE-ε4 allele and non-carriers) in the population controls for which follow-up
data were available (N=1,620). The p-value refers to the association of the PRS-5 in
the multivariate Cox regression model while adjusting for gender, APOE-ε4 carrier-
ship (dichotomized), and population substructure (PCs 1-5). The lower panel shows
the number of samples in each category.
probability (P50), this resulted in 3.86-year dierence in survival between
individuals with low-PRS that were APOE-ε4 carriers, and those with high-
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PRS that were not APOE-ε4 carriers (Figure 5.2). We observed that APOE-ε4
carriers with a low-PRS had the shortest survival (P50 CI=[0.39-0.65] at age
84.7), followed by non-APOE-ε4 carriers with low-PRS (P50 CI=[0.43-0.58]
at age 87.5), then, APOE-ε4 carriers with high-PRS (P50 CI=[0.38-0.63] at
age 88.5) while individuals non-APOE-ε4 carriers with high-PRS survived
longest (P50 CI=[0.43-0.59] at age 88.6) (Figure 5.2 and Table S11). However,
we did not observe a signicant interaction eect of PRS and APOE-ε4 status
(p=0.27). In line with the known dierence in longevity between males and
females, gender was signicantly associated with survival (HR=1.82 for males
compared to females, 95% CI=[1.48-2.26], p=2.72x10−8). A separate analysis
in males and females suggested that the PRS was more strongly associated
with survival in males than in females (HRM=0.88, 95% CIM=[0.75-1.03] and
pM=0.11; HRF =0.93, 95% CIF=[0.80-1.05] and pF =0.24, Figure 5.8). How-
ever, we did not nd a signicant interaction eect between PRS and gender
(p=0.60).
5.2.6 Functional annotation of PRS
We studied the functional implications of the 330 variants included in PRS-5.
First, we linked these variants to 471 unique genes (see section 5.4, Figure 5.9
and Table S12). Then, we looked in the GWAS catalog which variants and
associated genes, included in our PRS-5, were previously found to associate
with any trait. At the variant-level, of the 330 unique variants, 46 were
reported to associate with in total 115 previously analyzed traits, including
diseases such as coronary artery disease (CAD, NSNP =13), blood pres-
sure (NSNP =9), and cardiovascular diseases (NSNP =13), but also smoking
(NSNP =5) and parental longevity (NSNP =7) (Figure 5.3B). At the gene-
level, 300 of the 471 genes in our list were previously associated with lipid
metabolism, CAD, neurological traits, and immunological signatures (Fig-
ure 5.3C). Next, we performed a gene-set enrichment analysis to explore
the biological processes enriched in the 471 PRS-5-associated genes (see sec-
tion 5.4, also available at https://snpxplorer.eu.ngrok.io). We found
48 biological processes signicantly enriched after correction for multiple
tests (FDR<5%, Table S13), which we reduce to 8 by clustering similar terms
together based on semantic similarity measures. These terms pointed to-
wards regulatory and dierentiation processes, cellular response to stress,
and nervous system development (Figure 5.3A and Table S14). To evaluate
the performance of our novel sampling-based method with respect to a tra-
ditional gene-set enrichment analysis, we applied the latter to the same 471
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genes and we compared the results of both methods. The traditional gene-set
enrichment analysis yielded 122 signicantly enriched pathways, of which
45 pathways overlap with the 48 signicant pathways identied using the
sampling-based approach (Table S15). This suggests that our sampling-based
approach may be considered conservative compared to traditional gene-set
enrichment analyses.
5.2.7 Gene expression of longevity-associated genes
Finally, we studied the expression of the genes linked with the previously
identied longevity variants as well as with the PRS-5-associated variants,
using a publicly available dataset comprising RNA expression from the
hippocampus region in the brain. We compared the RNA-expression in
individuals aged 30-65 years (young, N=13) as opposed to those aged >80
years (old, N=16). We found that 174/432 available genes were dierentially
expressed after correction for multiple tests (FDR<5%, Figure 5.4 and Table
S16): 41 genes were over-expressed in old individuals, while 133 were over-
expressed in young individuals.
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Figure 5.3: Functional enrichment analysis of variants included in PRS-5
and likely associated genes. A. Signicantly enriched biological processes after
merging similar terms based on semantic similarity. Color: encodes signicance.
Dot size represents the total number of genes associated with that term. B. The 10
GWAS catalog terms that have the most overlapping variants in PRS-5. C. The top
GWAS catalog terms that have the most overlapping genes that associate with the
variants in PRS-5.
5.3 Discussion
In this study, we investigated the SNPs underlying extreme human longevity
using a sample of cognitively healthy centenarians from the 100-plus Study
cohort and a sample of population-matched older-adults. We constructed
a polygenic risk score (PRS) comprising 330 variants that was capable of
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distinguishing between cognitively healthy centenarians and population
controls. This PRS was signicantly associated with survival in an indepen-
dent sample of individuals and may compensate, in part, for the increased
mortality risk associated with the APOE-ε4 allele. Using a novel framework,
we functionally annotated the variants included in the PRS, which indicated
that these were previously associated with cardiometabolic, immunological,
oncological, and neurodegenerative conditions. Functional annotation of the
genes most likely aected by these variants revealed a signicant enrichment
for regulatory and dierentiation processes, cellular response to stress, and
nervous system development.
We constructed a PRS that was associated with becoming a cognitively
healthy centenarian and also with prolonged survival across an age contin-
uum, even after excluding the two APOE alleles which associated strongest
with longevity. Including APOE alleles, the PRS comprising 29 previously
associated variants signicantly associated with becoming a cognitively
healthy centenarian, and association statistics only slightly improved upon
the addition of variants that sub-signicantly associated with longevity.
After excluding APOE variants, the association of this PRS was not signi-
cant, likely due to the dierent populations and study designs in which the
longevity-association of the 29 variants were identied, their low number,
and the small eect-sizes. However, the inclusion of sub-signicant vari-
ants boosted the predictive performance of the PRS, which indicated that
these sub-signicant variants provide additional distinguishing power, but
in aggregate, this is relatively little compared to the strong APOE eect. The
predictive power of the PRS including 330 variants was highest, and having
a high-PRS score associated with longer survival in an independent sample
of older-adults. We did not identify single-variants driving the increase in
distinguishing power eect, such that we assume that all variants contributed
similarly. Adding even more variants with lower signicance to the PRS
decreased association statistics, which eventually stabilized, likely due to
random uctuation of the data.
We explored the relationship between PRS and APOE-ε4 carriership:
fully according to expectations, APOE-ε4 carriers with a low-PRS had the
lowest survival, while as expected, non-APOE-ε4 carriers with a high-PRS
survived longest, on average 3.86 years longer. Between these extremes, non-
APOE-ε4 carriers with low-PRS had lower survival compared to APOE-ε4
carriers with a high-PRS. This suggests that the variants in the PRS may
compensate for the strong disease/mortality risk-increasing eect exerted by
the APOE-ε4 allele, however, replication in a large and independent dataset
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is needed to conrm this nding. A number of studies described this eect in
dementia, and although the results did not strongly replicate across dierent
studies, several variants (e.g. rs5882 in the CETP gene and rs4934 in the
SERPINA3 gene) were reported to exhibit buering eects with respect to
APOE-ε4.[27, 28] The majority of the variants included in the best PRS were
previously associated with age-related conditions and parental longevity.
Given that the variants included were selected from a study on parental
longevity, this was not surprising. Functionally, genetic variants were asso-
ciated with metabolite- and lipid measurements (serum metabolites, total
cholesterol, high- and low-density lipoproteins), cardiovascular-related traits
(blood pressure, coronary artery diseases, obesity, smoking), neurological
conditions (multiple sclerosis, schizophrenia, bipolar disorder) and immuno-
logical signatures (IgG glycosylation levels, Crohn’s disease, celiac disease).
These traits have been associated with longevity either directly, as part of
known hallmarks of aging, or indirectly, through their eect on age-related
diseases.[1, 8] Likewise, when we investigated the genes associated with the
variants in the PRS, we observed an enrichment for mechanisms associated
with the aging individual: chronic low-grade inammation, cellular stress,
and a reduced speed of cell-replacement, development, and dierentiation.[1]
Recently, increased parental lifespan was associated with a lower PRS of
LDL-cholesterol levels, systolic blood pressure, and body mass index.[15] We
previously showed that cognitively healthy centenarians have a signicantly
lower PRS of Alzheimer’s Disease (AD) compared to population controls.[29]
The overlap between the variants that contribute to the AD-PRS and our
best longevity-PRS is limited: apart from APOE variants, the longevity-
associated variant rs9665907 is in LD with the known AD-variant rs11218343
(in/near SORL1, R2=0.39),[30] and the variant rs6558008 is in low LD with
the known AD-variant rs9331896 (in/near CLU, R2=0.05).[31] This suggests
that, in addition to the eect of APOE alleles, the SORL1- and CLU -associated
signals may partly overlap in the genetic association of AD and longevity
(in opposite directions). Two other studies investigated the relationship
between longevity and risk alleles for several age-related diseases: one
was able to discriminate between long-lived individuals and controls,[32]
while the other did not nd signicant dierences between centenarians
and controls.[33] We speculate that the main reason for this discrepancy is
that our PRS was constructed based on the association statistics from a well-
powered GWAS, which was not available when the previous studies were
performed. Additionally, the stricter selection criteria of the centenarians
from the 100-plus Study may have contributed to the discriminative power
5
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Figure 5.4: Volcano plot of 432 genes associated with the PRS-5 variants and
with the previously identied variants, representing the dierence in RNA
expression in thehippocampus region of the brain betweenyoung individu-
als (N=16) and old individuals (N=13) (publicly available dataset GSE11882).
All individuals were reported to be cognitively healthy at the time of death. Or-
ange diamonds refer to 33 genes associated with the previously identied variants.
Annotations are shown for the 15 most signicant genes as well as for the 3 most
signicant genes that overlap between the two gene sets.
of the PRS.
Across populations, extreme longevity is known to be more prevalent
among females than males, which likely reects gender dierences of envi-
ronmental exposure, disease predisposition, and genetics.[34] In our study,
we found that the eect-size of the PRS on male-survival was larger com-
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pared to female-survival, suggesting that males depend more on having
advantageous genetic variants to reach extreme ages than females. In the co-
hort investigated, an important environmental gender-dierence is smoking
behavior: in accordance with the smoking behaviors in their birth cohort,
76% of the centenarian males had smoked regularly during their lifetime,
compared to only 15% of the females.[35] Biological dierences may also
play a role: estrogens protect females from cardiovascular diseases during
their fertile period,[34, 36] produce more vigorous cellular and humoral
immune reactions, and are more resistant to infections caused by viruses
and other pathogens.[34] From a genetic perspective, impairments in DNA-
repair mechanisms become more prevalent with increasing ages, but there
are indications that this eect starts a decade earlier in males compared to
females.[36] Also, several studies reported that women have longer telomeres
compared to males.[36] Together, these studies suggest that females may be
more inherently predisposed to live longer than males and that dierential ex-
posure to hazardous environments may lead to selective survival of resilient
males. Although conclusive evidence that explains the gender-dierences
in longevity is still lacking, these aspects may in part explain our nding
that males are more dependent on an advantageous genetic background to
reach extreme ages than females. Note that we did not nd a signicant
interaction eect between PRS and gender, therefore these ndings will have
to be replicated in a larger cohort.
5.3.1 Strengths and limitations
Linking variants with genes likely aected is dicult: as such, exploiting
diverse sources of variant annotations, such as predicted variant conse-
quences, eQTLs, and genomic position is essential to pinpoint the genes
likely associated with a variant. We designed a novel framework that al-
lows multiple genes to associate with each variant, in which we consider
the annotation-certainties when performing gene-set enrichment analyses.
A limitation of our analysis is that our cohort of centenarians is relatively
small compared to the sample sizes of previous GWAS. Due to the rarity of
this phenotype in the general population, the collection of large cohorts is
prohibitive.[20] As a consequence of the limited size, we could not perform
exhaustive sex-stratied analyses and thus we cannot exclude that we failed
to identify sex-specic associations. Centenarians were compared with a
sample of controls combined from dierent cohorts, yet from the same Dutch
population, which may be considered as a strength of our study. While the
5
5.3 Discussion 143
inclusion of dierent cohorts with dierent inclusion criteria had maximized
the available sample size in our study, this could potentially result in con-
founding eects. However, we assessed that no signicant cohort-specic
association or population eect aected our results, both at the single-variant
and PRS level. We note that our cohort of centenarians was collected in a
specic area during a specic time such that location- and period-eects may
inuence genetic associations. This may in part challenge the replication
of the current ndings in long-lived individuals from other populations or
collected at dierent times.
5.3.2 Conclusions
We showed that a longevity PRS comprising 330 variants is signicantly
associated with cognitively healthy aging and with prolonged survival. We
found suggestive evidence that the PRS compensates for the deleterious eect
of high-impact APOE-ε4 allele and with a novel approach, we functionally
annotated the variants in this PRS, showing that many of these variants
were previously associated with age-related diseases and with aging-related
cellular mechanisms.
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5.4 Methods
5.4.1 Study population
As cases, we used a sample of 358 participants from the 100-plus Study
cohort.[20] This study includes Dutch-speaking individuals who can provide
ocial evidence for being aged 100 years or older and self-report to be
cognitively healthy. As controls, we used (i) a sample of 1,779 Dutch older-
adults from the Longitudinal Aging Study of Amsterdam (LASA),[37] (ii) a
sample of 1,206 older-adults with subjective cognitive decline that visited
the memory clinic of the Alzheimer center Amsterdam and SCIENCe project,
who were labeled cognitively normal after extensive examination,[38] (iii)
a sample of 40 healthy controls from the Netherlands Brain Bank,[39] (iv)
a sample of 201 individuals from the twin study,[40] and (v) a sample of 86
older-adults from the 100-plus Study (partners of centenarian’s children).
Individuals with subjective cognitive decline were followed over time in the
SCIENCe project, and only individuals who did not convert to mild-cognitive-
impairment (MCI) or dementia during follow-up were included in this study.
We checked whether the inclusion of controls from cohorts with dierent
inclusion criteria was problematic in terms of cohort-specic associations
both at the single-variant level (Table S10) and at the PRS-level (Figure 5.11).
The Medical Ethics Committee of the Amsterdam UMC (METC) approved all
studies. All participants and/or their legal representatives provided written
informed consent for participation in clinical and genetic studies.
5.4.2 Genotyping and imputation procedures
Genetic variants in our cohort were determined by standard genotyping
or imputation methods and we applied established quality control meth-
ods. All individuals were genotyped using Illumina Global Screening Array
(GSAsharedCUSTOM-20018389-A2). We used high-quality genotyping in
all individuals (individual call-rate >98%, variant call-rate >98%), individuals
with sex mismatches were excluded and departure from Hardy-Weinberg
equilibrium was considered signicant at p<1x10−6. Genotypes were pre-
pared for imputation using available scripts (HRC-1000G-check-bim.pl) to
compare variant ID, strand, and allele frequencies to the Haplotype Reference
Panel (HRC v1.1, April 2016).[41] All autosomal variants were submitted to
the Sanger imputation server (https://imputation.sanger.ac.uk). The
server uses MACH to phase data and imputation to the reference panel was
performed with PBWT. A total of 3,312 population subjects and 358 cente-
narians passed quality control. Prior to analysis, we excluded individuals of
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non-European ancestry based on 1000Genomes clustering and individuals
with a family relationship based on identity-by-descent >0.2.[42] This led
to the exclusion of 8 centenarians and 197 controls (non-European) and 7
centenarians and 210 controls (family relations), leaving 2,905 older-adults
and 343 cognitively healthy centenarians for the analyses.
5.4.3 Mapping genetic variants to aected genes
We selected 29 genetic variants for which there was evidence of a signicant
association with longevity from previous GWAS and candidate-gene studies
(Table S2), and we linked these variants to their likely aected genes (variant-
gene mapping). To do so, we combined annotation from CADD (v1.3),[24, 43]
eQTL in blood from GTEx consortium (v8)[25] and positional mapping up to
500 kb from the reported variants (RefSeq build 98).[44] CADD annotation
was used to inspect each variant’s consequences: in the case of coding
variants, we condently associated the variant with the corresponding gene.
For non-coding variants, we rst considered possible eQTLs and in case
these were not available, we included all genes at increasing distance d from
the variant (starting with d ≤ 50kb, up to d ≤ 500kb, increasing by 50kb
until at least one match is found).
5.4.4 Gene-based association
At the gene-level, we combined multiple variants in a gene-based test using
MAGMA (v1.06).[26] As genes, we used those that were associated with
our variant-gene mapping, and as variants, we used those with minor allele
frequency >1% in our population. In MAGMA, we used a anking window
of 2kb around each gene and as gene model, and adopted the snp-wise
top model (–gene-model snp-wise=top), which is most sensible when only
a small proportion of SNPs in a gene shows association.[26] Associations
were adjusted for population substructure (principal components 1-5) and
association p-values were corrected for multiple tests (FDR, correction for
the number of genes tested). The number of principal components used as
covariates was arbitrarily chosen: given the homogeneous population that
we used in this study, we believe this should account for any major population
eects. However, we repeated the main associations of the PRS including
5 additional PCs as covariates (Table S9). Before analyses, we explored
ination in MAGMA association statistics: we ran MAGMA with the stated
settings for 5,000 randomly selected genes and compared the observed p-
value distribution with an expected uniform distribution. The deviation
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between the median values of the observed and expected distributions is
indicative of test ination: we found that ination was 1.1.
5.4.5 Polygenic Risk Scores
We calculated a polygenic risk score (PRS) for each sample in our cohort. As
weights for the PRS, we used variant eect sizes (log of odds-ratios) available
in the summary statistics of the GWAS on parental longevity.[15] We decided
not to use weights from a case-control GWAS as the most recent included
our cohort, thus the resulting variant eect-sizes would be biased. Due to the
study setting, parental longevity eect-sizes are in general smaller than case-
control GWAS of longevity.[14, 15] This would aect the odds-ratios (OR) of
our associations, but not the signicance, as it would just shift the distribution
of the PRS while keeping the same distance between the groups (older-
adults and centenarians, in our case). It is then the power of the parental
longevity study, due to the large sample size, that determines replicability
and predictability of the PRS.[45] Therefore, we believe that using eect-
sizes from a parental longevity study has not impacted our ndings. The
PRSs were Z-standardized and regressed against case-control status (with
centenarians as cases and older-adults as controls), correcting for population
substructure (PC 1-5). P-values were corrected using False Discovery Rate
(FDR). Resulting OR can be interpreted as OR-dierence per one standard
deviation increase in the PRS. We calculated a set of dierent PRSs: rst, using
the set of 29 previously identied variants; then, we recursively included in
the PRS independent variants that associated sub-signicantly with longevity.
The inclusion of variants was based on the reported signicance in the GWAS
summary statistics: PRS-8: p<5x10−8, PRS-7: p<5x10−7, PRS-6: p<5x10−6,
PRS-5: p<5x10−5, PRS-4: p<5x10−4, PRS-3: p<0.005, PRS-2: p<0.05 and PRS-1:
p<0.5. The selection of independent variants to include in each PRS was
performed with LD-based clumping (R
2
<0.001 within 750kb window) using
the genotypes of the European samples from the 1000Genome project (phase
3, N=503).[42] Due to their large eect-size, we stratied all PRSs by APOE
variants, i.e. we calculated PRSs with and without APOE variants.
5.4.6 Survival analysis
We investigated whether the PRS was predictive for survival in a subset of
the older-adults for which follow-up data were available. A total of 1,620
subjects (mean age 62.7±6.4 , 53% female) were eligible for the survival
analysis. The age at study inclusion was regarded as T1, while the age at
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last visit, death, or loss to follow-up was regarded as T2, with the survival
time calculated as T2-T1. The mean follow-up time was 10.4±6.9 years, and
at the time of analyses 380 individuals had deceased (23%). Survival analysis
was performed implementing left truncation as we anticipated selection bias
at old ages, and using the function Surv(T1, T2, death, type=”counting”) as
implemented in R-package survival. We performed a survival analysis using
the (Z-standardized) PRS without APOE variants with the highest evidence
of association in our cohort (Figure 5.10). Resulting Hazard Ratios (HR)
have to be interpreted with respect to 1 unit increase in the PRS. First, we
used a multivariate Cox regression to investigate the association of the PRS
after correcting for APOE-ε4 status (dichotomized), gender, and population
stratication (PC 1-5). For visualization purposes, we split the population
into high-PRS and low-PRS categories based on the median PRS value of
the individuals with age <65 years . We then calculated survival dierences
between the individuals with low-PRS and those with high-PRS (stratifying for
APOE-ε4 status) in a univariate analysis and displayed survival probabilities
over age with Kaplan-Meier curves. We calculated dierences in years at
50% survival probability between the PRSs. We tested the interaction eect
of (i) PRS and gender and (ii) PRS and APOE-ε4 status on survival by adding
an interaction term in the Cox regression model. To evaluate gender-specic
eects of the PRS on survival, we repeated the multivariate Cox regression
analyses separately in males and females.
5.4.7 Functional annotation of variants comprising the best PRS
We inspected the functional consequences of the variants included in the
best PRS model. First, we investigated these variants in the GWAS catalog
seeking for previous associations with any trait.[46] Similarly, we looked at
whether the genes associated with these variants were previously reported
to associate with any trait in the GWAS catalog. To do so, we linked variants
to genes as done for the previously identied variants. However, we realized
that allowing multiple genes to associate with a variant could result in an
enrichment bias, as neighboring genes are often functionally related. To
control for this, we implemented sampling techniques (1000 iterations): at
each iteration, we (i) sampled one gene from the pool of genes associated
with each variant (thus allowing only a 1:1 relationship between variants and
genes), and (ii) looked whether the resulting genes were previously reported
in the GWAS catalog. Averaging by the number of iterations, we obtained
an unbiased estimation of the overlap of the PRS-associated genes with each
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trait in the GWAS catalog. Finally, we investigated the molecular pathways
enriched in the PRS-associated genes. Again, we used sampling techniques:
at each iteration, we (i) sampled one gene from the pool of genes associated
with each variant and (ii) performed gene-set overlap analysis with the re-
sulting list of genes. Gene-set enrichment analysis was performed with GOSt
function as implemented in R-package gproler2, with Biological Processes
(GO:BP) as background, excluding electronic annotations and correcting
p-values using FDR.[47] Finally, we averaged p-values for each enriched
term over the iterations (N=1,000). To reduce the complexity of the resulting
enriched biological processes, we exploited the tool REVIGO.[48] This tool
summarizes enrichment results by removing redundant terms based on a
semantic similarity measure, and displays remaining terms in an embedded
space via eigenvalue decomposition of the pairwise distance matrix. We
chose Lin as semantic distance measure and allowed small similarity among
terms to be clustered.[49] Last, we compared results from our sampling-based
approach with a traditional gene-set enrichment approach, by applying both
methods to the full set of genes associated with all variants.
5.4.8 Gene expression of longevity-associated genes
We investigated the expression of the longevity-associated genes using the
publicly available dataset GSE11882, which comprises RNA-expression from
the hippocampus region in the brain. We selected samples reported to be
cognitively healthy and aged 30-65 years (young, N=13) and samples aged 80
years or more (old, N=16). We performed dierential analysis (old vs. young)
on (i) the set of genes associated with the previously reported variants, and
(ii) the set of PRS-associated genes. Sample selection and dierential analysis
were performed using the GEO2R platform.[50] We corrected p-values for
multiple tests (FDR) and displayed results with Volcano plot.
5.4.9 Implementation
Quality control of genotype data, population stratication analysis, related-
ness analysis and association analysis were performed with PLINK (v2.00a2LM
and v1.90b4.6), whereas PRS analysis,[51] functional enrichment analysis,
and plots were performed with a mixture of homemade R (v3.5.2), bash and
Python (v2.7.14) scripts. All scripts are available at https://github.com/
TesiNicco/CentenAssoc. Variant-gene annotation and gene-set enrich-
ment analysis are implemented in a package available at https://github.




The following studies and consortia have contributed to this manuscript.
Amsterdam Dementia Cohort (ADC): Research at the Alzheimer center Ams-
terdam is part of the neurodegeneration research program of Amsterdam
Neuroscience. 100-plus Study: we are grateful for the collaborative eorts
of all participating centenarians and their family members and/or relatives.
Wiesje van der Flier holds the Pasman chair. Longitudinal Aging Study
of Amsterdam (LASA): the authors are grateful to all LASA participants,
the eldwork team, and all researchers for their ongoing commitment to
the study. Funding: The Alzheimer center Amsterdam is supported by
Stichting-Alzheimer-Nederland and Stichting-VUmc fonds. The clinical
database structure was developed with funding from Stichting Dioraphte.
The SCIENCe project is supported by a research grant from Gieskes-Strijbis
fonds. Genotyping of the Dutch case-control samples was performed in the
context of EADB (European Alzheimer DNA biobank), funded by the JPco-
fuND FP-829-029 (ZonMW project number-733051061). The 100-plus Study
was supported by Stichting Alzheimer Nederland (WE09.2014-03), Stichting
Diorapthe, horstingstuit foundation, Memorabel (ZonMW project number-
733050814), and Stichting VUmc Fonds. Genotyping of the 100-plus study
was performed in the context of EADB (European Alzheimer DNA biobank)
funded by the JPco-fuND FP-829-029 (ZonMW project number -33051061).
LASA is largely supported by a grant from the Netherlands Ministry of
Health, Welfare and Sports, Directorate of Long-Term Care. Conicts of
interest: all the authors in the study declared no conict of interest. The
funders had no role in the design of the study at any stage.
5.6 Full author list and ailiations
Niccolo’ Tesi,
1,2,3





















Alzheimer Centre, Department of Neurology, Amsterdam Neuroscience, Vrije Uni-
versiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
2
Section Genomics of Neurodegenerative Diseases and Aging, Department of Clinical
Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
3
Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands
4
Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Re-
5
150 Chapter 5. Genetic predisposition to longevity
search, VU, Amsterdam, The Netherlands
5
Department of Epidemiology and Data Sciences, Vrije Universiteit Amsterdam, Amster-
dam UMC, Amsterdam, The Netherlands
5
5.7 Supplementary Figures 151
5.7 Supplementary Figures
Figure 5.5: Variant-gene mapping for the 29 previously identied variants.
A. The sources used for the annotation of each variant to the likely aected genes.
Coding: variants that code for a change in the amino-acid sequence of the resulting
protein; eQTL: variants associated with RNA expression changes in blood from
GTEx consortium; Position: variants that are intronic or intergenic. B. Histogram of
the number of genes associated with each variant. C. Distribution of genes across the
chromosomes. In total, we mapped 29 variants to 65 unique genes. D. Distribution
of the previously identied variants along the genome and each variant’s minor
allele frequency and annotation.
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Figure 5.6: Regional plots of the genetic variants contributing to the gene-
based tests that were signicantly associated with cognitively healthy ag-
ing, in our cohort. A. Centered on the CDKN2B gene. Blue diamonds represent
the variants (N=11) that were included in the gene-based test as performed within
MAGMA framework. B. Centered on the APOE gene. Blue diamonds represent
the variants (N=13) included in the gene-based test as performed within MAGMA
framework. In both gures: genomic positions are plotted on the x-axis (with re-
spect to GRCh37); recombination rates are extracted from HapMap II; RefSeq genes
with the largest number of exons are displayed. The dashed blue line indicates the
threshold commonly adopted in GWAS for genome-wide signicance.
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Figure 5.7: Density distribution of the PRS-5 without APOE variants in pop-
ulation controls and cognitively healthy centenarians. The gure shows the
distribution density of the PRS-5 including 330 variants (excluding APOE variants).
PRS was Z-standardized.
Figure 5.8: Eect of PRS-5 on survival. Forest plot of the hazard ratios for PRS-5
in males (N=753), females (N=867), and combined (N=1620). The p-values refer to
the association of PRS-5 in the multivariate Cox regression model while adjusting
for gender (for the combined analysis only), APOE-ε4 carriership (dichotomized)
and population substructure (PCs 1-5).
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Figure 5.9: Variant-gene mapping for the variants included in PRS-5. A. The
resource used for the annotation of each variant. Coding: variants that code for a
change in the amino-acid sequence of the resulting protein; eQTL: variants associated
with RNA expression changes in blood from GTEx consortium; Position: variants
that are intronic or intergenic. B. Histogram of the number of genes associated
with each variant. C. Distribution of genes across the chromosomes. In total, we
mapped 330 variants to 471 unique genes. D. Distribution of variants included in
PRS-5 along the genome and each variant’s minor allele frequency and annotation
source.
5
5.7 Supplementary Figures 155
Figure 5.10: Distribution of PRS-5 in the subset of population controls used
in the survival analysis. The gure shows the distribution of PRS-5 in the subset
of controls (N=1630) from the Longitudinal Aging Study of Amsterdam for which
follow-up data was available, that we used for the survival analysis. PRS were
Z-standardized (µ=0, σ=1).
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Figure 5.11: Figure S7: Distribution of PRS-5 comprising 330 genetic variants
across the dierent cohorts of older-adults that were used as controls. The
gure shows the distribution of the PRS-5 including (plot above) and excluding
(plot below) APOE variants in individuals (i) from the Longitudinal Aging Study of
Amsterdam (LASA, N=1,648), (ii) with subjective cognitive decline that were labeled
cognitively healthy after cognitive examination (SCD, N=1,038), (iii) cognitively
healthy from the Netherlands Brain Bank (NBB, N=37), (iv) cognitively healthy from
the twin study of Amsterdam (Twin, N=100) and (v) the partners of the centenarian’s
children from the 100-plus Study (100-plus, N=82). We tested for dierences in PRS
across all cohorts with an anova test, and report the relative p-values in each plot.
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5.8 Supplementary Tables
Supplementary Tables can be accessed by scanning the following code or
accessing the journal’s website here.
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Common variants in Alzheimer’s disease and risk
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Genetic discoveries of Alzheimer’s disease are the drivers of our
understanding, and together with polygenetic risk stratication can
contribute towards planning of feasible and ecient preventive and
curative clinical trials. We rst perform a large genetic association
study by merging all available case-control datasets and by-proxy
study results (discovery n=409,435 and validation size n=58,190). Here,
we add six variants associated with Alzheimer’s disease risk (near
APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in
the SHARPIN gene). Assessment of the polygenic risk score and
stratifying by APOE reveal a 4 to 5.5 years dierence in median age
at onset of Alzheimer’s disease patients in APOE ε4 carriers. Because
of this study, the underlying mechanisms of APP can be studied to
rene the amyloid cascade and the polygenic risk score provides a
tool to select individuals at high risk of Alzheimer’s disease.
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6.1 Background
Thus far, multiple loci associated with Alzheimer’s disease (AD) have been de-
scribed next to causal mutations in two subunits of γ-secretases, membrane-
embedded aspartyl complexes (PSEN1, PSEN2 genes), and the gene encoding
one target protein of these proteases, the amyloid precursor protein gene
(APP). The most prominent locus, APOE, was detected almost 30 years ago
using linkage techniques.[1] In addition, genome-wide association studies
(GWAS) of AD case-control datasets and by-proxy AD case-control studies
have identied 30 genomic loci that modify the risk of AD.[2, 3, 4, 5, 6] These
signals account for 31% of the genetic variance of AD, leaving most of the
genetic risk as yet uncharacterized.[7] Further disentangling the genetic
constellation of common genetic variations underlying AD can drive our
biological insights of AD and can point toward novel drug targets. There are
over 50 million people living with dementia and the global cost of dementia is
well above 1 trillion US$.[8] This means there is a medical and economical ur-
gency to eciently test interventions that are under development. Therefore,
to increase power and reduce duration of trials, pre-symptomatic patients
that are at high genetic risk of disease are increasingly developed.[9] How-
ever, only carriers of causal mutations (APP, PSEN1, PSEN2) and the APOE ε4
allele are considered high risk, while other common and rare genetic variants
are ignored.[10] Despite that, the combined eects of all currently known
variants in a polygenic risk score (PRS) is associated with the conversion
of mild cognitive impairment (MCI) to AD,[11, 12], the neuropathological
hallmarks of AD, age at onset (AAO) of disease [13, 14, 15, 16] and lifetime
risk of AD.[17] Here, we aimed to comprehend and expand the knowledge of
the genetic landscape underlying AD and provide additional evidence that
a PRS of variants can be a robust tool to select high risk individuals with
an earlier age at onset. We rst performed a meta-GWAS integrating all
currently published GWAS case-control data, by-proxy case-control data, and
the data from the Genome Research at Fundació ACE (GR@ACE) study.[18]
We conrmed the novel observed associations in a large independent repli-
cation study. Then, we constructed an update of the PRS and tested whether
the eects of the PRS were inuenced by diagnostic certainty, sex and AAO
groups. Lastly, we tested whether the PRS could be used to identify individu-




Figure 6.1: Flow chart of analysis steps. Discovery meta-analysis in GR@ACE,
IGAP stage 1+2 and UKBiobank followed by a replication in 16 independent cohorts.
The genome-wide signicant signals found in meta-GWAS were used to perform a
Polygenic Risk Score in a clinical and pathological AD dataset. See Supplementary
Methods for more information about the cohorts included and methods to the PRS
generation.
a
, extended dataset (S.Moreno-Grau et al. 2019)[18]; b, stage I + stage
II (Kunkle et al. 2019)[19]; c, by proxy AD: meta-analysis of maternal and paternal
history of dementia (Marioni et al. 2018)[20]; d , extra and independent GR@ACE
dataset incorporated only for replication purposes;
e
, pathologically conrmed AD
cases;
f
, AD cases diagnosed based on clinical criteria;
g
, controls participants aged
55 years and younger. N=, total of individuals within specied data.
6.2 Results
6.2.1 Meta-GWAS of AD
We combined data from three AD GWASs: the summary statistics calculated
from the GR@ACE case-control study (6,331 AD cases and 6,055 controls),[18]
the IGAP case-control study (up to 30,344 AD cases and 52,427 controls) [19]
and the UKB AD-by-proxy case-control study (27,696 cases of maternal AD
with 260,980 controls and 14,338 cases of paternal AD with 245,941 controls,
Figure 6.1, Supplementary Table 1).[20] Although we observed ination in
the resulting summary statistics (λ=1.08; see Figure 6.7d), it was not driven
by an un-modeled population structure (LD score regression intercept=1.04).
The full details of the studies are described in the supplementary methods.
After study-specic variant ltering and quality-control procedures, we
performed a xed-eects inverse-variance-weighted meta-analysis on the
6
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summary statistics of the three studies.[21] Using this strategy, we identied
a genome-wide signicant (GWS) association (p<5x10−8) for 36 independent
genetic variants in 35 genomic regions (the APOE region contains signals
for ε4 and ε2). As a sensitivity analysis, we removed the AD-by-proxy study
and compared the resulted eect estimates with and without this dataset. We
found a high correlation between the eect estimates from the case-control
and by-proxy approaches for the signicant loci (R2 = 0.994, p = 8.1x10−37;
Figure 6.7e). Four genomic regions were not previously associated with AD
(see Manhattan Plot, Figure 6.2).
Figure 6.2: Manhattan plot of the overall GWAS meta-analysis for AD risk
(N = 467,623). Genome-wide associations with Alzheimer’s disease highlighting
the novel loci associated with AD (PRKD3/NDUFAF7, SHARPIN, CHRNE, PLCG2 and
APP).
Next, we aimed at replicating the associated loci in 16 cohorts (19,087
AD cases and 39,101 controls in total), many of them collected and analyzed
by the European Alzheimer’s Disease Biobank (JPND-EADB) project. We
tested all variants with suggestive association (p<10−5) located within a
200Kb region from the sentinel SNP. Overall, 384 variants were tested in
the replication datasets (Supplementary Table 2). Discovery and replication
were combined, and we identied novel associations in six variants com-
prising ve genomic loci annotated using FUMA (Table 6.1, Figure 6.3D-F,
Figure 6.8 and Supplementary Results).[22] In APP, we identied a common
(MAF = 0.46) intronic variant associated with a reduced risk of AD (rs2154481,
OR = 0.95 [0.93-0.96], p= 9.3x10−10, Figure 6.3F). In SHARPIN (SHANK As-
6
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sociated RH Domain Interactor) gene, we found two missense mutations
(rs34173062/p.Ser17Phe and rs34674752/p.Pro294Ser) that are in linkage equi-
librium (R2=1.3x10−6, D’=0.014, p = 0.96). Both missense variants increased
AD risk (p.Ser17Phe, MAF = 0.085, OR = 1.14 [1.10-1.18], p = 9.6x10−13 and
p.Pro294Ser, MAF = 0.052, OR = 1.13 [1.09-1.18], p = 1.0x10−9, Figure 6.3A-B).
A variant close to the genes PRKD3 and NDUFAF7 (rs876461, MAF = 0.143)
emerged as the most signicant variant in the region after the combined
analysis (OR = 1.07 [1.05-1.09], p = 1.3x10−9, Figure 6.3C). In the 3’-UTR re-
gion of CHRNE (Cholinergic Receptor Nicotinic Epsilon Subunit), rs72835061
(MAF = 0.085) was associated with a 1.09-fold increased risk of AD (95% CI
[1.06-1.11], p = 1.5x10−10, Figure 6.3E). Our analysis also strengthened the
evidence of association with AD for three additional genomic loci including
a novel association with a variant in PLCG2 (rs3935877, MAF= 0.13, OR =
0.92 [0.90-0.95], p = 6.9x10−9, Figure 6.3D), and conrmed another common
variant in PLCG2, a stop gain mutation in IL34 and a variant near HS3ST1
(Table 6.1, Figure 6.9 and Supplementary Tables 2-3). We were not able to
replicate two loci (ELK2AP and SPPL2A regions) that showed suggestive
association with AD (p<1x10−7 in discovery).
6.2.2 Polygenic Risk Scores
In order to assess the robustness and combined eect of the new genetic
landscape of AD (Figure 6.4, Supplementary Table 4), we constructed a
weighted PRS based on the 39 genetic variants (excluding APOE genotypes)
that showed GWS evidence of association with AD (see section 6.4, Figure 6.5
and Supplementary Table 5). We tested if the association of the PRS with AD
is independent of clinically important factors that are considered in the se-
lection of individuals for clinical trials. First, we showed that the association
of the PRS with clinically diagnosed AD cases is similar to the association
with pathologically conrmed AD (OR = 1.30 vs. 1.38, per 1-SD increase in
the PRS). In this setting, adding variants below the GWS threshold did not
lead to a more signicant association of the PRS with AD (Figure 6.5A). Next,
we tested whether the PRS was associated with AD in the presence of con-
comitant brain pathologies (besides AD). Among our autopsy-conrmed AD
patients (n=332), 84% had at least one concomitant pathology, and the PRS
was associated with AD in the presence of all tested concomitant pathologies
(Figure 6.5B). Moreover, the patients often had more than one concomitant
pathology (48.8%), but no dierence was observed in the eect estimate
of the PRS when more than one pathology was present (Figure 6.5B). Last,
6








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































170 Chapter 6. A large GWAS of Alzheimer’s disease
we investigated the eect of sex and age at onset (AAO, Figure 6.5C). Our
analysis revealed that the eect of the PRS was the same in both sexes (Fig-
ure 6.5C) and was consistent with both early-onset (onset before 65 years;
OR = 1.58, 95% CI [1.22–2.05], p = 5.8x10−4) as well as with late-onset AD
(onset later than 85 years; OR = 1.29, 95% CI [1.10–1.51], p = 1.5x10−3). PRSs
has the potential to early identify subjects at risk of complex diseases.[23]
To identify people at the highest genetic risk of AD based on the PRS, we
used the validated 39-variants PRS in the large GR@ACE dataset. The PRS
was associated with a 1.27-fold (95% CI [1.23–1.32]) increased risk for every
standard deviation increase in the PRS (p = 7.3x10−39) and with a gradual
risk increase when we stratied the dataset into 2% percentiles of the PRS
(Figure 6.6A, Supplementary Table 6). Next, we stratied the dataset in APOE
genotype risk groups. The PRS percentiles were associated with AD within
the APOE genotype groups (Figure 6.6B and Supplementary Table 7). Finally,
we compared the risk extremes and found a 16.2-fold (95% CI [8.84–29.5],
p = 1.5x10−19) increased risk for the highest-PRS group (APOE ε4ε4) com-
pared with the lowest-PRS group (APOE ε2ε2/ε2ε3; Supplementary Table 8).
When we compared the median AAO in AD patients in these extreme risk
groups we found a 9-year dierence in the median age (pWilcoxon = 1.7x10−6)
(Figure 6.6C). Lastly, we studied the eects on AAO of the PRS in the APOE
genotype groups. The PRS dierentiated AAO only within APOE ε4 carriers.
In APOE ε4 heterozygotes the PRS determined a 4-year dierence in median
AAO and in APOE ε4 homozygotes (pWilcoxon = 6.9x10−5), where the PRS
determined a median AAO dierence of 5.5 years (pWilcoxon = 4.6x10−5). For
the selection of high-risk individuals, it is important to note that we found
no dierence in the odds and AAO for AD for APOE ε4 heterozygotes with
the highest PRS compared to APOE ε4 homozygotes with the lowest PRS.
The Cox regression also showed an impact of APOE on AAO, mainly on




This work adds on the ongoing global eort to identify genetic variants
associated with AD (Figure 6.4). In the present work, we reported on the
largest GWAS for AD risk to date, comprising genetic information of 467,623
individuals of European ancestry. We identied six novel variants that were
not previously associated with the risk of AD and constructed a robust PRS
for AD demonstrating its potential value for selecting subjects at risk of
AD, especially within APOE ε4 carriers. This PRS was based on European
ancestries and may or may not generalize to other ancestries. Validation
in other populations will be required. We also acknowledge that controls
included in GR@ACE are younger than cases and some of the controls might
still develop AD later in life. This fact does not invalidate the analysis al-
though reported estimates must be considered conservative. The dierences
in risk and AAO determined by the PRS of AD are relevant for design clinical
trials that over-represent APOE ε4 carriers, as APOE ε4 heterozygous with
highest PRS values have a similar risk and AAO to APOE ε4 homozygotes
(Figure 6.6b). These represents ∼1% of our control population, which is the
same percentage as all APOE ε4 homozygotes. A trial that aims to include
APOE ε4 homozygotes, could consider widening the selection criteria and
in this way hasten the enrollment process. Also, our PRS could aid at the
interpretation of the results of clinical trials, as it determines a relevant
proportion of the AAO, which could either mimic or obscure a treatment
eect.
The most interesting nding from our GWAS is the discovery of a com-
mon protective (MAF (C-allele) = 0.483) intronic variant in the APP gene.
Our results directly support APP production or processing as a causal path-
way not only in familial AD but in common sporadic AD. The SNP is in
a DNase hypersensitive area of 295 bp (chr21:27473781-27474075) possibly
involved in the transcriptional regulation of the APP gene. rs2154481 is an
eQTL for the APP mRNA and an antisense transcript of the APP gene named
AP001439.2 in public eQTL databases (Figure 6.10).[26] Functional evidence
supports a modied APP transcription as an LD block of 13 SNPs within
the APP locus (including rs2154481) increased the TFCP2 transcription factor
avidity to its binding site and increased the enhancer activity of this specic
intronic region.[27] Based on this evidence, we can postulate that a life-long
slightly higher APP gene expression protects the brain from AD insults. Still,
this seems counterintuitive as duplications of the gene lead to early-onset
AD.[28] A U-shaped eect, or hormesis eect of APP might help explain
6























































































































































































































































































































































































































































































































































































Figure 6.5: Polygenic Risk Scores for AD. A. The 39-SNP PRS association with
clinical (OR = 1.38, per 1-SD increase in the PRS, 95% CI [1.21-1.58], p = 1.5x10−6) and
pathologically conrmed AD cases (OR = 1.30, 95% CI [1.18-1.44], p = 1.1x10−7). B.
PRS association with AD in the presence of concomitant brain pathologies (besides
AD). C. PRS association with AD stratied by sex and AAO. A similar association of
the PRS with AD was found in both sexes (ORmales = 1.33, [1.13-1.56], p = 5.8x10−4
vs. ORf emales = 1.32, [1.19-1.47], p = 2.5x10−7).
our observations and it might also t the accelerated cognitive deterioration
observed in AD patients treated with β-secretase inhibitors as these reduce
β-amyloid in their brain.[29, 30] An alternative hypothesis is that mecha-
nisms underlying the variant are related to the overexpression of protective
fragments of the APP protein.[31] Disentangling the molecular mechanism
6
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of our nding will help rene and steer the amyloid hypothesis.
Additionally, other three variants identied are altering protein sequence
or aecting regulatory motifs. Two independent missense mutations in
SHARPIN increased the AD risk. SHARPIN was previously proposed as
an AD candidate gene, and functional analysis of a rare missense variant
(NM_030974.3:p.Gly186Arg) resulted in the aberrant cellular localization of
the variant protein and attenuated the activation of NF-κB, a central me-
diator of inammatory and immune responses.[32, 33] Functional analysis
of the two identied missense variants will show if the eect on immune
reaction in AD is similar. The variant located in the CHRNE which encodes a
subunit of the cholinergic receptor (AChR) is a strong modulator of CHRNE
expression. The same allele that increases AD risk increases the expression
in the brain and other tissues according to GTEx (p = 2.1x10−13) (Figure 6.11).
The detection of a potential hypermorph allele linked to AD risk and aect-
ing cholinergic function could reintroduce this neurotransmitter pathway
into the search for preventative strategies. Further functional studies are
needed to consolidate this hypothesis. Altogether, we described six novel
loci associated with sporadic AD. These signals reinforce that AD is a com-
plex disease in which amyloid processing and immune response play key
roles. We add to the growing body of evidence that the polygenic scores
of all genetic loci to date, in combination with APOE genotypes, are robust
tools that are associated with AD and its AAO. These properties make PRS


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































176 Chapter 6. A large GWAS of Alzheimer’s disease
6.4 Methods
6.4.1 Samples and cohorts
Participants in this study were obtained from multiple sources, including raw
data from case-control samples collected by GR@ACE/DEGESCO, summary
statistics data from the case-control samples in the IGAP and the summary
statistics of AD-by-proxy phenotype from the UK Biobank (see Supplemen-
tary Methods). An additional case-control samples from 16 independent
cohorts (19,087 AD cases and 39,101 controls) was used for replication,
largely collected and analyzed by the European Alzheimer’s Disease Biobank
(JPND-EADB) project. Full descriptions of the samples and their respective
phenotyping and genotyping procedures are provided in the Supplementary
Methods.
6.4.2 Meta-GWAS of AD
After study-specic variant ltering and quality-control procedures, we
performed a xed-eects inverse-variance-weighted meta-analysis on the
discovery and follow-up stages.[21] To determine the lead SNPs (those with
the strongest association per genomic region), we performed clumping on
SNPs with a genome-wide signicant p-value (p<5x10−8) (PLINK v1.90, max-
imal linkage disequilibrium (LD) with R2 <0.001 and physical distance of
250Kb). In the APOE region, we only considered the APOE ε4 (rs429358)
and APOE ε2 (rs7412) SNPs.[34] LD information was calculated using the
GR@ACE imputed genotypes as a reference. Polygenicity and confounding
biases, such as cryptic relatedness and population stratication, can yield
an inated distribution of test statistics in GWAS. To distinguish between
ination from a true polygenic signal and bias we quantied the contribution
of each by examining the relationship between test statistics and linkage dise-
quilibrium (LD) using the LD Score regression intercept (LDSC software).[35]
Chromosomal regions associated with AD in previous studies were excluded
from follow-up.[3, 19, 25] We tested all variants with suggestive associa-
tion (p<10−5) located in proximity (200 Kb) of genomic regions selected
for follow-up to allow for the potential renement of the top associated
variant. Conditional analyses were performed in regions where multiple
variants were associated with AD using logistic regression models, adjusting
for the genetic variants in the region. Regional plots were generated with a
mixture of homemade Python (v2.7) and R (v3.6.0) scripts. Briey, given an
input variant, we calculated the LD between the input variant and all the
surrounding variants within a window of length dened by the user. The LD
6
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was calculated in the 1000Genomes samples of European ancestry. We used
gene positions from RefSeq (release 93); in the case of multiple gene models
for a given gene, we reported the model with the largest number of exons.
We used recombination rates from HapMap II and chromatin states from
ENCODE/Broad (15 states were grouped to highlight the predicted functional
elements). As a reference genome, we used GRCh37. Quantile-quantile (QQ)
plots, Manhattan plots, and the exploration of genomic ination factors were
performed using the R package qqman.
6.4.3 Polygenic Risk Score
We calculated a weighted individual PRS based on the 39 genetic variants that
showed genome-wide signicant (GWS) evidence of association with AD in
the present study, excluding APOE to check the impact of PRS modulating
APOE risk (Table 6.1 and Supplementary Table 3). The selected variants were
directly genotyped or imputed with high quality (median imputation score
R2 = 0.93). The PRSs were generated by multiplying the genotype dosage of
each risk allele for each variant by its respective weight and then summing
across all variants. We weighted this by the eect size from previous IGAP
studies: Kunkle et al. (36 variants),[19] Sims et al. (2 variants),[6] Jun et al.
(MAPT locus),[24] Supplementary Table 5. The newly generated PRS was
validated using logistic regression adjusted by four principal components
in a sample of 676 AD cases diagnosed based on clinical criteria and 332
pathologically conrmed AD cases from the European Alzheimer’s Disease
Biobank-Fundació ACE/Barcelona Brain Bank dataset (EADB-F.ACE/BBB,
Supplementary Information). This dataset was not used in prior genetic
studies. In this dataset, all pathologically conrmed cases were scored for the
presence or absence of concomitant pathologies. In all analyses, we compared
the AD patients to the same control dataset (N=1,386). We performed analyses
to test the robustness of the PRS. We tested the eect of adding variants below
the genome-wide signicance threshold using a pruning and thresholding
approach. For this, we used the summary statistics of the IGAP study,[19]
and we selected independent variants using the clump_data() function from
the TwoSampleMR R-package (v0.4.25). We used strict settings for clumping











). We tested the association
of the results with clinically diagnosed and pathologically conrmed AD
patients. To evaluate the eect of diagnostic certainty, we tested whether
the PRS was dierent between the two patient groups. For the PRS with 39
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genome-wide signicant variants, we tested whether the PRS had sex-specic
eects, whether it resulted in dierent age-of-onset groups of AD, and the
eect of the PRS in the presence of concomitant brain pathologies. Risk
stratication of the validated PRSs. We searched for the groups at the highest
risk of AD in the GR@ACE dataset (6,331 AD cases and 6,055 controls). We
stratied the population into PRS percentiles, taking into account survival
bias anticipated at old age.[17] To eliminate selection bias, we calculated the
boundaries of the percentiles in the control participants aged 55 years and
younger (N=3,546). Based on the boundaries from this population, the rest
of the controls and all AD cases were then assigned into their appropriate
percentiles. We rst explored risk stratication using only the PRSs. For
this, we split the PRSs into 50 groups (2 percentiles) and compared all groups
with that which had the lowest PRS. Second, we explored risk stratication
considering both the APOE genotypes and the PRSs. The APOE genotypes
were pooled in the analyses as APOE ε2ε2/ε2ε3 (N=998, split into 7 PRS
groups), APOE ε3ε3 (N=7,611, split into 25 PRS groups), APOE ε2ε4/ε3ε4
(N=3,399, split into 15 PRS groups) and APOE ε4ε4 (N=382, split into 3 PRS
groups). We studied the eect of PRS across groups of individuals stratied
by the APOE genotypes with the lowest PRS group (APOE as the reference
group using logistic regression models adjusted for four population ancestry
components). Finally, we compared the median age at onset using a Wilcoxon
test. We implemented a Cox regression model on the GR@ACE/DEGESCO
dataset case-only adjusted for covariates as APOE group, the interaction
between the PRS and APOE and four population ancestry components. All
analyses were done in R (v3.4.2).
6.4.4 Functional annotation
We used Functional Mapping and Annotation of Genome-Wide Associa-
tion Studies (FUMA, v1.3.4c) to interpret SNP-trait associations (see Supple-
mentary Methods).[22] FUMA is an online platform that annotates GWAS
ndings and prioritizes the most likely causal SNPs and genes using infor-
mation from 18 biological data repositories and tools. As input, we used
the summary statistics of our meta-GWAS. Gene prioritization is based on a
combination of positional mapping, expression quantitative trait loci (eQTL)
mapping, and chromatin interaction mapping. Functional annotation was
performed by applying a methodology similar to that described by Jansen et





Summary statistics will be made available for download upon publication
(www.niagads.org).
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6.7 Supplementary Figures
Figure 6.7: Genome-wide association study. a-c, Principal component analysis
and QQ-plot for the GR@ACE dataset. d, QQplot Discovery meta-analysis.e, Cor-
relation between the eect estimates from the AD case-control and AD by proxy
approach for the signicant loci. We compared the results obtained to a second
meta-analysis using only the case-control datasets (IGAP Stages 1–2) and GR@ACE
datasets as a sensitivity analysis to identify false negative results given possible
dilution by the by- proxy approach in the UK Biobank (Supplementary Data 3). The
meta-analysis, including the by-proxy summary statistics, identied 11 additional
loci reaching genome-wide signicance with respect to case-control-only results.
The incorporation of by-proxy summary statistics did not show an association in
two previously reported AD loci (rs7185636-IQCK and rs386572859-MAPT ) by the
IGAP consortium and replicated in the GR@ACE dataset (OR = 0.93[0.90-0.95], p =
4.5x10
−8
and OR = 0.81[0.75-0.87], p = 7.9x10−9, respectively).
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Figure 6.8: Forest plots for the six novel signals identied in overall meta-
analysis. See sample size in Supplementary Data 1. Data are presented as Odds
Ratio (95% CI).
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Figure 6.9: LocusZoom and forest plots: strengthened evidence of associa-
tion with AD for three additional genomic loci. a, HS3ST1 loci. b, IL34 loci
and c, PLCG2 loci. Data for the forest plots are presented as Odds Ratio (95% CI).
The rst was rs4351014 with AD (combined OR = 0.94 [0.92-0.95], p = 9.2x10−12).
This variant has been previously linked to HS3ST1. The second was a stop-codon
mutation (rs4985556, Tyr213Ter, MAF = 0.111) in the interleukin 34 (IL34) gene that
was previously reported in a by-proxy approach (combined OR = 1.08 [1.06-1.11], p
= 3.9x10
−10
). The third genomic region contains the PLCG2 gene, which has been
associated with AD twice before (the rare missense variant p.P522R in the PLCG2
gene and rs12444183 near the promotor region of PLCG2). After the combination
of discovery and follow-up, a third independent association signal emerged in the
PLCG2 region (rs3935877, eect allele frequency = 0.868, OR = 0.92 [0.90-0.95], p
= 6.9x10
−9
). We also strengthened the association of PLCG2-rs12444183 with AD
(MAF = 0.407, combined OR = 0.95 [0.93-0.96], p = 6.8x10−12). Conditional analyses
in the PLCG2 region showed that the association signals of all three variants are
independent. A conditional analysis on the nearby SCIMP locus (333 Kb) (Supple-
mentary Data 14) showed similar eects after adjustment for SCIMP, in line with
the fact that the two independent signals are in weak LD (R2 = 0.139, D’ = 0.446).
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Figure 6.10: Functional analysis. a Diagram of functional interpretation by 4
FUMA strategies. To link the novel variants to specic genes and functional motifs
in their genomic regions, we applied dierent strategies implemented on the FUMA
platform. FUMA helps to generate hypotheses that are testable in functional ex-
periments aimed at proving causal relations. The genes APP, IL34, CHRNE, PLCG2,
and SHARPIN were the most likely candidate genes in the regions as they were
implicated in at least three mapping strategies (Supplementary Data 15-18). b, Dif-
ferential tissue expression for APP eQTL according to GTEx. Data are presented
as Normalized eect size (NES) with 95% CI. c, Dierential expression of lncAPP
and mRNA in AD cases and controls (n=34 lncAPP and n=31 mRNA biologically
independent samples). No signicant dierences were found between the total ex-
pression of the lncAPP (AP001439.2) and mRNA expression in the brain case/control
samples. d, Dierential expression of lncAPP and mRNA stratied by genotype. The
allelic frequency was as expected (MAF = 0.41), as well as the eQTL eect for mRNA
(CC>TC>TT) and lncAPP (CC<TC<TT) according to GTEx. e, Expression of lncAPP
and mRNA stratied by rs2154481 allele C carriers or non-carriers in AD cases and
controls respectively. Interestingly, we saw an increase in the expression of the
lncAPP associated with the T allele that seems more exacerbated in the patients than
in the controls. If so, the protective C allele (rs2154481) would also be associated
with a decrease in the expression of the lncAPP, thus being able to modify the nal
expression of APP. In c-e, data are represented as boxplots where the middle line is
the median, the lower and upper hinges correspond to the rst and third quartiles,
the whiskers extend to the hinge to the inter-quartile range (IQR), while data beyond
the end of the whiskers are outlying points that are plotted individually according
to the manual of ggplot2 package in R.
6
6.7 Supplementary Figures 189
Figure 6.11: Expression for CHRNE eQTL. a, Dierential tissue expression for
CHRNE eQTL according to GTEX. Data are presented as Normalized eect size (NES)
with 95% CI. b-c, Expression of the CHRNE transcript in the brain according to
BrainSeq and GTEx respectively. Data are represented as boxplots where the middle
line is the median, the lower and upper hinges correspond to the rst and third
quartiles, the whiskers extend to the hinge to the inter-quartile range (IQR), while
data beyond the end of the whiskers are outlying points that are plotted individually
according to the manual of ggplot2 package in R
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6.8 Supplementary Tables
Supplementary Tables and Supplementary Information can be accessed by
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Human longevity is heritable, but genome-wide association (GWA)
studies have had limited success. Here, we perform two meta-analyses
of GWA studies of a rigorous longevity phenotype denition includ-





survival percentile, respectively, and 25,483 controls
whose age at death or at last contact was at or below the age corre-
sponding to the 60
th
survival percentile. Consistent with previous
reports, rs429358 (apolipoprotein E (ApoE) ε4) is associated with lower




percentile age, while rs7412
(ApoE ε2) shows the opposite. Moreover, rs7676745, located near
GPR78, associates with lower odds of surviving to the 90th percentile
age. Gene-level association analysis reveals a role for tissue-specic
expression of multiple genes in longevity. Finally, genetic correlation
of the longevity GWA results with that of several disease-related phe-
notypes points to a shared genetic architecture between health and
longevity.
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7.1 Background
The average human life expectancy has been increasing for centuries.[1]
Based on twin studies, the heritability of human lifespan has been estimated
to be ∼25%, although this estimate diers among studies.[2] On the other
hand, the heritability of lifespan based on the correlation of the mid-parent
(i.e., the average of the father and mother) and ospring dierence between
age at death and expected lifespan was estimated to be 12%.[3] A recent study
has indicated that the dierent heritability estimates may be inated due
to assortative mating, leaving a true heritability that is below 10%.[4] The
heritability of lifespan, estimated using the sibling relative risk, increases
with age and is assumed to be enriched in long-lived families, particularly
when belonging to the 10% longest-lived of their generation.[5, 2] To identify
genetic associations with human lifespan, several genome-wide association
(GWA) studies have been performed.[6, 2, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
18, 19] These studies have used a discrete (i.e., older cases versus younger
controls) or a continuous phenotype (such as age at death of individuals
or their parents). The selection of cases for the studies using a discrete
longevity phenotype has been based on the survival to ages above 90 or
100 years or belonging to the top 10% or 1% of survivors in a population.
Studies dening cases using a discrete longevity phenotype often need to
rely on controls from more contemporary birth cohorts, because all others
from the case birth cohorts have died before sample collection. Previous
GWA studies have identied several genetic variants, but the only locus that
has shown genome-wide signicance (P ≤ 5x10−8) in multiple independent
meta-analyses of GWA studies is apolipoprotein E (APOE),[20] where the
ApoE ε4 variant is associated with lower odds of being a long-lived case. The
lack of replication for many reported associations with longevity could be
due, at least partly, to the use of dierent denitions for cases and controls
between studies. Furthermore, even within a study, the use of a single age cut-
o phenotype for men and women and for individuals belonging to dierent
birth cohorts will give rise to heterogeneity, as survival probabilities dier by
sex and birth cohort,[21] and genetic eects are known to be age- and birth
cohort-specic.[5, 22] In an attempt to mitigate the eects of heterogeneous
case and control groups, we use country-, sex- and birth cohort-specic life
tables to identify ages that correspond to dierent survival percentiles to
dene cases and controls in our meta-analyses of GWA studies of longevity.
Furthermore, most studies in our meta-analyses use controls from the same
study population as the cases, which limits the impact of sampling biases that
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could confound associations. The current meta-analyses include individuals
from 20 cohorts from populations of European, East Asian, or African Amer-
ican descent. Two sets of cases are examined: individuals surviving at or









percentile cases) based on life
tables specic to the country where each cohort was based, sex, and birth
cohort (i.e., birth year). The same country-, sex-, and birth cohort-specic
life tables are used to dene the age threshold for controls, corresponding to
the 60
th
percentile of survival. We identify two genome-wide signicant loci,
of which one is replicated in two independent European cohorts that use de
novo genotyping. We also perform a gene-level association analysis based
on tissue-specic gene expression and identify additional longevity genes.
In addition, using linkage disequilibrium (LD) score regression,[23] we show
that longevity is genetically correlated with multiple diseases and traits.
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Table 7.1: Samples included in the dierent genome-wide association meta-





cases All controls Dead controls
Discovery
100-plus/LASA/ADC European 373 301 2271 245
AGES European 300 1,001 466
CEPH
a
European 1,234 1,112 831
CHS European 905 68 558 539
DKLS
a
European 960 610 1,917
FHS European 332 1,444 539
GEHA Danish
a
European 451 127 900
GEHA French European 271 81 358
GEHA Italy European 182 184
HRS European 361 3,312 657
LLFS European 1,110 338 552 82
LLS + GEHA Dutch European 1,037 377 712
Longevity European 548 271 584




RS European 774 79 2,965 1,731








European 944 298 772
GLS European 1,613 1,613 4,215
Total 2,557 1,911 4,987
Validation
UK Biobank European 19,742 928 19,698
Trans-ethnic
CLHLS East Asian 2,178 2,178 2,299
CHS African American 177 211
Total 13,617 5,662 27,993
100-plus: 100-plus Study; LASA, Longitudinal aging study of Amsterdam; ADC, Amsterdam
dementia cohort; AGES, Age/Gene Environment Susceptibility Study; CEPH, CEPH
centenarian cohort; CHS, Cardiovascular Health Study; DKLS, Danish longevity study; FHS,
Framingham Heart Study; GEHA, Genetics of Healthy Aging Study; HRS, Health and
Retirement Study; LLFS, Long Life Family Study; LLS, Leiden Longevity Study; Longevity,
Longevity Gene Project; MrOS, Osteoporotic Fractures in Men Study; Newcastle 85+,
Newcastle 85+ Study; RS, Rotterdam study; SOF, Study of Osteoporotic Fracture; Vitality 90+,
Vitality 90+ project; GLS, German longevity study; CLHLS, Chinese Longitudinal Healthy
Longevity Survey.
a
For these studies, controls were provided by a separate cohort. Further




7.2.1 Genome-wide association meta-analysis
We performed two meta-analyses in individuals of European ancestry com-
bining cohort-specic genome-wide association data generated using 1000
Genomes imputation: (i) 90th percentile cases versus all controls and (ii)
99
th
percentile cases versus all controls. The numbers of cases and controls
in each study are shown in Table 7.1. For both case denitions, multiple
genetic variants at the well-replicated APOE locus reached genome-wide
signicance (p≤5x10−8) (Table 7.2, Figure 7.1 and Figure 7.4). Consistent
with previous reports, rs429358 (ApoE ε4) was associated with lower odds of




percentile age at the genome-wide signicance
level. In addition, we report a genome-wide signicant association of rs7412
(ApoE ε2) with higher odds of surviving to the 90th and the 99th percentile
age. Conditional analysis in two of the cohorts with individuals of European
ancestry, CEPH and LLS (combined with GEHA Dutch) (representing 18%
of the 90
th
percentile cases and 6% of all controls), indicated that the signal
at the APOE locus was explained by these two independent variants, i.e.,
rs429358 (ApoE ε4) and rs7412 (ApoE ε2). There was no evidence of hetero-
geneity of eect across cohorts for ApoE ε2 (p-value for heterogeneity (phet)
= 0.619, Table 7.2). For ApoE ε4, on the other hand, there was evidence of
heterogeneity (phet = 0.004, Table 7.2), although the direction of eect of
this variant was consistent across cohorts (Figure 7.2). Besides ApoE ε4 and
ε2, one additional variant, rs7676745, located on chromosome 4 near GPR78,
showed a genome-wide signicant association in the 90
th
percentile cases
versus all controls analysis (p= 4.3x10−8, Table 7.2). The rare allele of this
variant (A) was associated with lower odds of surviving to the 90
th
percentile
age and there was no evidence of heterogeneity of eect across cohorts (Phet
= 0.462, Table 7.2). The regional association and forest plots for this locus
are depicted in Figure 7.1 and Figure 7.2. Most of the variants reported in
Table 7.2 show stronger eects in the 99
th
percentile as compared to the 90
th
percentile analysis (Figure 7.5), indicating that the use of a more extreme
phenotype results in stronger eects.
7.2.2 Replication
The eects of ApoE ε4 and ε2 were replicated in the two cohorts (i.e., DKLSII
and GLS) in which de novo genotyping, using predesigned Taqman SNP
Genotyping Assays, was applied (Table 7.2). However, we were not able to
replicate the eect of rs7676745 in these cohorts, since there was no Taqman
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Table 7.2: Samples included in the dierent genome-wide association meta-
analyses or the replication and validation
rsID Closest gene Alleles EAF OR [95% CI] P I
2
(%) Phet
90th percentile cases versus all controls (Discovery)




a GPR78 A/G 0.04 0.67 [0.57-0.77] 4.3x10−8 0 0.462
rs7754015 - G/T 0.43 0.90 [0.86-0.94] 6.8x10
−7
0 0.670
rs35262860 RP1 GCT/G 0.39 1.11 [1.07-1.15] 3.9x10−7 0 0.941
rs3138136 RDH5 T/C 0.10 0.83 [0.77-0.89] 5.4x10−7 14.5 0.284
rs429358 APOE C/T 0.13 0.60 [0.56-0.64] 1.3x10−56 54.3 0.004
rs7412 APOE T/C 0.09 1.28 [1.19-1.37] 2.4x10−11 0 0.619
90th percentile cases versus all controls (Replication)
rs429358 APOE C/T 0.45 [0.40-0.51] 5.2x10−36 85.4 0.009
rs7412 APOE T/C 1.32 [1.18-1.48] 2.4x10−6 16.6 0.274
99th percentile cases versus all controls (Discovery)
rs3830412 KALRN A/AT 0.22 1.21 [1.12-1.30] 4.3x10−7 0 0.767
rs138762279 - AT/A 0.16 0.79 [0.72-0.86] 1.2x10
−7
0 0.769
rs62502826 KIF13B A/G 0.15 1.23 [1.23-1.33] 5.6x10−7 14.9 0.298
rs7039467 CDKN2A/B A/G 0.48 1.20 [1.12-1.28] 1.1x10−7 0 0.843
rs429358 APOE C/T 0.13 0.52 [0.47-0.58] 3.9x10−34 0 0.833
rs7412 APOE T/C 0.09 1.47 [1.32-1.64] 3.2x10−12 0 0.639
99th percentile cases versus all controls (Replication)
rs429358 APOE C/T 0.44 [0.38-0.50] 4.0x10−32 84.0 0.012
rs7412 APOE T/C 1.35 [1.19-1.53] 2.0x10−6 0 0.534
Alleles, eect allele/other allele; EAF, eect allele frequency; OR, odds ratio (i.e., odds to
become long-lived when carrying the eect allele); 95% CI, 95% condence interval; I2,
heterogeneity statistic; phet , p-value for heterogeneity; a We were not able to replicate the
eect of this genetic variant, since there was no Taqman SNP Genotyping Assay available.
We only report the most signicant genetic variant for the loci with at least one variant with
a p-value≤1x10−6. The rsID is based on dbSNP build 150. The Chr:Position is based on
Genome Reference Consortium Human Build 37 (GRCh37)
SNP Genotyping Assay available for this variant.
7.2.3 Validation in parental age-based data sets
Given that all available studies with genome-wide genetic data that met
our inclusion criteria were included in our genome-wide association meta-
analyses, we additionally set out to validate our ndings in two UK Biobank
parental longevity data sets (Table 7.1) and the parental lifespan data set
recently created by Timmers and colleagues.[13] Since the genotyped individ-
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uals in the UK Biobank were recruited at relatively young ages (40-69 years),
these data sets were based on the age reached by the parents of the study
participants. Hence, the phenotypes used for validation were dierent from
those used in our meta-analyses, resulting in smaller eect sizes. Moreover,
the reference panels used to impute the genetic variants (a merged panel
of UK10K, 1000G Phase 3, and Haplotype Reference Consortium (HRC) for
parental longevity and HRC alone for parental lifespan)[13] were dierent
from the one used in our meta-analyses (1000G Phase 1), which could have
inuenced the outcome of the analyses. Of the variants that showed a p-
value≤ 1x10−6 in our meta-analyses (Table 7.2), only ApoE ε4 and ε2 were
signicantly associated with both parental longevity and lifespan (p≤0.05)
in these data sets (Table 7.3). Moreover, the rare allele (A) of the second most
signicant variant at the CDKN2A/B locus, rs2184061, was associated with
increased parental lifespan (p=8.4x10−6), but not with parental longevity (p
= 0.329). However, we had adequate power to validate all of our identied
variants, even when the eect sizes were halved in the parental longevity
data sets.
7.2.4 Trans-ethnic meta-analyses




percentile cases versus all controls) to see if the increase in sample size
would lead to identication of additional longevity loci. In this analysis we
included individuals of European (all previously used data sets), East Asian
(CLHLS), and African American (CHS) ancestry. However, with the exception
of APOE and rs2069837, located in IL6, which has previously been associated
with longevity in CLHLS9, this analysis did not identify additional genome-
wide signicant loci (Table 7.4, Figure 7.3 and Figure 7.6). The observed
association of the genetic variant in IL6 in the trans-ethnic meta-analyses
was mainly driven by the association in the East Asian population. The other
variant previously associated with longevity in CLHLS9, rs2440012, located
in ANKRD20A9P, did not pass quality control in the large majority of the
included cohorts from populations of European descent and was thus not
analysed in the trans-ethnic meta-analyses.
7.2.5 Comparison of control definitions
To examine the impact of the denition of controls, we performed a sensitivity
analysis in which we compared the results of the meta-analysis using the
same case denition (90
th
percentile) with (i) all controls and (ii) dead controls
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Figure 7.1: Results of the European genome-wide associationmeta-analyses.
Manhattan plot presenting the − log10 P-values from the European genome-wide
association meta-analysis of the 90
th
percentile cases versus all controls (a) and
99
th
percentile cases versus all controls (b). The red line indicates the threshold for
genome-wide signicance (p≤5x10−8), while the blue line indicates the threshold for
genetic variants that showed a suggestive signicant association (p≤1x10−6). The
variants that are reported in Table 7.2 are highlighted in green. For representation
purposes, the maximum of the y-axis was set to 14. Regional association plot for
the APOE (c) and GPR78 (d) loci based on the results from the 90th percentile cases
versus all controls meta-analysis. The colour of the variants is based on the linkage
disequilibrium with rs429358 (ApoE ε4) (c) or rs7676745 (d)
only. For this analysis, only cohorts that contributed results using both
control denitions were considered (i.e., 100-plus/LASA/ADC, AGES, CHS,
FHS, HRS, LLFS, MrOS, RS, and SOF). The results of the two meta-analyses
with dierent control groups were very similar (Figure 7.7). Among the
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Figure 7.2: Study-specic results for the genetic variants inAPOE andGPR78.
Forest plots for the ApoE ε4 (a) and ε2 (b) variants and rs7676745 (c) based on the
results from the 90
th
percentile versus all controls analysis. The size of the boxes
represents the sample size of the cohort. We had no data available for ApoE ε4 in
LLFS and for rs7676745 in DKLS, GEHA Italy, GEHA Danish, LLS (combined with
GEHA Dutch), Longevity, and Newcastle 85+. The data for ApoE ε2 in FHS was
based on imputation using the Haplotype Reference Consortium reference panel
due to the low-imputation quality of this variant when using the 1000 Genomes
reference panel.
three loci with at least one genetic variant with a p-value≤1x10−6 in either
meta-analysis (and analysed in the same cohorts in both meta-analyses),
the most signicant variants had odds ratios (ORs) that diered by <1%
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(Supplementary Table 1).
7.2.6 Replication of previously identified loci for human lifespan
To determine the association of previously identied loci for human lifespan
and longevity, we performed a look-up of the reported genetic variants within
these loci in our meta-analyses data sets. The only previously identied loci
that contained variants that showed a signicant (p<7.8x10−4, i.e., Bonferroni
adjusted for the number of tested loci (N=64)) and directionally consistent
associations in our study were FOXO3 and CDKN2A/B (Supplementary Data
1). As depicted in Figure 7.8, the eects of the most frequently reported
variants within these loci (i.e., rs2802292 and rs1556516) uctuate between
cohorts and there seems to be no correlation with the genetic background of
the included populations. However, for the reported variants within both
loci, the odds of surviving to the 99
th
percentile age is higher than the odds
of surviving to the 90
th
percentile age, indicating they likely aect both
early and late-life mortality. Several of the loci that have been associated
with increased parental lifespan in the most recent and largest meta-analysis
of GWA studies for this phenotype (i.e., KCNK3, HTT, LPA, ATXN2/BRAP,
and LDLR)[13] contain genetic variants that show a nominal signicant
association (p< 0.05) with higher odds of surviving to the 90th and/or 99th
percentile age. Since the phenotypes used in our study (i.e., cases surviving





dierent from the one used in the previous study (i.e., parental lifespan), we
performed an additional look-up of these variants in one of the UK Biobank
data sets we created for validation of our ndings (i.e., the 90th percentile
cases versus all controls data set). With the exception of the variant in
HTT, all variants showed a nominal signicant association in this data set
(Supplementary Table 2), indicating that the lack of signicant replication of
these loci in our discovery phase data set is not likely to be due to a dierence
in the used phenotype.
7.2.7 Gene-level association analysis
In addition to genetic variant associations, GWA studies can also be used
to identify gene-level associations by integrating results from expression-
quantitative-trait-locus (eQTL) studies that relate variants to gene expression.
In order to identify gene-level associations, we used MetaXcan, an analytic
approach that uses tissue-specic eQTL results from the GTEx project to
estimate gene-level associations with the trait examined from summary-level
7
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Table 7.3: Results of the validation in the UK Biobank parental age-based
data sets
rsID Closest gene Alleles EAF OR 95% CI P
99th percentile cases versus all controls (Parental longevity)
rs116362179 - T/C 0.04 1.01 0.94-1.08 0.775
rs7676745
a GPR78 A/G 0.04 0.98 0.92-1.06 0.667
rs7754015 - G/T 0.43 1.00 0.97-1.03 0.832
rs35262860 RP1 GCT/G 0.39 0.97 0.94-0.99 0.021
rs3138136 RDH5 T/C 0.11 1.00 0.95-1.04 0.863
rs429358 APOE C/T 0.16 0.85 0.81-0.88 1.1x10−16
rs7412 APOE T/C 0.08 1.12 1.06-1.18 2.2x10−5
90th percentile cases versus all controls (Parental longevity)
rs116362179 - T/C 0.04 1.00 0.98-1.02 0.697
rs7676745
a GPR78 A/G 0.05 1.01 0.99-1.03 0.247
rs3138136 RDH5 T/C 0.11 0.99 0.98-1.00 0.135
rs429358 APOE C/T 0.15 0.90 0.89-0.91 3.1x10−83
rs7412 APOE T/C 0.08 1.06 1.05-1.08 7.6x10−17
99th percentile cases versus all controls (Parental longevity)
rs3830412 KALRN A/AT 0.20 1.11 0.99-1.24 0.081
rs138762279 - AT/A 0.34 1.05 0.95-1.17 0.299
rs62502826 KIF13B A/G 0.14 1.04 0.90-1.19 0.614
rs7039467 CDKN2A/B A/G 0.69 0.93 0.83-1.05 0.245
rs2184061 CDKN2A/B A/C 0.40 0.95 0.87-1.05 0.329
rs429358 APOE C/T 0.16 0.76 0.66-0.87 9.6x10−5
rs7412 APOE T/C 0.08 1.23 1.05-1.45 0.011
99th percentile cases versus all controls (Parental longevity)
rs62502826 KIF13B A/G 0.14 1.00 0.99-1.02 0.376
rs2184061 CDKN2A/B A/C 0.40 1.02 1.01-1.03 8.4x10−6
rs429358 APOE C/T 0.15 0.90 0.89-0.91 3.1x10−84
rs7412 APOE T/C 0.08 1.06 1.05-1.08 7.6x10−17
For the CDKN2A/B locus we have also reported the second most signicant variant in
this locus (rs2184061), since the allele frequency of the most signicant variant (rs7039467 )
is not comparable between the meta-analyses and UK Biobank data sets due to dierence
in the reference panel used for imputation. The rsID is based on dbSNP build 150. The
Chr:Position is based on Genome Reference Consortium Human Build 37 (GRCh37). Alleles,
eect allele/other allele; EAF, eect allele frequency; OR [95% CI], odds ratio (i.e., odds of
parent(s) to become long-lived when carrying the eect allele), and relative 95% condence
interval.
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GWA study results.[24] Tissue-specic genetically predicted expression of
14 genes (ANKRD31, BLOC1S1, KANSL1, CRHR1, ARL17A, LRRC37A2, ERCC1,
RELB, DMPK, CD3EAP, PVRL2, GEMIN7, BLOC1S3, and APOC2) was signi-





adjustment for multiple testing (Table 7.5). Eight of these genes (ERCC1,
RELB, DMPK, CD3EAP, PVRL2, GEMIN7, BLOC1S3, and APOC2) are located
near the APOE gene, raising the likely possibility that these associations re-
ected the inuence of variants in this well-established longevity-associated
locus. The remaining genes are located on chromosome 5, 12, and 17. As
depicted in Supplementary Data 2, distinct sets of genetic variants were used
by MetaXcan for all signicant tissue-specic gene expression associations





7.2.8 Genetic correlation analyses
LD score regression was performed to determine the genetic correlation
between the dierent case denitions used for our meta-analyses (based on
the results from the European cohorts only), and between longevity and




percentile analysis, using all controls for both groups, was 1.01 (SE
= 0.06, p = 3.9x10−66). Using LD Hub,[25] which performs automated LD
score regression, we subsequently estimated the genetic correlation of our
phenotypes with 246 diseases and traits available in their database. We found
a signicant genetic correlation of our phenotypes with the father’s age
at death phenotype from the UK Biobank. The most signicant (negative)
genetic correlation of both our phenotypes was with coronary artery disease
(CAD) (rg (SE) = -0.40 (0.07) and rg (SE) = -0.29 (0.07), respectively) and
several traits involved in type 2 diabetes (T2D) also showed a signicant
association with one or both phenotypes after Bonferroni adjustment for
multiple testing (Table 7.6 and Supplementary Data 3).
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Table 7.4: Results of the trans-ethnic genome-wide association meta-analyses
rsID Closest gene Alleles EAF OR [95% CI] P I
2
(%) phet
90th percentile cases versus all controls
rs12143832 ECE1 C/T 0.46 0.90 [0.87-0.94] 2.0x10−7 0 0.722
rs7676745
a GPR78 A/G 0.04 0.67 [0.58-0.78] 1.7x10−7 1.8 0.428
rs1262476 - A/G 0.24 1.12 [1.07-1.17] 9.8x10
−7
0 0.574
rs2069837 IL6 G/A 0.08 0.90 [0.82-0.99] 5.2x10−8 50.7 0.005
rs35262860 RP1 GCT/G 0.39 1.11 [1.07-1.15] 5.6x10−7 0 0.955
rs62127362 CEP89 C/G 0.13 0.87 [0.82-0.93] 4.3x10−7 21.4 0.190
rs429358 APOE C/T 0.13 0.60 [0.55-0.66] 1.0x10−61 52.1 0.004
rs7412 APOE T/C 0.09 1.26 [1.19-1.35] 1.7x10−12 0 0.718
99th percentile cases versus all controls
rs2758603 PMF1 C/T 0.34 1.12 [1.02-1.22] 9.8x10−7 57.2 0.005
rs3830412 KALRN A/AT 0.22 1.21 [1.12-1.30] 8.2x10−7 0 0.767
rs138762279 - AT/A 0.16 0.79 [0.72-0.86] 2.2x10
−7
0 0.769
rs2069837 IL6 G/A 0.09 0.90 [0.76-1.08] 1.4x10−8 67.7 3.5x10−4
rs7039467 CDKN2A/B A/G 0.48 1.20 [1.12-1.28] 2.1x10−7 0 0.843
rs429358 APOE C/T 0.13 0.55 [0.50-0.61] 1.3x10−36 20.0 0.247
rs7412 APOE T/C 0.09 1.39 [1.26-1.53] 1.7x10−12 10.0 0.347
We only report the most signicant genetic variant for the loci with at least one variant with
a p-value ≤1x10−6. The reported p is the p-value from the Han-Eskin random-eects (RE2)
model from METASOFT. The rsID is based on dbSNP build 150; the Chr:Position is based on
Genome Reference Consortium Human Build 37 (GRCh37); Alleles, eect allele/other allele;
EAF, eect allele frequency (based on individuals of European ancestry only); OR, odds ratio
(i.e., odds to become long-lived when carrying the eect allele); 95% CI, 95% condence interval;
I2, heterogeneity statistic; phet , p-value for heterogeneity.
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Figure 7.3: Results of the trans-ethnic genome-wide association meta-
analyses. Manhattan plot presenting the − log10 p-values from the trans-ethnic
genome-wide association meta-analysis of the 90
th
percentile cases versus all con-
trols (A) and 99th percentile cases versus all controls (B). The red line indicates the
threshold for genome-wide signicance (p≤5x10−8), while the blue line indicates
the threshold for genetic variants that showed a suggestive signicant association
(p≤1x10−6).
7.3 Discussion
We brought together studies from all over the world to perform GWA study
meta-analyses in over 13,000 long-lived individuals of diverse ethnic back-
ground, including European, East Asian and African American ancestry,
to characterise the genetic architecture of human longevity. We used the
1000 Genomes reference panel for imputation to expand the coverage of the
genome in comparison to previous GWA studies of longevity. Consistent with
previous reports, rs429358, dening ApoE ε4, was associated with decreased
odds of becoming long-lived. Moreover, we report a genome-wide signicant
association of rs7412, dening ApoE ε2, with increased odds of becoming
long-lived. We additionally found a genome-wide signicant association of a
locus near GPR78. Gene-level association analysis revealed association of in-
creased KANSL1, CRHR1, ARL17A, and LRRC37A2 expression and decreased
ANKRD31 and BLOC1S1 expression with increased odds of becoming long-
lived. Genetic correlation analysis showed that our longevity phenotypes
are genetically correlated with father’s age at death, CAD and T2D-related
phenotypes. Genetic variation in APOE is well known to be associated with
longevity and lifespan, with the rst report more than two dec- ades ago
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in a small candidate gene study.[26] Since then, there have been numerous
candidate gene studies, including individuals of diverse ancestry, which have
identied associations of ApoE with longevity.[27, 28, 29, 30] However, thus
far, rs7412, the ApoE ε2-dening, genetic variant has not been reported to
show a genome-wide signicant association in GWA studies of longevity
and lifespan. This could be due to the fact that we performed imputation
using the 1000 Genomes reference panel, while earlier GWA studies used the
HapMap reference panel, which has limited coverage of this variant. ApoE
mediates cholesterol metabolism in peripheral tissues and is the principal
cholesterol carrier in the brain. The ApoE ε2 and ε4 variants have previously
been associated with a decreased (ε2) or increased (ε4) risk for several age-
related diseases, such as cardiovascular disease and Alzheimer’s disease,[31]
which could explain their eect on longevity. The fact that the two variants
in ApoE show opposite eects may be attributable to dierences in structural
and biophysical properties of the protein, since ApoE ε2 shows high stability
and ApoE ε4 low stability upon folding.[32] We also found a genome-wide
signicant association of rs7676745, located on chromosome 4 near GPR78.
We have to note that this locus would benet from replication in independent
cohorts in the future, given that we were not able to replicate this variant
in the cohorts in which de novo genotyping was applied. There is no re-
port of association of this locus with other traits according to Phenoscanner
(http://www.phenoscanner.medschl.cam.ac.uk/),[33] although other
genetic variants in this gene have been associated with several diseases and
traits in the UK Biobank, including death due to a variety of disorders. The
GPR78 protein, belongs to the family of G-protein-coupled receptors, whose
main function is to mediate physiological responses to various extracellular
signals, including hormones and neuro-transmitters.[34] However, the spe-
cic function of GPR78 is still largely unknown, although it has been shown
to play a role in lung cancer metastasis.[35] To maximise power for discovery,
we meta-analysed results from all of the studies that contained long-lived




percentile case denitions, had
genome-wide genetic data, and were able to participate. Hence, we were
not able to replicate our ndings in an independent cohort with genome-
wide genotype data and participants reaching the age of our case denitions.
Therefore, we tried to validate our ndings using two related phenotypes,
parental longevity and lifespan, in the UK Biobank. We applied our case
and control denitions to the parental lifespan of genotyped middle-aged
UK Biobank participants rather than the participants themselves, as none
of the latter fullled the age criteria for cases in our study. Although this
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analysis, the power to replicate our ndings using the parental longevity
traits was lower in comparison to replication using the traits based on the
genotyped individuals themselves, since these individuals share only half of
their parental genomes. In addition, many of the genotyped individuals, who
were 40-69 years at recruitment, will never reach the age belonging to the
90
th
, let alone the 99
th
, percentile of their birth cohort. This may explain why
we were unable to validate any of our suggestive associations (p≤1x10−6),
with the exception of the genetic variants at the APOE locus in these data sets.
On the other hand, we were able to validate one additional locus, CDKN2A/B,
in the parental lifespan data set. This is not surprising, since this locus had
already been reported to associate with parental lifespan.[13] However, it
is unclear why our reported variants at this locus, rs7039467 and rs2184061,
are not associated with parental longevity, given that the most signicant
parental lifespan-associated variant at this locus, rs1556516, also shows a
nominal signicant eect on parental longevity (see Supplementary Table 2).
We hypothesise that this may be due to a dierence in the LD structure of
the reference panels used for imputation.
We were able to detect signicant genetic associations at two previously
identied longevity-related loci, FOXO3 and CDKN2A/B. For the other loci,
we did not nd evidence for replication (p>7.8x10−4), despite having ade-
quate power (≥0.8) for replication of all but one of the examined genetic
variants (rs28926173) associated with the discrete longevity phenotypes. We
were not able to calculate our power to replicate the variants associated with
the continuous lifespan-related phenotypes, although we should have had
adequate power to replicate variants with a minor allele frequency (MAF) >
12% and an OR > 1.1 (based on the 90
th
percentile versus all controls anal-
ysis). However, several of the variants associated with parental lifespan
show a directionally consistent and nominal signicant association with
our phenotypes, indicating they may also be relevant for longevity. The
failure to replicate previously reported loci could be due to the use of a
dierent longevity phenotype then what was used in previous studies, the
small eect size of some of the variants associated with parental lifespan,
and the modest power of our study. The fact that we detect signicant as-
sociations of variants in the FOXO3 locus is not surprising, since this locus
was previously reported in the longevity GWA study from the CHARGE con-
sortium,[6] from which many cohorts are included in these meta-analyses.
So far, three functional longevity-associated variants have been identied
at the FOXO3 locus (rs2802292, rs12206094, and rs4946935). For all of them,
7
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Table 7.5: Results of the trans-ethnic genome-wide associationmeta-analyses
Genes Tissue OR90 p90 OR99 p99
ANKRD31 Stomach 0.63 1.1x10−6 0.61 9.0x10−4
BLOC1S1 Adipose subcutaneous 0.49 4.5x10−7 0.56 0.009
KANSL1 Skin sun exposed lower leg 1.22 1.5x10−6 1.26 1.9x10−4
CRHR1 Nerve tibial 1.54 3.4x10−7 1.81 6.2x10−6
ARL17A Artery aorta 1.24 8.1x10−7 1.31 5.9x10−5
ARL17A Breast mammary tissue 1.18 1.8x10−6 1.22 3.2x10−4
ARL17A Colon sigmoid 1.21 2.2x10−6 1.21 0.002
LRRC37A2 Minor salivary gland 1.17 2.2x10−6 1.20 4.4x10−4
ERCC1 Ovary 1.19 2.8x10−6 1.24 1.8x10−4
RELB Lung 0.57 2.0x10−7 0.44 2.9x10−6
DMPK Stomach 1.64 1.7x10−6 2.31 1.8x10−6
CD3EAP Brain substantia nigra 0.51 8.0x10−17 0.36 3.8x10−15
PVRL2 Artery coronary 1.36 5.0x10−7 1.59 1.6x10−6
PVRL2 Oesophagus muscularis 1.62 6.6x10−7 2.31 4.4x10−8
GEMIN7 Brain nucleus accumbens basal ganglia 0.85 1.5x10−4 0.70 1.4x10−7
BLOC1S3 Oesophagus muscularis 2.80 6.4x10−16 4.47 1.3x10−13
APOC2 Skin not sun exposed suprapubic 0.75 4.2x10−7 0.74 9.3x10−4
OR, odds ratio (i.e., odds to become long-lived when having an increased tissue-specic gene
expression); p-values, highlighted in bold are signicant after adjustment for multiple testing
of 247,999 longevity associations with gene-tissue pairs (Storey q-value<0.05); OR90 and p90
are based on the analysis of the 90
th
percentile cases versus all controls meta-analysis data set,
while OR99 and p99 are based on the analysis of the 99th percentile cases versus all controls
meta-analysis data set
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an allele-specic response to cellular stress was observed. Consistently, the
longevity-associated alleles of all three variants were shown to induce FOXO3
expression.[36, 37] The CDKN2A/B locus has previously been associated with
parental lifespan and parents’ attained age in the UK Biobank as well as
a diversity of age-related diseases.[38, 13, 39] The longevity-associated al-
lele of the most signicant variant at this locus (rs1556516) has also been
associated with lower odds of developing CAD.[40] Although the molecular
mechanism behind this association is still unclear, it is known that genes
encoded at the CDKN2A/B locus are involved in cellular senescence,[41] a
known hallmark of ageing in animal models.[42] The gene-level association
analysis identied several associations between increased (KANSL1, CRHR1,
ARL17A, and LRRC37A2) or decreased (ANKRD31 and BLOC1S1) genetically
driven tissue-specic gene expression with survival to the 90
th
percentile
age. The increased expression of KANSL1, CRHR1, ARL17A, and LRRC37A2
on chromosome 17q21.31 is regulated by dierent genetic variants, indicat-
ing that these associations may be independent. More functional work is
needed to determine the exact relationship between the altered genetically
driven tissue-specic expression of these genes and longevity in humans.
A limitation of MetaXcan is that the underlying GTEx models might not
have been adequately adjusted for age, which could be problematic for an
age-related phenotype like longevity. However, MetaXcan has successfully
been used to identify gene-level associations with age-related diseases and
traits, such as Alzheimer’s disease and age-related macular degeneration.[24]
The genetic correlation analyses showed that survival to ages correspond-




percentile shared genetic associations with father’s
age at death, CAD and T2D-related phenotypes, suggesting that survival to
old ages may at least partially be explained by protective inuences on the
mechanisms underlying these traits. The genetic correlation with CAD and
T2D-related phenotypes is expected, since it has previously been reported
that individuals from long-lived families show a decreased prevalence of
cardiovascular disease and T2D.[43, 44] The higher genetic correlation of
our longevity phenotypes with father’s in comparison to mother’s age at
death may be explained by the dierence in the prevalence of cardiovas-
cular diseases and T2D between men and women in the last century,[45,
46] which may be, at least partially, attributable to a dierence in smoking
prevalence.[47] Hence, the correlation of our longevity phenotypes with
the parental age at death phenotypes from UK Biobank is likely due to the
absence of death from specic diseases (i.e., those with a higher prevalence
in men). For longevity-specic loci, on the other hand, one would expect
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that they will have benecial eects on multiple diseases simultaneously,
since long-lived individuals show a delay in overall morbidity.[48] Our study
design imposed an age gap between cases and controls to reduce outcome
misclassication, which we expected could potentially increase power by
increasing the genetic eect size. It has been correctly noted that longevity
study designs that include an age gap between cases and controls result in
an eect estimate that is based on an OR and a relative risk (RR) term, which
could lead to the identication of genetic variant associations related to early
mortality (OR), rather than survival past the case age threshold (RR) (for
more details see Sebastiani et al.).[49] However, we have presented evidence
that imposing a case-control age gap did not greatly inuence our results or
prevent our replication of variant associations previously discovered using
study designs without a case-control age gap. First, our sensitivity analysis
indicated that reducing the age gap between cases and controls had a min-
imal eect on our results. Our sensitivity analysis compared results using
dead controls, where all individuals had died before they reached the 60
th
percentile age, and all controls, which included dead controls and individuals
whose age at last contact was below the 60
th
percentile age but whose age
of death was unknown. There is likely to be some outcome misclassication
of the living controls, since a small percentage may survive beyond the age




survival percentile. On the other hand, the
age gap between cases and controls was narrower for all controls compared
to dead controls. However, despite the narrower age gap, the suggestively
signicant results in all controls and dead controls comparisons with 90
th
per-
centile cases were essentially unchanged, and there was a very high genetic
correlation between the results of these two meta-analyses, indicating that
the age gap had little or no impact on our results. Second, if we had discov-
ered a large number of genome-wide signicant variant associations in our
study, it could be argued that the OR, reecting early mortality, contributed
to some or all of them. However, the only genome-wide signicant variant
associations we detected were in the APOE locus, which have been identied
using multiple study designs, including designs with no prespecied age gap
between cases and controls,[12] and the GPR78 locus. Third, it is unlikely
that our study design prevented the replication of ndings from previous
GWA studies of survival to extreme ages (i.e., 99th percentile cases) that did
not include a case-control age gap, since such studies would only identify
variants associated with survival past the minimum case age and not with
early mortality. For variants with no early mortality association, it would be
expected that the association estimate in our study would have an OR equal
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Table 7.6: Results of the genetic correlation analyses of the 90th and 99th
percentile phenotypes with other diseases and traits
Disease/Trait rg90 (SE90) p90 rg99 (SE99) p99
Coronary artery disease -0.40 (0.07) 1.7x10−8 -0.29 (0.07) 1.2x10−5
Fathers age at death 0.74 (0.13) 2.5x10−8 0.54 (0.13) 2.7x10−5
HDL cholesterol 0.36 (0.07) 1.0x10−7 0.22 (0.07) 0.002
Age of rst birth 0.33 (0.07) 3.8x10−7 0.16 (0.07) 0.019
Years of schooling 2016 0.26 (0.05) 9.6x10−7 0.12 (0.05) 0.017
Waist circumference -0.26 (0.05) 2.4x10−6 -0.19 (0.06) 0.001
Type 2 diabetes -0.44 (0.10) 4.4x10−6 -0.42 (0.10) 2.0x10−5
Overweight -0.28 (0.06) 1.2x10−5 -0.23 (0.07) 9.0x10−4
Fastin insulin main eect -0.45 (0.11) 3.0x10−5 -0.33 (0.11) 0.002
Urate -0.26 (0.07) 5.0x10−5 -0.15 (0.06) 0.013
Body mass index -0.21 (0.05) 9.2x10−5 -0.19 (0.07) 0.004
Cigarettes smoked per day -0.49 (0.13) 1.0x10−4 -0.31 (0.13) 0.016
Mothers age at death 0.51 (0.14) 2.0x10−4 0.14 (0.13) 0.289
Waist-to-hip ratio -0.24 (0.07) 2.0x10−4 -0.15 (0.07) 0.028
p-values highlighted in bold are signicant after Bonferroni adjustment for multiple testing
(p < 0.05/246). rg90, SE90, and p90 are based on the analysis of the 90th percentile cases
versus all controls meta-analysis data set, while rg99, SE99, and p99 are based on the analysis
of the 99
th
percentile cases versus all controls meta-analysis data set. rg, genetic correlation;
SE, standard error of the rg estimate; HDL, high-density lipoprotein.
to one and a RR greater than one. Nothing prevents our study design from
also detecting this type of variant association, as our estimated association
parameter reects both the OR and RR.
The majority of the previously performed GWA studies of longevity
used the survival of individuals to a pre-dened age threshold (i.e., 85, 90,
or 100 years) as selection criterion to dene long-lived cases. Although
these studies used a consistent phenotype for each cohort included in the
GWA study, this type of selection may gave rise to heterogeneity, given that
survival probabilities dier between sexes and birth cohorts.[21] Moreover,
it was recently shown that the heritable component of longevity is strongest
in individuals belonging to the top 10% survivors of their birth cohort.[2]
Hence, instead of using a pre-dened age threshold, we decided to select
cases based on country-, sex- and birth cohort-specic life tables. For the
denition of controls we used the 60
th
percentile age, since we wanted to
include as many controls as possible (preferably from the same cohort as
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the cases), while leaving a large enough age gap between our cases and





percentile age is 14 years (men) or 11 years (women), which





age, on the other hand, is considerably smaller (9 years (men) or 7 years
(women)) and the living controls are more likely to reach the 90
th
percentile
age, which increases the risk of outcome misclassication. Moreover, even
when selecting the 60
th
percentile controls from much later birth cohorts (i.e.,
1940) than the cases (i.e., 1900) the ages will not overlap. Our study has several
limitations. First, we did not analyse the sex and mitochondrial chromosomes,
since we were unable to gather enough cohorts that could contribute to the
analysis of these chromosomes. However, these chromosomes may harbour
loci associated with longevity that we thus have missed. Second, although
we included as many cohorts as possible, the sample size of our study is still
relatively small (especially for the 99
th
percentile analysis) in comparison
to GWA studies of age-related diseases, such as T2D and cardiovascular
disease, and parental age at death.[9, 50, 51] Hence, this limited our power
to detect loci with a low MAF (<1%) that contribute to longevity. Third,
we did not perform sex-stratied analyses and may thus have missed sex-
specic longevity-related genetic variants. The reason for this is that (i)
we only identied a limited number of suggestive signicant associations




percentile analyses, (ii) our sample size is
modest (especially when stratied by sex), and (iii) thus far, there has been
no report of any genome-wide signicant sex-specic longevity locus. Given
that we have included nearly all cohorts with long-lived individuals with
genome-wide genetic data in our study, it will be challenging to increase
the sample size in future GWA studies using the same extreme phenotypes.
Future genetic studies of longevity may therefore benet from the use of
alternative phe- notypes or more rigorous phenotype denitions. Alternative
phenotypes that could be used are the parental lifespan or healthspan-related
phenotypes that were analysed in the UK Biobank or biomarkers of healthy
aging.[13, 52, 53] One way to strengthen the longevity phenotype is by
selecting cases from families with multiple individuals belonging to the top
10% survivors of their birth cohort.[2] Moreover, given the limited number
of longevity-associated genetic variants identied through GWA studies and
the availability of aordable exome and whole-genome sequencing, future
genetic studies of longevity may also benet from the analysis of rare genetic
variants. Ideally, such studies should also try to include participants from
genetically diverse populations. Most cohorts that are currently included in
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genetic longevity studies originate from populations of European descent,
while some longevity loci may be specic for non-European populations, as
exemplied by the previously reported genome-wide associations of genetic
variants in IL6 and ANKRD20A9P in Han Chinese.[8] Moreover, a recent
genetic study of multiple complex traits has shown the benet of analysis
of diverse populations.[54] In conclusion, we performed a genome-wide
association study of longevity-related phenotypes in individuals of European,
East Asian and African American ancestry and identied theAPOE andGPR78
loci to be associated with these phenotypes in our study. Moreover, our gene-
level association analyses highlight a role for tissue-specic expression of
genes at chromosome 5q13.3, 12q13.2, 17q21.31, and 19q13.32 in longevity.
Genetic correlation analyses show that our longevity-related phenotypes
are genetically correlated with several disease-related phenotypes, which
in turn could help to identify phenotypes that could be used as potential





In this collaborative eort, we included cohorts that participated in one or
more of the previously published GWA studies on longevity.[6, 7, 8] The
sample sizes and descriptive characteristics of the cohorts used in this study
are provided in Table 7.1, Supplementary Data 4, and the Supplementary
Methods. We have complied with all relevant ethical regulations for work
with human subjects. All participants provided written informed consent
and the studies were approved by the relevant institutional review boards.
7.4.2 Case and control definitions





based on cohort life tables from census data from the appropriate country,
sex, and birth cohort. Controls were individuals who died at or before the
age at the 60
th
percentile or whose age at the last follow-up visit was at
or before the 60th percentile age. Hence, the number of selected cases and







percentile age and is independent of the study population
used (i.e., the number of controls and cases within a study population is
not based on the percentiles of that specic population, but instead on that
of their birth cohorts). As part of their recruitment protocol, many of the
studies enroled participants that were already relatively old at the time
of recruitment (i.e., close to (or even over) the 60th percentile age). The
majority of these individuals subsequently survived past the 60
th
percentile
age threshold of their respective birth cohorts, resulting in a small number
of controls in comparison to the number of cases for some of these studies.
The cohort life tables were available through the Human Mortality Database
(www.mortality.org),[55] the United States Social Security Administration






percentile correspond to ages of 75, 89, and 98 years for men and 83, 94, and
102 years for women for the 1920 birth cohort from the US. For cohort life
tables providing birth cohort by decade, linear model predictions were used
to estimate the ages corresponding to survival percentiles at yearly birth
cohorts. For the parental longevity analyses in the UK Biobank, cases were




percentile and who had not themselves died, while controls were individuals
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7.4.3 Genome-wide association analysis of individual cohorts
Details on the genotyping (platform and quality control criteria), imputation
and genome-wide association analyses for each cohort are provided in Sup-
plementary Data 5. In all cohorts, genetic variants were imputed using the
1000G Phase 1 version 3 reference panel. The logistic regression analyses
were adjusted for clinical site, known family relationships, and/or the rst
four principal components (if applicable). All cohorts used a Hardy-Weinberg
equilibrium (HWE) p-value that was between 1x10−4 and 1x10−6 to exclude
variants not in HWE, which is considered standard in GWA studies. However,
this may have resulted in removal of variants that were out of HWE in the
cases due to mortality selection.[56]
7.4.4 ality control of individual cohorts
Quality control of the summary statistics from each cohort was performed
using the EasyQC software and the standard script (leqc-1000G.ecf) avail-
able on their website.[57] The only dierence was that we used the expected
minor allele count (eMAC) instead of the MAC. To this end, we rst calcu-
lated the Eective N (2/(1/Ncases + 1/Ncontrols)) for each cohort. The use of
the Eective N instead of the Total N leads to a more stringent ltering of
genetic variants and decreases the chance of false positive ndings due to
an imbalance between the number of cases and controls.[57] The Eective N
was subsequently used to calculate the eMAC (2 x minor allele frequency x
Eective N x imputation quality) for each variant. Variants were excluded
when eMAC < 10, with the exception of the Newcastle 85 + (90
th
percentile
cases versus all controls) and the RS (99
th
percentile cases versus all controls)
data sets in which we excluded variants when eMAC < 25 due to the large
imbalance between the number of cases and controls in these data sets (1:24
and 1:38, respectively) in comparison to the other ones (all < 1:10). For the
CLHLS and LLFS data sets, we ipped the strands of several variants based
on the dis- cordance of allele frequencies with the reference panel. We only
ipped palindromic variants with a MAF < 0.4 and an allele frequency that
diered from the reference panel by <10% after switching.
7.4.5 Meta-analyses
The xed-eect meta-analyses based on the data sets with individuals of
European ancestry were performed on the cleaned les using METAL,[58]
with the Eective N as weight and adjustment for genomic control (lambda
(λ)) for each cohort. Cohorts with an Eective N < 50 were excluded from
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the meta- analyses. We did not apply genomic control on the meta-analyses
results, since there was limited ination (all λ < 1.04, Figure 7.4). The trans-
ethnic meta-analyses were performed using the random-eects model of Han
and Eskin, implemented in METASOFT.[59] This model separates hypothesis
testing from the estimation of the eect size, which allows the test to better
model the between-study heterogeneity that is typically encountered in a
trans-ethnic meta-analysis. Prior to using METASOFT, study-specic results
were ltered as described above, which included removing genetic variants
with eMAC < 10, and applying genomic control by multiplying each variant’s
standard error by the inverse of the square root of the lambda for cohorts
with λ > 1. Genetic variants for which the total Eective N was less than half
of the maximum Eective N were removed from the meta-analyses results.
7.4.6 Conditional analyses
Conditional analyses were performed using the -condition-on option im-
plemented in SNPTEST to determine the number of independent signals at
the APOE locus. We performed this analysis in the cohorts that were anal-
ysed using SNPTEST and for which both the ApoE ε4 and ApoE ε2 variant
showed a signicant association in the unadjusted analysis (i.e., CEPH and
LLS (combined with GEHA Dutch)). In both cohorts, the association of ApoE
ε2 remained signicant (p < 0.05) after adjustment for ApoE ε4, indicating
an independent eect.
7.4.7 Gene-level association analysis
MetaXcan was used to identify genetically predicted tissue-specic expres-




percentile cases versus all controls meta-analyses.[24] GTEx version 7 tissue
models of genetically predicted expression were used. To maximize the num-
ber of genetic variants that MetaXcan could match with tissue models, the
MetaXcan SNP annotation le (gtex_v7_hapmapceu_dbsnp150_snp_annot.txt)
was used to map variants from the GWA study results le to rsIDs by chro-
mosome, position, and alleles. To control for the false discovery rate when
testing multiple genes across multiple tissues, the Storey q-value was applied
and a q-value < 0.05 was considered signicant.[60] Colocalization of the
tissue-specic eQTL results from the GTEx project and our longevity meta-
analyses results was performed using the coloc.abf function implemented in
the R-package coloc.[61]
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7.4.8 Genetic correlation analysis
To estimate the genetic correlation between the dierent phenotypes used in
this study, we used LD score regression.[23] The genetic correlation between




percentile cases versus all controls meta-
analyses and 246 diseases and traits were estimated using the LD Hub web
portal (http://ldsc.broadinstitute.org/ldhub/).[25] Since LD score
regression is currently only possible with data from individuals of European
ancestry, we used our meta-analyses results based on the cohorts from
populations of European descent only.
7.4.9 Power calculation
The power calculations for the validation in the UK Biobank and for the
replication of previously identied loci associated with human lifespan were
performed using the Genetic Association Study Power Calculator (available
here) using an additive disease model and a disease prevalence of 0.1 (90
th




Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
7.5 Data availability
The full meta-analyses summary statistics are available for download at this
address, through GRASP website (accessible here), and through the NHGRI-
EBI GWAS Catalog website (here). All other data that supports the ndings
of this study are available from the corresponding authors upon request.
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7.8 Supplementary Figures
Figure 7.4: Quantile-quantile plots for the European genome-wide associa-
tion meta-analyses. Quantile-quantile plots of the expected versus (unadjusted)
observed − log10 P-values for the European genome-wide association meta-analyses
of the 90
th
percentile cases versus all controls (λ = 1.036, a) and 99th percentile
cases versus all controls (λ = 1.036, b).
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Figure 7.5: Results of the suggestive signicant genetic variants from the
European genome-wide association meta-analyses. Forest plot for the sug-
gestive signicant genetic variants from the European genome-wide association




percentile versus all controls. We had insuf-
cient studies with data for rs7676745 in the 99th percentile versus all controls
meta-analysis to reliable analyse this genetic variant due to its relatively low minor
allele frequency.
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Figure 7.6: Quantile-quantile plots for the trans-ethnic genome-wide asso-
ciation meta-analyses. Quantile-quantile plots of the expected versus (unad-
justed) observed − log10 P-values for the trans-ethnic genome-wide association
meta-analysis of the 90
th
percentile cases versus all controls (λ = 0.97, a) and 99th
percentile cases versus all controls (λ = 0.93, b).
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Figure 7.7: Results for the European genome-wide association meta-
analyses using dierent control denitions. Manhattan plot presenting the
− log10 P-values from the European genome-wide association meta-analysis of the
90
th
percentile cases versus all controls (a) or dead controls only (b). The red line
indicates the threshold for genome-wide signicance (P ≤5x10−8), while the blue
line indicates the threshold for genetic variants that showed a suggestive signicant
association (P ≤ 1x10−6). For representation purposes, the maximum of the Y-axis
was set to 14.
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Figure 7.8: Study-specic results for the genetic variants in FOXO3 and
CDKN2A/B. Forest plots for rs2802292 (a) and rs1556516 (b) based on the results
from the 90
th
percentile versus all controls analysis. The size of the boxes represents
the sample size of the cohort.
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7.9 Supplementary Tables
Supplementary Tables and Supplementary Information can be accessed by
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snpXplorer: aweb application to explore SNP-associations
and annotate SNP-sets
Niccolo’ Tesi, Sven J. van der Lee, Marc Hulsman, Henne Holstege
and Marcel J.T. Reinders





Genetic association studies are frequently used to study the genetic
basis of numerous human phenotypes. However, the rapid interro-
gation of how well a certain genomic region associates across traits
as well as the interpretation of genetic associations is often complex
and requires the integration of multiple sources of annotation, which
involves advanced bioinformatic skills. We developed snpXplorer, an
easy-to-use web-server application for exploring Single Nucleotide
Polymorphisms (SNP) association statistics and to functionally anno-
tate sets of SNPs. snpXplorer can superimpose association statistics
from multiple studies, and displays regional information including
SNP associations, structural variations, recombination rates, eQTL,
linkage disequilibrium patterns, genes and gene-expressions per tis-
sue. By overlaying multiple GWAS studies, snpXplorer can be used
to compare levels of association across dierent traits, which may
help the interpretation of variant consequences. Given a list of SNPs,
snpXplorer can also be used to perform variant-to-gene mapping and
gene-set enrichment analysis to identify molecular pathways that are
overrepresented in the list of input SNPs. snpXplorer is freely available
at https://snpxplorer.net. Source code, documentation, exam-
ple les and tutorial videos are available within the Help section of
snpXplorer and at https://github.com/TesiNicco/snpXplorer.
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8.1 Background
Genome-wide association studies (GWAS) and sequencing-based association
studies are a powerful approach to investigate the genetic basis of complex
human phenotypes and their heritability. Facilitated by the cost-eectiveness
of both genotyping and sequencing methods and by established analysis
guidelines, the number of genetic association studies has risen steeply in the
last decade: as of February 2021, the GWAS-Catalog, a database of genetic
association studies, contained 4,865 publications and 247,051 variant-trait
associations. [1] To understand how genetic factors aect dierent traits,
it is valuable to explore various annotations of genomic regions as well as
how associations relate between dierent traits. But this requires combining
diverse sources of annotation such as observed structural variations (SV),
expression-quantitative-trait-loci (eQTL), or chromatin context. Moreover, a
framework to quickly visualize and compare association statistics of specic
genomic regions across multiple traits is missing, and may be benecial to
the community of researchers working on human genetics. In addition, the
functional interpretation of the eects of genetic variants on a gene-, protein-
or pathway-level is dicult as often genetic variants lie in non-coding re-
gions of the genome. As a one- to one mapping between genetic variants
and aected genes is not trivial in these circumstances, it might be wise
to associate multiple genes with a variant. Hence, a profound knowledge
of biological databases, bioinformatics tools, and programming skills is of-
ten required to interpret GWAS outcomes. Unfortunately, not everyone is
equipped with these skills. To assist human geneticists, we have developed
snpXplorer, a web-server application written in R that allows (i) the rapid
exploration of any region in the genome with customizable genomic features,
(ii) the superimposition of summary statistics from multiple genetic associ-
ation studies, and (iii) the functional annotation and pathway enrichment
analysis of SNP sets in an easy-to-use user interface.
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Figure 8.1: snpXplorer graphical abstract. The gure shows an overview of the
exploration and annotation capabilities of snpXplorer.
8.2 Methods
8.2.1 Web server structure
snpXplorer is a web-server application based on the R package shiny that
oers an exploration section and a functional annotation section. The ex-
ploration section represents the main interface (Figure 8.1) and provides an
interactive exploration of a (set of) GWAS data sets. The functional annota-
tion section takes as input any list of SNPs, runs a functional annotation and
enrichment analysis in the background, and send the results by email.
8.2.2 Exploration section
First, input data must be chosen, which can either be one of the available
summary statistics datasets and/or the user can upload their own association
dataset. One of the main novelties in snpXplorer is the possibility to select
multiple association datasets as inputs (including data uploaded by the user).
These will be displayed on top of each other with dierent colours. The avail-
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able summary statistics will be kept updated. As of February 2021, snpXplorer
includes genome-wide summary statistics of 23 human traits classied in 5
disease categories: neurological traits (Alzheimer’s disease, family history
of Alzheimer’s disease, autism, depression, and ventricular volume),[2, 3,
4, 5, 6] cardiovascular traits (coronary artery disease, systolic blood pres-
sure, body-mass index and diabetes), [7, 8, 9, 10] immune-related traits
(severe COVID infections, Lupus erythematosus, inammation biomark-
ers and asthma),[11, 12, 13, 14] cancer-related traits (breast, lung, prostate
cancers, myeloproliferative neoplasms and Lymphocytic leukaemia),[15, 16,
17, 18] and physiological traits (parental longevity, height, education, bone-
density and vitamin D intake).[9, 19, 20, 21, 22] These summary statistics
underwent a process of harmonization: we use the same reference genome
(GRCh37, hg19) for all SNP positions, and in case a study was aligned to the
GRCh38 (hg38), we translate the coordinates using the liftOver tool.[23] In
addition, we only store chromosome, position and p-value information for
each SNP-association. The user may upload own association statistics to
display within snpXplorer : the le must have at least chromosome-, position-,
and p-value columns, and the size should not exceed 600Mb. snpXplorer
automatically recognizes the dierent columns, supports PLINK (v1.9+ and
v2.0+) association les,[24] and we provide several example les in the Help
section of the web-server. After selecting the input type, the user should
set the preferred genome version. By default, GRCh37 is used, however, all
available annotation sources are available also for GRCh38, and snpXplorer
can translate genomic coordinates from one reference version to another. In
order to browse the genome, the user can either input a specic genomic
position, gene name, variant identier, or select the scroll option, which
allows to interactively browse the genome. The explorative visualisation
consists of 3 separate panels showing (i) the SNP summary statistics of the
selected input data (Figure 1A), (ii) the structural variants in the region of
interest (Figure 1B), and (iii) the tissue-specic RNA-expression (Figure 1C).
The rst (and main) visualization panel shows the association statistics of
the input data in the region of interest: genomic positions are shown on the
x-axis and association signicance (in − log10 scale) is reported on the y-axis.
Both the x-axis and the y-axis can be interactively adjusted to extend or
contract the genomic window to be displayed. Linkage disequilibrium (LD)
patterns are optionally shown for the most signicant variant in the region,
the input variant, or a dierent variant of choice. The linkages are calculated
using the genotypes of the individuals from the 1000Genome project, with
the possibility to select the populations to include.[25] There are two ways to
8
8.2 Methods 241
visualise the data: by default, each variant-association is represented as a dot,
with dot-sizes optionally reecting p-values. Alternatively, associations can
be shown as p-value proles: to do so, (i) the selected region is divided in bins,
(ii) a local maximum is found in each bin based on association p-value, and
(iii) a polynomial regression model is tted to the data, using the p-value of
all local maximum points as dependent variable and their genomic position
as predictors. Regression parameters, including the number of bins and the
smoothing value, can be adjusted. Gene names from RefSeq (v98) are always
adapted to the plotted region.[26] Finally, recombination rates from HapMap
II, which give information about recombination frequency during meiosis,
are optionally shown in the main plot interface.[27] The second panel shows
structural variations (SV) in the region of interest. These are extracted from
three studies that represent the state-of-the-art regarding the estimation
of major structural variations across the genome using third-generation
sequencing technologies (i.e. long read sequencing).[28, 29, 30] Structural
variations are represented as segments: the size of the segment codes for the
maximum dierence in allele sizes of the SVs as observed in the selected stud-
ies. Depending on the dierent studies, structural variations are annotated
as insertions, deletions, inversions, copy number alterations, duplications,
mini-, micro- and macro-satellites, and mobile element insertions (Alu el-
ements, LINE1 elements, and SVAs). The third panel shows tissue-specic
RNA-expression (from the Genotype-Tissue-expression consortium, GTEx)
of the genes displayed in the selected genomic window.[31] The expression
of these genes across 54 human tissues is scaled and reported as a heatmap.
Hierarchical clustering is applied on both the genes and the tissues, and the
relative dendrograms are reported on the sides of the heatmap.
The side panel allows the user to interact with the exploration section.
In order to guide the user through all the available inputs and options, help
messages automatically appear upon hovering over items. The side panel
reports (i) the top 10 variants with highest signicance (together with the
trait they belong to, in case multiple studies were selected), and (ii) the top
eQTLs associations (by default, eQTLs in blood are shown, and this can
be optionally changed), and cross-references including GeneCards, GWAS-
catalog, and LD-hub.[1, 32, 33] Finally, download buttons allow to download
a high-quality image of the dierent visualisation panels as well as the tables
reporting the top SNP and eQTL associations, the SVs in the selected genomic
window, and the LD table.
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Figure 8.2: snpXplorer exploration section. A. First and main visualisation
interface reporting summary statistics of multiple genetic studies as shown with
p-value proles. B. Structural variants within the region of interest are reported as
segments and colored according to their type C. Tissue-specic RNA-expression




8.2.3 Functional Annotation section
The functional annotation pipeline consists of a two-step procedure: rstly,
genetic variants are linked to likely aected genes (variant-gene mapping);
and, secondly, the likely aected genes are tested for pathway enrichment
(gene-pathway mapping). In the variant-gene mapping, genetic variants are
linked to the most likely aected gene(s) by (i) associating a variant to a gene
when the variant is annotated to be coding by the Combined Annotation
Dependent Depletion (CADD, v1.3), (ii) annotating a variant to genes based
on found expression-quantitative-trait-loci (eQTL) from GTEx (v8, with
possibility to choose the tissue(s) of interest), or (iii) mapping a variant to
genes that are within distance d from the variant position, starting with d ≤
50kb, up to d ≥ 500kb, increasing by 50kb until at least one match is found
(from RefSeq v98).[26, 31, 34] Note that this procedure might map multiple
genes to a single variant, depending on the eect and position of each variant.
Then, we rst report whether the input SNPs as well as their likely associated
genes were previously associated with any trait in the GWAS-Catalog (traits
are coded by their Experimental Factor Ontology (EFO) term). For this
analysis, we downloaded all signicant SNP-trait associations of all studies
available in the GWAS-Catalog (v1.0.2, available at https://www.ebi.ac.
uk/gwas/docs/file-downloads), which includes associations with p <
9x10−6. Given a set of input SNPs associated with a set of genes, this
analysis results in a set of traits (provided that the SNPs and/or the genes
were previously associated with a trait). Hereto, we plot the number of SNPs
in the list of uploaded SNPs that associate with the trait (expressed as a
fraction). To correct for multiple genes being associated with a single variant,
we estimate these fractions by sampling (500 iterations) one gene from
the pool of genes associated with each variant, and averaging the resulting
fractions across the sampling. Summary tables of the GWAS-Catalog analysis,
including also EFO URI links for cross-referencing are provided as additional
output. Next, we report on the structural variations that lie in the vicinity
(10kb upstream and downstream) of the input SNPs, and present information
such as SV start and end position, SV type, maximum dierence in allele
size, and genes likely associated with the relative SNPs. Finally, we perform
a gene-set enrichment analysis to nd molecular pathways enriched within
the set of genes associated with the input variants. Also, here we use the
mentioned sampling technique to avoid a potential enrichment bias due to
multiple genes being mapped to the same variant (this time the sampling is
used to calculate p-values for each term). The gene-set enrichment analysis
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is performed using the Gost function from the R package gproler2.[35] The
user can specify several gene-set sources, such as Gene Ontology (release
2020-12-08),[36] KEGG (release 2020-12-14),[37] Reactome (release 2020-12-
15),[38] and Wiki-pathways (release 2020-12-10).[39] The full table of the
gene-set enrichment analysis comprising all tested terms and their relative
sampling-based p-values is sent to the user. For each of the selected gene-set
sources, the signicant enriched terms are plotted (up to FDR<10%). In case
the Gene Ontology is chosen as gene-set source, we additionally reduce the
visual complexity of the enriched biological processes using (i) the REVIGO
tool and (ii) a term-based clustering approach.[40] We do so because the
interpretation of gene-set enrichment analyses is typically dicult due to
the large number of terms. Clustering enriched terms then helps to get an
overview, and thus eases the interpretation of the results. Briey, REVIGO
masks redundant terms based on a semantic similarity measure, and displays
enrichment results in an embedded space via eigenvalue decomposition of the
pairwise distance matrix. In addition to REVIGO, we developed a term-based
clustering approach to remove redundancy between enriched terms. To do
so, we rst calculate a semantic similarity matrix between all enriched terms,
and then apply hierarchical clustering on the obtained distance matrix. We
estimate the optimal number of clusters using a dynamic cut tree algorithm
and plot the most recurring words of the terms underlying each cluster using
wordclouds. We use Lin as semantic distance measure for both REVIGO
and our term-based clustering approach.[41] Figures representing REVIGO
results, the semantic similarity heatmap (showing relationships between
enriched terms), the hierarchical clustering dendrogram, and the wordclouds
of each clusters, are generated. Finally, all tables describing REVIGO analysis
and our term-based clustering approach (including all enriched terms and
their clustering scheme) are produced and sent as additional output to the
user for further manipulation. Note that the initial signicant GO terms are





To illustrate the performances of snpXplorer, we explored the most recent set
of common SNPs associated with late-onset Alzheimer’s disease (AD, N=83
SNPs, Table S1).[42] Using this dataset as case study, we show the benets of
using snpXplorer in a typical scenario. Briey, AD is the most prevalent type
of dementia at old age, and is associated with a progressive loss of cognitive
functions, ultimately leading to death. In its most common form (late-onset
AD, with age at onset typically >65 years), the disease is estimated to be
60-80% heritable. With an attributable risk of ∼30%, genetic variants in APOE
gene represent the largest common genetic risk factor for AD. In addition
to APOE, the genetic landscape of AD now counts 83 common variants that
are associated with a slight modication of the risk of AD. Understanding
the genes most likely involved in AD pathogenesis as well as the crucial
biological pathways is warranted for the development of novel therapeutic
strategies for AD patients. We retrieved the list of AD-associated genetic
variants in Table 1 of the preprint from Bellenguez et al, 2020.[42] This study
represent the largest GWAS on AD performed to date, and resulted in 42
novel SNPs reaching genome-wide evidence of association with AD. The
exploration section of snpXplorer can be rstly used to inspect the association
statistics of the novel SNP-associations in previous studies of the same trait
(i.e. International Genomics of Alzheimer Project (IGAP) and family history
of AD (proxy AD)). Specically, a suggestive degree of association in these
regions is expected to be found in earlier studies. As expected, suggestive
association signals were already observed for the novel SNPs, increasing the
likelihood that these novel SNPs are true associations (Figure 8.4).
After the rst explorative analysis, we pasted the variant identiers
(rsIDs) in the annotation section of snpXplorer, specifying rsid as input type,
Gene Ontology and Reactome as gene-sets for the enrichment analysis, and
Blood as GTEx tissue for eQTL (i.e. the default value). The N=83 variants
were linked to a total of 162 genes, with N=54 variants mapping to 1 gene,
N=12 variants mapping to 2 genes, N=7 variants mapping to 3 genes, N=2
variants mapping to 4 genes, N=1 variant mapping to 5 genes, N=4 variants
mapping to 4 genes, and N=1 variant mapping to 7, 8 and 11 genes (??). N=10
variants were found to be coding variants, N=31 variants were found to be
eQTL, and N=42 variants were annotated based on their genomic position.
These results are returned to the user in the form of a (human and machine-
readable) table, but also in the form of a summary plot (Figure 8.3A and ??).
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Figure 8.3: Results of the functional annotation of N=83 variants associated
with Alzheimer’s disease (AD). A. The circular summary gure shows the type
of annotation of each genetic variant used as input (coding, eQTL or annotated by
their positions) as well as each variant’s minor allele frequency and chromosomal
distribution. B. REVIGO plot, showing the remaining GO terms after removing
redundancy based on a semantic similarity measure. The colour of each dot codes
for the signicance (the darker, the more signicant), while the size of the dot
codes for the number of similar terms removed from REVIGO. C. Results of our
term-based clustering approach. We used Lin as semantic similarity measure to
calculate similarity between all GO terms. We then used ward-d2 as clustering
algorithm, and a dynamic cut tree algorithm to highlight clusters. Finally, for each
cluster we generated wordclouds of the most frequent words describing each cluster.
8
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These graphs not only inform the user about the eect of the SNPs of interest
(for example, a direct consequence on the protein sequence in case of coding
SNPs, or a regulatory eect in case of eQTLs or intergenic SNPs), but also
suggest the presence of more complex regions: for example, ??B indicates
the number of genes associated with each SNP, which normally increases for
complex, gene-dense regions such as HLA-region or IGH -region. In order to
prioritize candidate genes, the authors of the original publication integrated
(i) eQTLs and colocalization (eQTL coloc) analyses combined with expres-
sion transcriptome-wide association studies (eTWAS) in AD-relevant brain
regions; (ii) splicing quantitative trait loci (sQTLs) and colocalization (sQTL
coloc) analyses combined with splicing transcriptome-wide association stud-
ies (sTWAS) in AD-relevant brain regions; (iii) genetic-driven methylation
as a biological mediator of genetic signals in blood (MetaMeth).[43] In order
to compare the SNP-gene annotation of the original study with that of snpX-
plorer, we counted the total number of unique genes associated with the SNPs
(i) in the original study (N=97), (ii) using our annotation procedure (N=136),
and (iii) the intersection between these gene sets (N=79). When doing so, we
excluded regions mapping to the HLA-gene cluster and IGH -gene clusters (3
SNPs in total) as the original study did not report gene names but rather HLA-
cluster and IGH -cluster. Nevertheless, our annotation procedure correctly
assigned HLA-related genes and IGH -related genes with these SNPs. The
number of intersecting genes was signicantly higher than what could be
expected by chance (p=0.03, based on one-tail p-value of binomial test, Table
S2). For 6 SNPs, the gene annotated by our procedure did not match the gene
assigned in the original study. Specically, for 4/6 of these SNPs, we found
signicant eQTLs in blood (rs60755019 with ADCY10P1, rs7384878 with PILRB,
STAG3L5P, PMS2P1, GIGYF1, and EPHB4 genes, rs56407236 with FAM157C
gene, and rs2526377 with TRIM37 gene), while the original study reported the
closest genes as most likely gene (rs60755019 with TREML2 gene,rs7384878
with SPDYE3 gene,rs56407236 with PRDM7 gene and rs2526377 with TSOAP1
gene). In addition, we annotated SNPs rs76928645 and rs139643391 to SEC61G
and WDR12 genes (closest genes), while the original study, using eQTL and
TWAS in AD-relevant brain regions, annotated these SNPs to EGFR and
ICA1L/CARF genes. While the latter two SNPs were likely mis-annotated in
our procedure (due to specic datasets used for the annotation), our annota-
tion of the former 4 SNPs seemed robust, and further studies will have to
clarify the annotation of these SNPs. With the resulting list of input SNPs and
(likely) associated genes, we probed the GWAS-Catalog and the datasets of
structural variations for previously reported associations. We found a marked
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enrichment in the GWAS-Catalog for Alzheimer’s disease, family history of
Alzheimer’s disease, and lipoprotein measurement (??, Table S3 and Table
S4). The results of this analysis are relevant to the user as they indicate other
traits that were previously associated with the input SNPs. As such, they may
suggest relationships between dierent traits, for example in our case study
they suggest the involvement of cholesterol and lipid metabolism in AD, a
known relationship.[43] Next, we searched for all structural variations in a re-
gion of 10kb surrounding the input SNPs, and we found that for 39/83 SNPs,
a larger structural variations was present in the vicinity (Table S5), including
the known VNTR (variable number of tandem repeats) in ABCA7 gene,[44]
and the known CNV (copy number variation) in CR1, HLA-DRA, and PICALM
genes (Table S5).[45, 46, 47] This information may be particularly interesting
for experimental researchers investigating the functional eect of SVs, and
could be used to prioritize certain genomic regions. Because of the complex
nature of large SVs, these regions have been largely unexplored, however
technological improvements now make it possible to accurately measure
SV alleles. We then performed our (sampling-based) gene-set enrichment
analysis using Gene Ontology Biological Processes (GO:BP, default setting)
and Reactome as gene-set sources, and Blood as tissue for the eQTL analysis.
After averaging p-values across the number of iterations, we found N=132
signicant pathways from Gene Ontology (FDR<1%) and N=4 signicant
pathways from Reactome (FDR<10%) (Figure 8.7 and Table S6). To facili-
tate the interpretation of the gene-set enrichment results, we clustered the
signicantly enriched terms from Gene Ontology based on a semantic simi-
larity measure using REVIGO (Figure 8.3 B) and our term-based clustering
approach (Figure 8.3C). Both methods are useful as they provide an overview
of the most relevant biological processes associated with the input SNPs.
Our clustering approach found ve main clusters of GO terms (Figure 8.3C
and Figure 8.8). We generated wordclouds to guide the interpretation of
the set of GO terms of each cluster (Figure 8.3C). The ve clusters were
characterized by (1) tracking and migration at the level of immune cells, (2)
activation of immune response, (3) organization and metabolic processes, (4)
beta-amyloid metabolism and (5) amyloid and neurobrillary tangles forma-
tion and clearance (Figure 8.3C). All these processes are known to occur in
the pathogenesis of Alzheime’s disease from other previous studies.[42, 43,
48, 49] We observed that clusters generated by REVIGO are more conserva-
tive (i.e. only terms with a high similarity degree were merged) as compared
to our term-based clustering which generates a higher-level overview. In the
original study (Table S15 from [42]), the most signicant gene sets related
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to amyloid and tau metabolism, lipid metabolism and immunity. In order to
calculate the extent of term overlap between results from the original study
and our approach, we calculated semantic similarity between all pairs of
signicantly enriched terms in both studies. In addition to showing pairwise
similarities between all terms, this analysis also shows how the enriched
terms in the original study relate to the clusters found using our term-based
approach. We observed patterns of high similarity between the signicant
terms in both studies (Figure 8.9). For example, terms in the “Activation of
immune system” and the “Beta-amyloid metabolism” clusters (dened with
our term-based approach), reported high similarities with specic subsets of
terms from the original study. This was expected as these clusters represent
the most established biological pathways associated with AD. The cluster
“Tracking of immune cells” had high similarity with a specic subset of
terms from the original study, yet we also observed similarities with the
Activation of immune system cluster, in agreement with the fact that these
clusters were relatively close also in tree structure (Figure 8.3C). Similarly,
high similarities were observed between the Beta-amyloid metabolism and
the Amyloid formation and clearance clusters. Finally, the Metabolic processes
had high degree of similarity with a specic subset of terms, but also with
terms related to Activation of immune system cluster. Altogether, we showed
that (i) enriched terms from the original study and our study had a high
degree of similarity, and (ii) that the enriched terms of the original study
resembled the structure of our clustering approach. The complete analysis
of 83 genetic variants took about 30 minutes to complete.
8.4 Discussion
Despite the fact that many summary statistics of genetic studies have been
publicly released, the integration of such a large amount of data is often
dicult and requires specic tools and knowledge. Even simple tasks, such
as the rapid interrogation of how well a certain genomic region associates
with a specic trait or multiple traits can be frustrating and time consuming.
Our main objective to develop snpXplorer was the need for an easy-to-use
and user-friendly framework to explore, analyse and integrate outcomes
of GWAS and other genetic studies. snpXplorer showed to be a robust tool
that can support a complete GWAS analysis, from the exploration of specic
regions of interest to the variant-to-gene annotation, gene-set enrichment
analysis and interpretation of associated biological pathways. To our knowl-
edge, the only existing web-server that oers a similar explorative framework
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as snpXplorer is the GWAS-Atlas.[50] GWAS-Atlas was primarily developed
as a database of publicly available GWAS summary statistics. It oers possi-
bilities to visualise Manhattan and quantile-quantile (QQ) plots, to perform
downstream analyses using MAGMA statistical framework, and to study
genetic correlation between traits by means of LD score regression.[51, 52]
However, snpXplorer was developed mainly for visualisation purposes, and
thus incorporate multiple unique features such as the possibility to visualise
multiple GWAS datasets simultaneously or to upload an external association
dataset for additional comparisons with existing datasets. Moreover, snpX-
plorer annotates these visualisations with several genomic features such as
structural variations, recombination rates, LD patterns and eQTLs. All the
relevant information showed in snpXplorer, such as top SNP information,
eQTL tables, LD tables and structural variants can be easily downloaded for
further investigations. Further, we would like to stress the relevance of over-
laying the GWAS results with structural variants found by third-generation
sequencing. Such structural variations have already been shown to play a
signicant role for several traits, in particular for neurodegenerative diseases,
and snpXplorer is thus far the only web-server where such information can
be visualized in the context of GWAS summary statistics.[44, 45, 53, 54]
We do acknowledge that for an in-depth functional annotation analysis of
GWAS, the possibility of integrating additional ad-hoc information (such
as eQTLs, sQTLs, eTWAS and sTWAS from specic disease-related regions)
may improve the analysis, but such data is not always available, is time
consuming and requires deep knowledge. Several online and oine tools
have been developed with a similar goal, e.g. SNPnexus, ANNOVAR, FUMA
and Ensembl VEP.[55, 56, 57, 58] Some of these tools are characterized by a
larger list of annotation sources, for example implementing multiple tools
for variant eect prediction (e.g. SNPnexus, Ensembl VEP or ANNOVAR), or
more extensive pathway enrichment analyses at the tissue- and cell-type
level (e.g. FUMA). We have shown that snpXplorer provides similar results in
terms of annotation capabilities and gene-set enrichment analysis as com-
pared to existing tools. Yet, snpXplorer has several unique features for the
functional annotation section, such as the extensive interpretation analysis
implemented in REVIGO, our term-based clustering approach and the word-
cloud visualisation, or the possibility to associate multiple genes with each
SNP during gene-set enrichment analysis. Moreover, snpXplorer develop-
ment will continue by implementation of additional annotation sources and
analyses. Altogether, we showed that snpXplorer is a promising functional
annotation tool to support a typical GWAS analysis. As such, it has been
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previously applied for the annotation and downstream analysis of genetic
variants associated with Alzheimer’s disease and human longevity.[49]
8.4.1 Future updates
For future updates, we plan to keep updated and increase the list of summary
statistics available to be displayed in the exploration section. In its current
version, the exploration section of snpXplorer requires the user to dene a re-
gion of interest to look, while genome-wide comparisons are not considered.
However, it is our intention to implement a genome-wide comparison across
GWAS studies that, given a set of input GWASs and a signicance threshold
alpha, reports all SNPs with a p<α across the studies, allowing for a more
rapid visualisation of overlapping SNP-associations. Moreover, we plan to
increase the number of annotation sources and available options in the an-
notation section (for example, including methylation-QTL, protein-QTL and
splicing-QTL). Finally, we are also working towards adding a framework to
calculate weighted polygenic risk scores given a set of individuals’ genotypes
and a reference study to take variant eect-sizes from.
8.5 Availability
snpXplorer is an open-source web-server available at https://snpxplorer.
net. Tutorial videos, full documentation and link to code are available in the
Help page of the web-server. snpXplorer is running as from March-2020, was
tested both within and outside our group, and runs steadily on both Unix
and Windows most common browsers (Safari, Google Chrome, Microsoft
Edge, Internet Explorer, and Firefox). For certain steps, snpXplorer does rely
on external tools and sources (e.g. REVIGO), and consequently depends on
their availability. Although discouraged, the tool can also be installed locally
on your machine: additional information on how to do it are available in
our github at https://github.com/TesiNicco/SNPbrowser, however, we
note that for the stand-alone version additional les should be downloaded
separately, for example, all summary statistics. snpXplorer requires R (v3.5+)
and python (v3+) correctly installed and accessible in your system. snpXplorer
uses the following R packages: shiny, data.table, stringr, ggplot2, liftOver,
colourpicker, rvest, plotrix, parallel, SNPlocs.Hsapiens.dfSNP144.GRCh37, lme4,
ggsci, RColorBrewer, gproler2, GOSemSim, GO.db, org.Hs.eg.db, pheatmap,
circlize, devtools, treemap, basicPlotteR, gwascat, GenomicRanges, rtracklayer,
Homo.sapiens, BiocGenerics, and the following python libraries: re, werkzeug,
robobrowser, pygosemsim, numpy, csv, networkx and sys.
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Figure 8.4: Rapid exploration of novel SNP-associations in existing GWAS
datasets. A. The gure shows the region surrounding WDR12 gene, for which a
novel SNP-association was found in the case-study GWAS of Alzheimer’s disease
(AD). Two previous studies of AD are plotted, and show that suggestive association
signals were present in earlier studies, yet the association did not reach genome-
wide statistical signicance, likely due to sample size. Similar plots show the regions
surrounding TSPAN14 (B), SHARPIN (C),PRDM7 (D) ,PLEKHA1 (E) and NCK2 (F).
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8.8 Supplementary Figures
Figure 8.5: Extreme AD cases vs. normal controls: EkEA−NC .Variant- gene
mapping procedure. A. The gure shows the type of genetic variants used as
input, classied as coding, eQTL or annotated by their positions. B. The barplot
shows the number of genes associated with each variant. C. The barplot shows the
chromosomal distribution of all input variants.
Figure 8.6: Fraction of SNPs and Genes association with traits in the GWAS
Catalog. A. Number of input SNPs previously associated with traits in the GWAS
catalog. B. Fraction of genes (associated with input SNPs) previously associated
with traits in the GWAS Catalog.
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Figure 8.7: Gene-set enrichment analysis. The gure shows the barplot of the
most signicant pathways (FDR<10%) from Reactome.
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Figure 8.8: Semantic similarity matrix.The plot shows the semantic similarity
matrix between all signicantly enriched GO (Gene Ontology) biological processes
terms (N=132). As semantic similarity, we used Lin.
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Figure 8.9: Comparison of gene-set enrichment results in the original study
and using snpXplorer functional annotation section.The heatmap shows the
pairwise semantic similarity values between all signicantly enriched terms in the
original study (y-axis, N=92) and using snpXplorer functional annotation section (x-
axis, N=132). The terms from our study (x-axis) are ordered based on their assigned
cluster as a result of our term-based clustering approach. Large similarity patterns
are visible in the heatmap, especially of terms (from the original study) mapping to
Activation of immune response cluster (red cluster) and to Beta-amyloid metabolism
cluster (green cluster). Some enriched terms mapping to Tracking of immune
cells (black cluster) had high similarity with Activation of immune response (purple
cluster) cluster, and some terms mapping to Amyloid formation and clearance had
high similarity with Beta-amyloid metabolism, resembling the structure of the tree
constructed in our study. The remaining Metabolic processes cluster (blue cluster)
had high similarity with a specic subset of enriched terms, but we also observed
high similarity with the Activation of immune system cluster.
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The overall objective of this thesis was to investigate the genetic
factors underlying maintained cognitive health until extreme ages, in
the context of Alzheimer’s disease (AD) and extreme human longevity.
Here, we provide a summary of our key ndings:
• Cognitively healthy centenarians have a lower frequency of
common variants that increase the risk to develop AD and have
a higher frequency of variants that protect against the disease.
• The risk to develop, or being resilient against, AD changes
on a pathway basis: we found that the polygenic risk of vari-
ants involved in immune response and endocytosis processes
associated the most with the resilience against AD
• The majority of alleles that increase the risk of AD, negatively
aect lifespan. While for most alleles the negative eect on
lifespan is explained through the increased risk of AD, a subset
of alleles appeared to be benecial for healthy aging, and as
such, decreased the risk of AD
• A polygenic risk score of longevity comprising 330 variants
associated with becoming a cognitively healthy centenarian, led
up to 4-year dierence in survival and functionally associated
with hallmarks of longevity
• We combined previous GWAS of clinical AD and AD by-proxy
in the largest genome-wide meta-analysis of AD to date, which
led to the discovery of six novel genetic variants that inu-
ence the risk of AD, expanding the knowledge of the genetic
landscape of AD
• In the largest genome-wide association meta-analysis of
longevity to date, we discovered one variant in addition to
APOE variants near GPR78 gene to be signicantly associated
with longevity, and identied a shared genetic architecture of
health and longevity
• We have developed snpXplorer, an open-source web application
that allows the exploration of GWAS association results, as
well as the functional annotation and the pathway enrichment
analysis of any given set of genetic variants
9
266 Chapter 9. General discussion
9.1 General discussion
The study of individuals with extreme longevity has enabled the discovery of
environmental and genetic factors that impact lifespan.[1, 2] However, with
an increasing fraction of individuals reaching old age, the next challenge is
to determine which factors are associated with a healthy lifespan. Reaching
100 years is only satisfying when chronic illnesses and cognitive decline due
to dementia can be escaped as much as possible. The 100-plus Study and
other centenarian studies around the world have demonstrated that although
rare, this is possible. About ∼10% of all centenarians can be considered to be
in good cognitive and physical conditions.[3, 4] This subgroup of individuals
may have specic characteristics that protect or delay the onset of cognitive
impairment and other age-related diseases, which emphasizes the need to
explore the underlying mechanisms that maintained their cognitive health.
In this chapter, we interpret the most important ndings presented in this
thesis, including the exploration of genetic factors in cognitively healthy
centenarians. We will further discuss challenges, limitations, and future
perspectives.
9.2 Genetic factors influencing resilience against Alzheimer’s dis-
ease
Resilience is the process that allows individuals to withstand adverse con-
ditions.[5] In the context of Alzheimer’s disease (AD) research, this refers
to the ability to escape the development of clinical symptoms of AD, while
being exposed to risk factors that would normally result in cognitive de-
cline.[6] Given the high heritability of AD, such resilience mechanisms may
also be genetically encoded. However, while cognitive resilience is an ac-
tive research eld in psychology and psychiatry, the extent of the role of
the genetically encoded resilience, in AD and other age-related disease, is
largely unexplored. In this thesis, we investigated for the rst time the role
of genetic factors underlying the resilience against Alzheimer’s disease in
individuals that reached extremely old ages without suering from demen-
tia. In chapter 2 and chapter 3, we studied the frequency of AD-associated
genetic variants in cognitively healthy agers, middle-aged population con-
trols, and relatively young AD cases.[7, 8] These individuals together cover
the entire cognitive spectrum, with cognitively healthy agers and AD cases
representing the two extremes. Therefore, using the healthy population
subjects as the middle point, we were able to study, on the one end, the risk
to develop AD (in a comparison of young AD cases and population controls),
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and, on the other end, the resilience against AD (by comparing population
controls and cognitively healthy agers). Comparing the two extremes in the
cognitive spectrum, we observed a remarkable average 2-fold enrichment
in the variant eect-sizes compared to expected eect-sizes from published
GWAS. At the level of the single variant, the eect-size increase was as high
as 6-fold. Importantly, this enrichment was mainly driven by the cognitively
healthy centenarians. This means that cognitively healthy agers are depleted
with genetic variants associated with increased AD-risk compared to the
general population, and that the study of individuals with extreme pheno-
types is protifable for the research of genetic factors associated with AD.
However, our research raises additional questions regarding the nature of
extreme cases, e.g. the existence of rare, undiscovered genetic variations
that may explain the early onset of the disease. Interestingly, the degree
of depletion/enrichment of the dierent AD variants in the centenarians
was not constant but appeared to cluster on a pathway basis. In chapter 3,
we focused on the major pathways thought to underly AD pathogenesis,
and we combined the eect of multiple variants in Polygenic Risk Scores
(PRSs) and pathway-specic PRSs. We showed that a PRS including all AD-
associated variants signicantly associated with both the increased risk and
the resilience against AD. Furthermore, we found that the escaping AD was
genetically encoded by variants associated with immune-related processes,
even after excluding the large eect of APOE-associated variants. Although
not specically on AD, previous animal and human studies have highlighted
the relationship between immune response and psychological resilience in
humans.[5] Genetic variants involved in immune-related mechanisms may
also contribute to such eect, eventually making resilient individuals able
to better recover from inammation-induced stressors.[5] Altogether, we
observed that achieving extreme ages with maintained cognitive health is
encoded, at least in part, by genetic factors that are specically involved in
immune-related mechanisms. This suggests that modulating immune-related
pathways may be a feasible strategy to prevent AD.
9.3 APOE alleles in cognitively healthy centenarians
The strongest genetic factors associated with increased AD-risk, protec-
tion against AD, and human longevity, are the ε2 and ε4 alleles in the
APOE gene.[9, 10, 11, 12] Despite >20 years of research, the mechanisms by
which APOE aects molecular pathways of AD is not completely understood.
Although more research will eventually lead to a deeper understanding
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of APOE functions, it seems that the APOE gene is involved in all major
known AD-associated pathways (β-amyloid metabolism, lipid and choles-
terol metabolism, and immunity), which we also showed in chapter 3 and
chapter 4. Likely due to the combination of eect on both AD and longevity,
our cohort of cognitively healthy centenarians is remarkably enriched for
the ε2 allele and depleted for the ε4 allele. That is, while the frequency of
ε2 and ε alleles is respectively 8% and 16% in the general population, in AD
is about 4% and 43%, and in our centenarians the frequencies were 16% and
8%.[7] For this reason, it was necessary to correct the analyses in chapter 3
and chapter 5 according to carriership of APOE variants: after correction, we
still observed a signicant dierence in the PRS and pathway-PRS between
centenarians and population subjects, on both AD and longevity. Of note:
in our cohort of centenarians, N=47 carried at least one APOE ε4 allele, and
a single centenarian was homozygous for APOE ε4 (ε4/ε4); compared to
those who did not carry a deleterious APOE ε4 allele, the carriers reported a
signicantly lower polygenic risk score for AD (excluding APOE variants),
suggesting that even the negative eects of APOE ε4/ε4 genotype can be
balanced out through other (protective) variants.
9.4 The aging eect of AD-associated variants
In chapter 2 and chapter 3, we showed that cognitively healthy centenarians
are genetically protected against AD, largely due to genetic variants involved
in immune-related processes. As cognitively healthy centenarians are both
free from dementia and extremely old, this suggests that the etiology of
AD and healthy lifespan might overlap across these biological pathways. In
chapter 4 and chapter 5, we have studied in depth to what extent genetic
variants associated with AD and other age-related diseases are related to
extreme human longevity. The current view of the genetics of longevity
is that it depends on a depletion of genetic elements associated with an
increased risk of age-related diseases.[1, 13, 14] Therefore, given the large
prevalence of AD at old ages and the increased mortality due to the disease,
one would expect that variants increasing the risk of AD, would negatively
aect lifespan. In accordance with this hypothesis, we showed that the
majority of alleles increasing the risk of AD, negatively aected longevity.
However, we identied dierent trajectories of eect on healthy aging of
AD-associated genetic variants. Firstly, genetic variants that increase the risk
of AD and as a consequence, they harm longevity; these genetic variants are
likely the variants with the "purest" AD-eect (e.g. CR1, CD33, BIN1, PICALM,
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and MS4A6A).[15] Secondly, genetic variants that primarily aect longevity,
suggesting that the negative eect on lifespan contributes to the increased
risk to develop AD, but potentially also other diseases. For example, in this
group of variants we nd the non-synonymous variant in PLCG2 which was
recently found to be protective against other conditions than AD, but also
genetic variants in APOE, SHARPIN, IQCK, PRKD3, CD2AP, HLA, and SPI1
genes, which were previously associated with respiratory system disease,
cardiovascular diseases, autoimmune disorders, and cancer.[16, 17, 18, 19,
20, 21, 22] In line with the ndings from chapter 2 and chapter 3, this group
of genetic variants was also strongly enriched at the functional level for
immune system response and endocytosis, which align to known hallmarks
of aging. Before us, only one study investigated the relationship between
AD-associated variants and longevity: they did not have access to extremely
old (and healthy) individuals, used a relatively small sample size and did
test only a small number of variants.[23] Apart from APOE, they could not
nd any signicant eect on the longevity of AD-associated variants.[23]
Likely, due to a larger number of variants that we studied as well as the
extreme phenotype of the cognitively healthy centenarians, we were the rst
to investigate genetic factors and pathways associated with the resilience
against AD, and to show potential pleiotropic eects on longevity of genetic
variants associated with AD.
9.5 Genetic predisposition to extreme longevity
Whilst the analysis in chapter 4 was limited to AD, in chapter 5 we used
the summary statistics from the largest GWAS on parental longevity to date
to prioritize the genetic factors that have the largest eect on becoming a
cognitively healthy centenarian.[24] This resulted in a PRS comprising 330
genetic variants that not only associated with becoming a cognitively healthy
centenarian but interestingly, associated with up to a 4-year dierence in
survival in an independent cohort of healthy, middle-aged individuals. A
previous study in literature showed that a PRS of parental longevity was
signicantly associated with survival, and we validate these results in a
cohort of cognitively healthy centenarians. In line with expectations, the
majority of the genetic variants included in the PRS were previously as-
sociated with several age-related conditions, including cardiovascular and
autoimmune diseases, as well as cancer. Interestingly, we found suggestive
evidence of the compensation-eect between the PRS and the APOE ε4 allele,
as individuals who carried an APOE ε4 allele and had a high longevity-PRS
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survived longer than those that did not carry an APOE ε4 allele and had
a lower PRS. Such compensation mechanisms for the APOE ε4 allele were
previously observed in a number of studies of AD, and although the results
did not strongly replicate across dierent studies, several variants (i.e. rs5882
in the CETP gene, rs10553596 in the CASP7 gene, and rs4934 in the SERPINA3
gene) were reported to exhibit buering eects with respect to the presence
of the APOE ε4 allele.[25, 26] In functional terms, aging is associated with
a high degree of inammation, cellular stress, as well as reduced capacity
of cell-dierentiation and development.[1, 13] We showed that the variants
included in the PRS were functionally enriched for oxidative stress reduction
and cell/tissue dierentiation. Altogether, we conrmed in a cohort of cogni-
tively healthy agers, that the human lifespan is inuenced by a constellation
of genetic variations distributed along the genome, likely acting to diminish
the risk of age-related diseases and to balance out the alterations that physi-
ologically take place in the aging individual. Further studies concerning the
downstream eects of such genetic variants and their implications at the
gene- and pathway-level may be of interest to the development of anti-aging
drugs.
9.6 Extreme phenotypes in GWAS
In the previous chapters, we have shown that using extreme phenotypes
represent an added value for the genetic research of complex polygenic
traits. While we focused mainly on common and low-frequency genetic
variants (minor allele frequency >1%), before this thesis, the use of extreme
phenotypes in genetic studies was mainly applied to discover rare, causative,
mutations responsible for various age-related diseases.[27, 16, 14, 17, 18] In
such a setting, usually, extreme cases (for example, individuals that man-
ifested clinical symptoms of a disease at a younger age or with extreme
clinical manifestations) were compared to healthy controls. Only a handful
of studies included both extremes of a disease spectrum, and showed, simi-
larly to us, a relative increase in eect-size. For example, centenarians were
labeled "super-controls" for the study of genetic factors underlying diabetes
and possibly other age-related diseases.[28] In chapter 2 and chapter 3, we,
for the rst time, reported similar ndings in the context of AD. The inclusion
of individuals with extreme phenotypes in genetic studies led to an increase
in the variant eect-sizes, which translates to higher statistical power to
detect signicant associations. While the main drawback of extreme phe-
notypes is their availability, which precludes the possibility to gather very
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Figure 9.1: The updated genetic landscape of Alzheimer’s disease from ge-
netic studies. The top panel of the gure shows the course of the genetic research
of AD, from early 1990’s with the discovery of the causal mutations in APP, PSEN1
and PSEN2, until nowadays, with the discovery of ∼40 common genetic variants
signicantly associated with AD. However, the research of new genetic determinants
is continuing, and larger GWAS will likely nd association of additional rare and
common genetic variants with AD.
large sample sizes, our ndings might have methodological implications in
terms of study design and sample selection for future genetic studies of AD,
other age-related diseases, and longevity.[29]
9.7 Large collaborative eorts make the dierence
With the knowledge of the protective elements retained in the genome of
cognitively healthy agers, we sought to join other researchers in chapter 6
and chapter 7 by participating in two of the largest, collaborative genome-
wide meta-analyses of AD and longevity to date. These collaborative eorts
were important to further improve the knowledge of the genetic landscape
underlying these traits. For AD, our study resulted in the discovery of 6
additional genetic variants associated with an increased risk of AD, which
raised the total number of genetic variants associated with AD to 41.[30]
This number will likely increase in the future due to an increased number of
samples compared. [31] Although the number of centenarians included was
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small compared to the total number of controls, we note that the majority of
all the newly discovered variants associated signicantly and in the correct
direction in a comparison of centenarians and AD cases within our cohort
only (Figure 9.1). Another practical implication of our meta-analysis of AD
concerned the eectiveness of the PRS in a clinical setting. To date, despite
the strong predictive eect exerted by PRS, it is currently not used as an
additional tool for AD diagnosis.[30, 32, 33] Nevertheless, the identication,
before onset of AD, of individuals at the highest risk of developing AD or
individuals who are compromised in a certain pathway, is a promising tool in
a diagnostic setting, and for the development and the application of preventa-
tive personalized treatment strategies.[34, 35] Unlike AD, genetic factors that
inuence longevity are more complex to study. For example, the phenotype
denition is not clear, and which individuals should be used as cases or con-
trols is not easily denable. In chapter 7, we and our collaborators dened
a novel, signicantly improved classication method of cases and controls




percentile of survival probability per
country. This resulted in a harmonization of the criteria to dene cases and
controls across dierent cohorts and countries, facilitating collaborative ef-
forts. In terms of ndings, we conrmed the longevity-association of variants
in the APOE gene and propose the association of a novel variant (rs7676745)
near the GPR78 gene.[14] This variant was previously associated with psychi-
atric disorders, and its association was signicant and in the correct direction
in our study alone. Besides, through genetic correlation analyses, we showed
that the genetic architecture between health and longevity overlaps, which
nds accordance with previous studies, and our results from chapter 5. Nev-
ertheless, the major challenge to study human longevity is the lack of a large
sample size, as such individuals are rare and need to be approached indi-
vidually.[4] One way out is to combine case-controls studies with by-proxy
studies, similarly to what we have done in chapter 6 for AD, which then may
lead to a better understanding of the genetic landscape of extreme human
longevity.
9.8 Towards an updated disease model of AD
Our results in chapter 6 had important implications in terms of AD biology.
On the one end, we identied a common genetic variation in the APP (Amy-
loid Precursor Protein) gene that increased the risk of AD, which enforces
the evidence that APP processing is an important risk factor of AD, next
to other strong risk factors, and, moreover, links the sporadic form of AD
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with the autosomal dominant form. On the other end, we added on the
growing importance of the immune system in AD development, as multi-
ple new genetic loci pointed to genes involved in immune-signaling (e.g.
PLCG2, SHARPIN, CD33, and IL34). This is in line with what we showed in
chapter 3 where we have quantied the contribution of each AD-associated
pathway to the total polygenic risk of AD, showing that, excluding APOE
variants, ∼65% of the total risk of AD is due to variants involved in immune
response and endocytosis pathways (Figure 9.2). These latter two biological
pathways have been, in fact, proposed as potential central pathways whose
dysfunction may trigger the molecular cascade leading to β-amyloid and
tau accumulation, and synaptic and neuronal damage. Physiologically, the
resident immune cells within the brain are involved, among other functions,
in the clearing of cellular debris including aggregated β-amyloid peptides.
However, the brain immune response may not react suciently or vice versa,
it may react too strongly, possibly starting a molecular cascade typical of
AD that leads to cognitive decline.[36] Genetic variants involved in immune
response may modify how cellular debris and β-amyloid deposits in the brain
are recognized, captured, and cleared (Figure 9.2).[37] To this end, the post-
mortem analysis of the brains of cognitively healthy centenarians showed
that, despite being cognitively healthy, these centenarians are not free from
the typical neuropathological hallmarks of AD (accumulation of β-amyloid
plaques and neurobrillary tangles), yet, these are not severe enough to cause
cognitive decline.[38] This capacity of monitoring the neuropathological hall-
marks of the disease may be maintained in cognitively healthy centenarians
due to a lower vulnerability of age-related decline, possibly as a result of a
depletion of deleterious genetic variants and a concurrent enrichment of pro-
tective genetic elements, as we saw in chapter 2, chapter 3, and chapter 5. An
alternative theory explaining AD development identies in the endosomal
tracking pathway the trigger that starts the pathological events associated
with Alzheimer’s disease, culminating in β-amyloid and tau pathology, neu-
ronal and microglial dysfunction. The endosomal tracking pathway is a
crucial molecular pathway that regulates the tracking of intracellular and
extracellular proteins and lipids (including the toxic β-amyloid peptides),
and allows to direct them to other cellular compartments, to sort them for
degradation, or to recycle them to the extracellular space. [39] An abnormal
tracking of endosomes, together with a potential dysfunction within the
clearence system, may be the rst step leading to amyloid, tau deposition,
and synaptic and neuronal loss (Figure 9.2).[40]
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Figure 9.2: An updated hypothetical model of Alzheimer’s disease.
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9.9 Interpretation of GWAS
One of the major complexities in GWAS studies is the functional interpreta-
tion of the eect that a certain genetic variant has at the gene-, protein- and
pathway-level, because the majority of genetic variants analyzed through
GWAS relies in non-coding regions. In chapter 3, we approached this com-
plexity by using published variant-gene associations as found in two pre-
vious GWASs of AD, which implemented dierent techniques to ne-map
the variant-gene association.[41, 42] However, this approach was limited
to AD. For other traits, several tools have been developed to address the
variant-gene association,[43, 44] including the approach that we propose in
chapter 4, that we further improved in chapter 5, and that evolved in the
web-server application that we presented in chapter 8. Our approach was to
use multiple resources, such as tissue-specic RNA expression and predicted
variant eect, to allow multiple genes to associate with each variant, depend-
ing on the annotation certainties.[45, 46] However, because neighboring
genes are often functionally related, allowing multiple genes to associate
with a variant could result in an enrichment bias. The main advantage of our
method is that it relies on a sampling-based framework to perform gene-set
enrichment analysis, which takes into consideration annotation uncertainties
and avoids enrichment bias. In addition, gene-set enrichment results are
often redundant and dicult to interpret, which we addressed by means of
a semantic similarity-based algorithm to cluster similar terms and reduce
the complexity of the enriched pathways.[47] We used such an approach to
perform gene-set enrichment analysis in chapter 4 (in the context of AD) and
chapter 5 (on longevity), and the resulting enriched pathways overlapped
and improved those from previous studies. For example, in chapter 3 we
studied ve major pathways previously associated with AD from literature,
while in chapter 4 we estimated these pathways using our sampling-based
approach. As a result, in chapter 4 we clustered together all immune-related
pathways (immune response and endocytosis), and added a cluster of path-
ways pointing to synaptic plasticity and remodeling. This rened and fully
automated classication of each variant’s eect on pathways may be used to
further improve pathway-specic PRSs for patient stratication. Next to the
functional interpretation of GWAS, to compare genetic association statistics
across dierent traits can highlight a shared genetic basis of dierent traits.
The state-of-the-art method to do so is LD-score regression and genetic cor-
relation analysis, however, these approaches are limited to studies with large
sample size.[48] An alternative approach is either to visually explore associ-
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ation statistics in the same region across phenotypes or to browse existing
datasets of variant-trait associations, such as the GWAS catalog.[49] We have
addressed these limitations in snpXplorer (chapter 8), where we allow the
visual superimposition of summary statistics from any study and the analysis
of any given set of genetic variants in terms of functional enrichment and
overlap with previous traits.
9.10 Becoming a cognitively healthy centenarian
In this thesis, we attempted to discover genetic signatures that are associated
with becoming a cognitively healthy centenarian, which likely represents
the ideal model of aging in good cognitive and physical conditions. Previous
studies from our cohort showed that cognitively healthy centenarians were
signicantly more educated and performed signicantly better in neuropsy-
chological tests compared to centenarians from the same birth cohort.[50,
51] A possible explanation for this could be an advantageous genetic back-
ground as these individuals have a lower genetic risk to develop AD and other
age-related diseases. Importantly, our studies shed light on the relationship
between resilience against factors associated with AD risk, and longevity.
Due to the diculties in gathering a large number of cognitively healthy
super-agers, this was never explored before and might explain why, apart
from APOE, genetic variants inuencing AD risk do not seem to inuence
longevity in large GWAS. In terms of functional implications, our ndings
from chapter 2, chapter 3, chapter 4, and chapter 5 pose great importance
to genetic variants involved in immune-related pathways. These ndings
t well in the context of a compromised immune response and a higher
degree of chronic inammation that are typically associated with aging. Ge-
netic factors may result in improved regulatory mechanisms of the immune
response, that might compensate for age-related changes and result in a
better immune and metabolic system, at least in the context of Alzheimer’s
disease, that we observe in our cognitively healthy centenarians through
the pathway-specic PRSs.[1, 13, 2] We also observed a similar pattern in
the context of longevity, where we highlighted pathways such as dierentia-
tion processes, cellular response to stress, and nervous system development.
The maintenance of these biological pathways may be associated with a
slower progression of the aging mechanisms and with a concurrent delay of
age-related diseases.
9
9.11 Drawbacks of studying centenarians 277
9.11 Drawbacks of studying centenarians
The study of individuals with extremely old age is not without aws. Next to
the diculty in collecting a large sample of cognitively healthy centenarians
due to their rareness in the population,[4] the denition of a cognitively
healthy centenarian is not straightforward. In our study, all participants
self-reported to be cognitively healthy, which was also conrmed by a family
member or proxy-acquaintance. However, to date, there are no specic
neuropsychological tests developed to score the cognitive performances of
such old individuals. The 100-plus Study implements a battery of cognitive
tests that typically are carried out in a memory clinic and, therefore, are
specialized for the diagnosis of cognitive decline and dementia. While these
tests allow to score dierent cognitive domains, they are not developed
for extremely old individuals, and are usually not implemented in other
centenarian studies. Our study has pioneered towards the identication of
cognitive tests that may be more specic for centenarians.[51] Given this
protocol, virtually any centenarian study around the world can identify a
subset of individuals that maintained their cognitive and physical abilities
in a same standardized way. This will eventually lead to more collaborative
eorts, essential for genetic studies. An additional drawback relates to the
short follow-up time available for these individuals, as well as diculties
in studying environmental factors. However, due to the high heritability
estimates of longevity within families, a more feasible approach may be
to investigate the children of the cognitively healthy centenarians, which
should have inherited part of the protective genetic elements of their parents,
are younger and thus could be followed-up for a longer time. This is an
on-going eort in the 100-plus Study.
9.12 Future perspectives
The 100-plus Study is currently enrolling additional cognitively healthy cen-
tenarians and their family members, allowing the further exploration of the
unique characteristics of these individuals. Our cohort of centenarians will
continue to be part of large-collaborative studies investigating common (and
rare) genetic factors associated with longevity and age-related diseases. Ow-
ing novel developments in the genetics eld, the impact of larger structural
genetic variations in diseases and longevity may be explored. In fact, with an
increasing understanding of the architecture of our genome, it has become
clear that structural variants (especilly those comprising repeated elements),
are not only junk DNA, but may be implicated in diseases by interfering with
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the normal gene transcription and translation processes. For AD, recently
evidence of such mechanisms in the ABCA7 gene was shown. The common
ABCA7 AD-associated variant is in linkage with an intronic variable number
of tandem repeats (VNTR), a type of structural variation characterized by
specic patterns of DNA that are repeated in tandem.[52] In this ABCA7
VNTR, an excessive number of repeat units was associated with increased
AD risk. To be able to infer the length of VNTRs at genomic level (either by
direct measurement or by imputation), will allow to test whether such struc-
tural variations inuence AD-risk.Apart from AD, such structural variations
may also inuence longevity directly, for example, the terminal parts of the
chromosomes, i.e. the telomeres, are enriched with repetitive sequences, and
the shortening of telomers is thought to be a direct consequence of aging.
Therefore, the study of such variations will likely open new scenarios in
the way we look at a genetic predisposition to aging and diseases. This will
eventually allow to ll-in the missing heritability gap that still underlies the
genetics of AD, longevity, and other age-relted traits. Finally, these eort
will improve the predictive power of the PRS, which will hopefully be used
as a valuable clinical parameter.
9.13 Conclusions
The main nding of this thesis was the characterization of the role of genetic
variants associated with AD in cognitively healthy agers, and to discover
molecular pathways that associate with the resilience against AD and other
age-related diseases. We provided evidence for the eectiveness of using
extreme phenotypes in genetic studies, the use of a PRS in a clinical setting
for AD diagnosis, and actively improved the knowledge of the genetic factors
that are associated with AD and longevity. The ndings in this thesis are
instrumental for future studies dealing with longevity, AD and other age-
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10.1 English summary
One important accomplishment of humankind is the extension of the av-
erage life expectancy. However, a consequence of an aged population is
the increased prevalence of age-related diseases, and, as a consequence, an
increasing fraction of individuals will spend part of their old age in disability
or dependence on others. Of all age-related diseases, a major contribution to
poor health is cognitive decline and dementia, of which Alzheimer’s disease
(AD) is the most common type. However, dementia and AD are not inevitable:
in fact, a small proportion of the population (<0.1%) reaches at least 100 years
of age while maintaining a high level of cognitive and physical functions,
so-called cognitively healthy centenarians. To investigate the genetic and
environmental factors that characterize these individuals, the 100-plus Study
was initiated.
Alzheimer’s disease is a progressive neurodegenerative disorder charac-
terized by loss of cognitive functions that leads to loss of independence, and
death. Currently, there is no eective treatment to prevent of to slow down
AD progression. The main risk factor for AD is aging: while the disease is
rare before the age of 65 years, the prevalence increases exponentially and
reaches ∼ 40% per year at 100 years of age. Next to aging, genetic factors
play an important role as heritability estimates range 60-80%. The largest
common genetic risk factor for AD is APOE genotype,which leads up to
30-fold increased risk for the disease. In addition to APOE, today ∼80 single
nucleotide polymorphisms have been associated with the modulation of the
risk of AD. Furthermore, these ndings have been pivotal to understand the
molecular events that are associated with AD development. While the most
accepted hypothesis explaining AD pathogenesis puts amyloid accumulation
at the basis of the molecular cascade that leads to cognitive decline, genetic
studies have led to an evolution of this traditional hypothesis to encompass
more complex aspects of the disease. As such, today it is thought that a
dysregulation of the endo-lysosomal tracking and immune systems are
also major causal pathways of AD. Since AD is lethal at old age, it would
be expected that genetic variants that increase the risk of AD, should aect
negatively human lifespan.In fact, the main genetic risk factor for AD, APOE
genotype, is also the largest genetic risk factor for longevity. Surprisingly,
apart from APOE, none of the other genetic variants known to aect AD, also
aects human longevity. Genetic factors are also though to aect human
longevity: in fact, heritability of longevity up to ∼70 years of age ranges
10-25%, but to reach higher ages, we become increasingly dependent on the
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favourable genetic elements in our genomes. In addition to APOE, several
genetic variations have been found to aect human longevity, but these fac-
tors were not conrmed in dierent studies and populations, likely reecting
both technical and biological dierences.Nevertheless, a common term to
all previous genetic studies of longevity is that the genetic variants found
to inuence human longevity were previously associated with the risk of
several age-related diseases. This suggests that an extended human lifespan
is associated with a lower genetic risk of age-related diseases. Given this
background, the overall objective of this thesis was to investigate the genetic
factors underlying extreme human longevity and the escape of Alzheimer’s
disease, for which we explore the genetic architecture of the cognitively
healthy centenarians from the 100-plus Study.
10.1.1 Part I
In the rst part of the thesis, which comprises chapter 2-5, we focus on the
comparison of the cognitively healthy centenarians with young AD patients
and population controls in the context of Alzheimer’s disease and human
longevity. In chapter 2, we exploited extreme phenotypes in the genetic
research of AD by comparing extreme controls, i.e. cognitively healthy
centenarians, and extreme AD cases, i.e. relatively young AD patients, in a
case-control study of AD. We report that cognitively healthy centenarians
have a lower frequency of genetic variants associated with increased AD risk
compared to the general population, and a higher frequency of protective
genetic variants. This led to a 2-fold enrichment in the variant eect-size,
showing that the use of extreme phenotypes in genetic studies of complex
traits is protable. In chapter 3, we investigated the molecular pathways
that are known to play a role in AD pathogenesis and their association
with the resilience against AD. In this study, we combined the eect of
multiple variants together into polygenic risk scores (PRS) and pathway-
specic polygenic risk scores, which incorporate the eect of multiple genetic
variants acting on the same molecular pathway. We report that cognitively
healthy centenarians have the lowest PRS and pathway-specic PRS for
all major AD-associated pathways. Moreover, only the PRS of immune
system and endocytosis pathways signicantly inuenced the resilience
against AD, even after excluding APOE variants. In chapter 4, we attempted
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to disentangle the eect on longevity from the eect on AD risk of the
genetic variants that are associated with AD. We found that most genetic
variants that increase the risk of AD were associated with lower odds of
longevity. Based on our analysis, most AD-associated variants negatively
aect longevity through their increased risk of AD. However, a subset of
variants preferentially involved in immune-related processes seemed to aect
not only AD but also other age-related diseases, such that the cumulative
eect on longevity was larger than the eect on AD alone. In chapter
5, we focused on human longevity and, using publicly available data, we
constructed a polygenic risk score (PRS) that associated with becoming a
cognitively healthy centenarians and independently with survival. This PRS
included 330 genetic variants, did not include APOE variants, associated
with up to 4-years longer survival, and showed functional enrichment for
hallmarks of longevity, such as slow cell dierentiation and replacement,
and regulation of oxidative stress.
10.1.2 Part II
In the second part of the thesis, we present the contribution of the cogni-
tively healthy centenarians from the 100-plus Study to large, collaborative
GWAS of AD and longevity. In chapter 6, we combined clinical studies of
AD and by-proxy studies of AD into one of the largest GWAS of AD. This
collaborative eort led to the discovery of six additional genetic variants
associated with AD. Our ndings reinforced the role of β-amyloid processing
and immune response as central biological pathways in AD. Furthermore,
we add on the growing literature showing the applicability of polygenic
risk score (PRS) of AD in order to stratify patients based on their genetic
background and to identify those at highest risk for the disease. In chapter
7, we collaborated on the, to date, largest GWAS of longevity. We introduced
a new, unbiased, method to identify cases (i.e. the long-lived individuals)
and controls, based on country- and sex-specic survival percentiles. In
addition to APOE variants, we found a novel association near GPR78 gene,
and through genetic correlation and gene expression analyses, we showed a
marked overlap between the genetics of diseases and the genetics of longevity.
In chapter 8, the last chapter, we present snpXplorer, a tool freely available
to the scientic community to explore summary statistics of genetic stud-
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ies, compare levels of association between dierent traits, and functionally
annotate sets of genetic variants.
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10.2 Nederlandse samenvaing
De verlenging van de gemiddelde levensverwachting is een belangrijke
prestatie van de mensheid, maar heeft wel de vergrijzing van de bevolking als
gevolg. Hierdoor komen leeftijdsgebonden ziekten steeds vaker voor en is een
steeds groter deel van de mensen op hun oude dag invalide of afhankelijk van
anderen. Van alle leeftijdsgebonden ziekten dragen cognitieve achteruitgang
en dementie, waarvan de ziekte van Alzheimer de meest voorkomende is, in
belangrijke mate bij aan een slechte gezondheid. Dementie en AD zijn echter
niet onvermijdelijk: een klein deel van de bevolking (<0,1%) bereikt ten minste
de leeftijd van 100 jaar en behoudt daarbij een hoog niveau van cognitieve
en fysieke functies; de zogenaamde cognitief gezonde honderdjarigen. Om de
genetische en omgevingsfactoren te onderzoeken die deze individuen maken
tot wie ze zijn, werd het 100-plus Onderzoek opgezet.
De ziekte van Alzheimer is een progressieve neurodegeneratieve aan-
doening die wordt gekenmerkt door verlies van cognitieve functies met als
gevolg verlies van onafhankelijkheid en uiteindelijk de dood. Momenteel is
er geen eectieve behandeling om de progressie van de ziekte van Alzheimer
te voorkomen of te vertragen. De belangrijkste risicofactor voor de ziekte van
Alzheimer is veroudering: hoewel de ziekte zeldzaam is voor de leeftijd van
65 jaar, neemt de prevalentie exponentieel toe en bereikt ∼40% per jaar op de
leeftijd van 100 jaar. Naast veroudering spelen genetische factoren een belan-
grijke rol, waarbij de erfelijkheidsschattingen variëren van 60-80%. De meest
voorkomende genetische risicofactor voor de ziekte van Alzheimer is het
APOE-genotype, dat leidt tot een tot 30-voudig verhoogd risico op de ziekte.
Naast APOE zijn vandaag ∼80 single-nucleotide polymorsmen in verband
gebracht met de modulatie van het risico op de ziekte van Alzheimer. Boven-
dien zijn deze bevindingen van cruciaal belang geweest om de moleculaire
processen te begrijpen die in verband worden gebracht met de ontwikkel-
ing van de ziekte van Alzheimer. De meest geaccepteerde hypothese over
de pathogenese van de ziekte van Alzheimer stelt dat de accumulatie van
amyloïd het begin is van een moleculaire cascade die leidt tot cognitieve
achteruitgang. Genetische studies hebben geleid tot een herziening van deze
traditionele hypothese die nu ook de complexe aspecten van de ziekte omvat.
Zo wordt tegenwoordig gedacht dat een ontregeling van de endo-lysosomale
processen in de cel en het immuunsysteem belangrijke causale routes van de
ziekte van Alzheimer zijn. Aangezien de ziekte van Alzheimer dodelijk is op
oudere leeftijd, zou men verwachten dat genetische varianten die het risico
op de ziekte van Alzheimer verhogen, een negatieve invloed op de levensduur
10
290 Chapter 10. Summary
van mensen hebben. Dit is ook zo want de belangrijkste genetische risico-
factor voor de ziekte van Alzheimer, het APOE-genotype, is ook de grootste
genetische risicofactor voor levensduur. Verrassend genoeg heeft, afgezien
van APOE, geen van de andere genetische varianten waarvan bekend is dat
ze invloed hebben op de ziekte van Alzheimer ook invloed op levensduur.
Levensduur is echter wel erfelijk bepaald; de erfelijkheid van de levensduur
tot ∼70 jaar wordt geschat op 10-25%, maar om hogere leeftijden te bereiken,
worden we steeds afhankelijker van de gunstige genetische elementen in
ons genoom. Naast APOE zijn verschillende genetische variaties gevonden
die de menselijke levensduur beïnvloeden, maar deze factoren werden niet
bevestigd in verschillende studies en populaties, waarschijnlijk als gevolg
van zowel technische als biologische verschillen. Niettemin is een gemeen-
schappelijk kenmerk van alle eerdere genetische studies van levensduur dat
de genetische varianten die de levensduur van de mens bleken te beïnvloe-
den, eerder in verband werden gebracht met het risico van verschillende
leeftijdsgebonden ziekten. Dit suggereert dat een langere levensduur van
de mens geassocieerd is met een lager genetisch risico op leeftijdsgebonden
ziekten.
Gezien deze achtergrond was het algemene doel van dit proefschrift om
de genetische factoren te onderzoeken die ten grondslag liggen aan extreme
menselijke levensduur en het ontsnappen aan de ziekte van Alzheimer. Hi-
ervoor onderzochten we de genetische architectuur van patiënten met de
ziekte van Alzheimer en de cognitief gezonde honderdjarigen uit de 100-plus
Studie.
10.2.1 Part I
In het eerste deel van het proefschrift (hoofdstukken 2-5) richtten we ons
op de verschillen in erfelijke factoren tussen cognitief gezonde honderdjari-
gen, jonge patiënten met de ziekte van Alzheimer en een controle groep uit
de algemene bevolking.
In hoofdstuk 2 hebben we gekeken naar de toegevoegde waarde van
de analyse van extreme fenotypes in het genetisch onderzoek naar de ziekte
van Alzheimer. We vergeleken extreme controles, d.w.z. cognitief gezonde
honderdjarigen, met extreme jonge patiënten met de ziekte van Alzheimer.
Wij vonden dat cognitief gezonde honderdjarigen een lagere frequentie van
genetische risico varianten hebben en een hogere frequentie van bescher-
mende genetische varianten. Gemiddeld zagen we een 2-voudige verrijking
in de variant eect-grootte, waaruit blijkt dat het gebruik van extreme feno-
10
10.2 Nederlandse samenvaing 291
types kunnen helpen bij genetische studies naar de oorsprong van de ziekte
van Alzheimer.
In hoofdstuk 3 onderzochten we de moleculaire pathways waarvan
bekend is dat ze een rol spelen in de pathogenese van de ziekte van Alzheimer
en hun associatie met de weerbaarheid tegen de ziekte van Alzheimer. In
deze studie hebben we het eect van meerdere varianten samengevoegd tot
polygene risicoscores (PRS) en pathway-specieke polygene risicoscores.
Deze laatste omvatten het eect van meerdere genetische varianten die
inhaken op dezelfde moleculaire pathway. Wij vonden dat cognitief gezonde
honderdjarigen de laagste PRS en pathway-specieke PRS hebben voor alle
belangrijke Alzheimer-geassocieerde pathways. Bovendien bleken alleen
de PRS van de immuunsysteem- en endocytose-pathways een signicante
invloed te hebben op de weerbaarheid tegen de ziekte van Alzheimer, zelfs
na het uitsluiten van APOE-varianten.
In hoofdstuk 4 hebben we geprobeerd om het eect van genetische
varianten op de levensduur los te koppelen van het eect op het risico op
de ziekte van Alzheimer. We ontdekten dat de meeste genetische varianten
die het risico op de ziekte van Alzheimer verhogen, geassocieerd waren
met een lagere kans op een lange levensduur. Op basis van onze analyse
hebben de meeste Alzheimer-geassocieerde varianten een negatieve invloed
op de levensduur door hun verhoogde risico op de ziekte van Alzheimer.
Echter, een subset van varianten die bij voorkeur betrokken zijn bij immuun-
gerelateerde processen leken niet alleen invloed te hebben op de ziekte van
Alzheimer, maar ook op andere ouderdomsziekten, zodat het cumulatieve
eect op de levensduur groter was dan het eect op de ziekte van Alzheimer
alleen.
In hoofdstuk 5 richtten we ons op de menselijke levensduur en maakten
we gebruik van publiek beschikbare gegevens om een polygene risicoscore
te maken die de kans verhoogd om cognitief gezond honderd jaar te worden
en ook associeerde met overleving. Deze polygene risicoscore bevatte 330
genetische varianten (geen APOE-varianten) en associeerde tot 4 jaar langere
overleving. De varianten in de polygene risicoscore toonde functionele
verrijking voor kenmerken van een lange levensduur, zoals langzame cel-
dierentiatie en vervanging, en regulatie van oxidatieve stress.
10.2.2 Part II
In hoofdstuk 6 hebben we klinische studies van de ziekte van Alzheimer
en by-proxy studies van de ziekte van Alzheimer gecombineerd in één van
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de grootste GWAS. Deze gezamenlijke inspanning leidde tot de ontdekking
van zes extra genetische varianten die geassocieerd zijn met de ziekte van
Alzheimer. Onze bevindingen versterken de rol van beta-amyloïd verw-
erking en immuunrespons als centrale biologische pathways in de ziekte
van Alzheimer. Verder dragen we bij aan de groeiende literatuur die de
toepasbaarheid van polygene risicoscore van AD aantoont. Met de polygene
risicoscore konden we patiënten straticeren op basis van hun genetische
achtergrond en diegenen met het hoogste risico op de ziekte identiceren.
In hoofdstuk 7 werkten we mee aan de, tot nu toe, grootste GWAS
van langlevendheid. We introduceerden een nieuwe, onbevooroordeelde
methode om gevallen (d.w.z. de langlevende individuen) en controles te iden-
ticeren, gebaseerd op land- en geslachtsspecieke overlevingspercentielen.
Naast APOE-varianten vonden we een nieuwe associatie in de buurt van het
GPR78-gen, en door middel van genetische correlatie en genexpressieanaly-
ses toonden we een duidelijke overlap aan tussen de genetica van ziekten en
de genetica van een lang leven.
In hoofdstuk 8, het laatste hoofdstuk, presenteren we snpXplorer, een
instrument dat vrij beschikbaar is voor de wetenschappelijke gemeenschap
om samenvattende statistieken van genetische studies te verkennen. snpX-
plorer combineert meerdere niveaus van associatie en verricht functionele
annotatie van sets van genetische varianten.
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10.3 Riassunto in Italiano
Un importante traguardo del genere umano consiste nell’aumento dell’aspettativa
di vita media. Tuttavia, una consequenza di una crescente popolazione
anziana risulta essere l’aumento di diverse patologie legate all’invecchiamento.
Ne consegue che una frazione in aumento di individui spenderà parte della
loro età avanzata in disabilità e/o dipendenza da altri. Tra tutte le patologie
collegate all’invecchiamento, il declino cognitivo e la demenza, di cui la
malattia di Alzheimer è la causa più frequente, rappresentano le cause mag-
giori di impedimento. Ciò nonostante, lo sviluppo di demenza e/o malattia
di Alzheimer non è una conseguenza inevitabile dell’invecchiamento: infatti,
una piccola frazione di individui (<0.1%) raggiunge età superiori ai 100 anni
mantenendo un livello sorprendentemente alto di funzioni cognitive e siche,
i cosiddetti centenari cognitivamente sani. Per individuare fattori genetici ed
ambientali che caratterizzano questi speciali individui, lo studio 100-plus è
stato iniziato.
La malattia di Alzheimer è una patologia caratterizzata da un progressivo
deterioramento delle funzioni cognitive che porta a mancanza di indipen-
denza, risultando letale. Attualmente, non ci sono rimedi e/o trattamenti
farmacologici in grado di prevenire, attenuare, o revertire il progresso della
malattia. Il fattore di rischio maggiore per lo sviluppo della malattia è l’età:
mentre la patologia risulta essere rara prima dei 65 anni, la prevalenza au-
menta esponenzialmente all’aumentare dell’età, e raggiunge il ∼40% all’anno
a 100 anni di età. Inoltre, fattori genetici giocano un ruolo centrale nello
sviluppo della malattia dato che l’ereditarietà della malattia di Alzheimer
varia tra 60% e 80%. Il maggiore fattore di rischio genetico per la malattia
di Alzheimer è dato dal genotipo del gene APOE. Il genotipo di APOE è
determinato da due mutazioni genetiche a livello del gene APOE. Nella sua
forma a più alto rischio, il genotipo di APOE aumenta il rischio di sviluppare
la malattia di Alzheimer no a 30 volte. Oltre ad APOE, oggi conosciamo ∼80
singole mutazioni genetiche che inuenzano signicativamente il rischio
di sviluppare la patologia. La scoperta di questi fattori di rischio ha perme-
sso l’identicazione dei processi molecolari che sono associati allo sviluppo
della malattia. L’ipotesi più accreditata per lo sviluppo della malattia di
Alzheimer pone l’accumulo di frammenti della proteina amiloide nel cervello
come evento scatenante la cascata molecolare che porta al declino cogni-
tivo. Tuttavia, studi genetici hanno evidenziato l’importanza di altri processi
molecolari. Di conseguenza, si è assistito ad un’evoluzione della tradizionale
ipotesi amiloidea in modo da includere aspetti più complessi della malattia.
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Oggi, si pensa che una deregolazione dei sistemi endo-lisosomiali e del sis-
tema immunitaria siano a loro volta processi centrali per lo sviluppo della
malattia di Alzheimer.
Dato che la malattia di Alzheimer risulta letale ad età avanzata, ci si
aspetterebbe che mutazioni genetiche che aumentano il rischio di svilup-
pare la malattia, abbiano un eetto negativo su longevità e sopravvivenza.
Infatti, il maggiore fattore di rischio genetico per la malattia di Alzheimer,
il genotipo di APOE, rappresenta anche il principale fattore genetico che
inuenza la longevità. Specicatamente, i genotipi di APOE che aumentano
il rischio di sviluppare la malattia di Alzheimer, sono anche associati a una
ridotta longevità. Soprendentemente, ad esclusione di APOE, nessuna della
altre mutazioni genetiche associate alla malattia di Alzheimer, inuenzano
signicativamente la longevità umana.
In precedenza, numerosi studi hanno esaminato il contributo dei fattori
genetici nel modicate la durata della vita umana. Ne emerge un panorama
contrastante: infatti l’ereditarietà della longevità no a ∼70 anni risulta es-
sere relativamente bassa (10-25%), tuttavia, per raggiungere età più avanzate,
diventiamo sempre più dipendenti dai fattori favorevoli nascosti nel nostro
genoma. In altre parole, più si invecchia, più i fattori genetici diventano
importanti. Oltre ad APOE, diverse altre mutazioni genetiche sono state
associate a longevità, anche se l’eetto di queste mutazioni genetiche non
è stato confermato in diversi studi, od in diverse popolazioni. Queste di-
vergenze tra studi probabilmente riettono sia problematiche tecniche (di
set-up dello studio e/o di metodologie statistiche), sia dierenze a livello
biologico. Ciò nonostante, un fattore comune a tutti i precedenti studi di
genetica di longevità è che le mutazioni genetiche identicate erano state
precedentemente associate a diverse patologie conseguenti l’invecchiamento.
Questo suggerisce che una durata più lunga della vita umana dipende da una
predisposizione genetica che diminuisce il rischio di sviluppare patologie
associate all’età avanzata.
Nel complesso, lo scopo di questa tesi consiste nello studio dei fattori
genetici alla base dell’estrema longevità e dalla resilienza nei confronti della
malattia di Alzheimer che osserviamo nei centenari cognitivamente sani
dello Studio 100-plus.
10.3.1 Prima parte
La prima parte di questa tesi, corrispondente ai capitoli 2-5, focalizza sulla
comparazione tra centenari cognitivamente sani, pazienti aetti da Alzheimer
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ed individui adulti sani nella popolazione (controlli), nel contesto dei fattori
genetici associati alla malattia di Alzheimer, e longevità.
Nel capitolo 2, abbiamo utilizzato fenotipi estremi nella ricerca genetica
applicata alla malattia di Alzheimer. Abbiamo contrapposto controlli estremi,
i.e. centenari cognitivamente sani, a casi estremi, i.e. pazienti aetti da
Alzheimer con un’età relativamente bassa.Abbiamo trovato che i centenari
avevano una frequenza più bassa di mutazioni genetiche associate ad un
aumento del rischio di Alzheimer (rispetto alla popolazione generale), ed una
frequenza più alta di mutazioni genetiche che risultano protettive nei con-
fronti della malattia (rispetto alla popolazione generale). Una consequenza
pratica di questo studio è che l’utilizzo di fenotipi estremi nella ricerca di fat-
tori genetici associati a patologie complesse (come la malattia di Alzheimer),
è redditizio.
Nel capitolo 3, abbiamo studiato i processi molecolari che svolgono un
ruole importante nello sviluppo e nel processo di resilienza contro la malat-
tia di Alzheimer. In questo studio, abbiamo combinato l’eetto di multiple
mutazioni genetiche in un valore di rischio poligenico (polygenic risk score,
PRS). Questi valori di rischio poligenici quanticano il rischio genetico di
sviluppare una determinata patologia, in questo caso la malattia di Alzheimer.
Di conseguenza, più il valore di rischio è alto, maggiore è il rischio di svilup-
pare la patologia. Inoltre, abbiamo combinato l’eetto di più mutazioni che
agiscono a livello del medesimo processo molecolare, creando un valore
di rischio poligenico specico per ciascun processo molecolare. Abbiamo
trovato che i centenari possedevano i valori di rischio poligenici (PRS) più
bassi in una comparazione tra centenari, pazienti aetti da Alzheimer, ed
individui adulti sani nella popolazione. Soprattutto, abbiamo identicato
che i valori di rischio poligenici specico per il sistema immunitario ed il
sistema endosomiale erano associati signicativamente alla resilienza contro
la malattia di Alzheimer, anche escludendo il fattore genetico di APOE.
Nel capitolo 4, abbiamo ragionato che mutazioni genetiche che aumen-
tano il rischio di sviluppare la malattia di Alzheimer dovrebbero essere asso-
ciate ad una maggiore mortalità, e di conseguenza, ad un rischio minore di
longevità. In questo studio, abbiamo tentato di separare l’eetto su longevità
da quello su Alzheimer da parte delle mutazioni genetiche che sono associate
al rischio di sviluppare la malattia di Alzheimer. Abbiamo trovato che la
maggioranza delle mutazioni genetiche che aumentano il rischio di svilup-
pare Alzheimer sono anche associate a minori probabilità di longevità. In
base alla nostra analisi, la maggioranza delle mutazioni genetiche diminuisce
la longevità a causa del rischio aumentato di Alzheimer. Tuttavia, un sot-
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togruppo di mutazioni specicatamente coinvolte in processi immunitari,
conferisce protezione non solo nei confronti della malattia di Alzheimer, ma
anche nei confronti di altre patologie dell’età avanzata, cosicchè l’eetto
cumulativo sulla longevità risulti maggiore dell’eetto su Alzheimer da solo.
Nel capitolo 5 abbiamo focalizzato sulla longevità umana, ed utilizzando
dati pubblicamente disponibili, abbiamo costruito un valore di rischio poli-
genico (PRS) che associava signicativamente con il diventare un centenario,
ed in un campione independente di invididui di mezza età, con sopravvivenza.
Questo PRS includeva 330 mutazioni genetiche comuni nella popolazione
generale, non includeva APOE, e determinava no a 4 anni in più di so-
pravvivenza. A livello molecolare, queste mutazioni hanno eetto a livello
di processi che solitamente sono alterati in età avanzata, come una ridotta
velocità di dierenziazione e sostituzione cellulare, e la regolazione dello
stress ossidativo.
10.3.2 Seconda parte
Nella seconda parte della tesi,abbiamo presentato il contributo dei centenari
dello Studio 100-plus in grandi studi di associazione genomica (GWAS) di
Alzheimer e longevità.
Nel capitolo 6, abbiamo combinato studi clinici di Alzheimer e studi di
proxy (o di delega) di Alzheimer in uno dei piu grandi GWAS di Alzheimer.
Questo studio, che includeva più di mezzo milione di individui in totale, ha
portato alla scoperta di 6 nuove mutazioni genetiche associate ad Alzheimer.
Questi risultati hanno rinforzato il ruolo del metabolismo dell’amiloide e
del sistema immunitario come processi centrali nello sviluppo di Alzheimer.
Inoltre, abbiamo sviluppato un valore di rischio poligenico (PRS) signicativa-
mente predittivo per la malattia di Alzheimer, che potrebbe essere utilizzato
nella clinica per la straticazione di pazienti di Alzheimer e l’identicazione
di individui con il rischio più alto di sviluppare la malattia.
Nel capitolo 7, abbiamo partecipato al più grande (no ad ora) studio
di associazione genomica (GWAS) di longevità. In questo studio, abbiamo
introdotto un metodo nuovo ed imparziale per l’idencazione di casi (indi-
vidui longevi) e controlli, basato su percentili di sopravvivenza specici per
paese e sesso. Oltre ad APOE, abbiamo individuato una nuova mutazione
vicino al gene GPR78, ed attraverso analisi di correlazione genetica ed espres-
sione genica, abbiamo identicato una soprapposizione tra la genetica della
longevità e quella di alcune patologie dell’età avanzata.
Nel capitolo 8, l’ultimo della tesi, presentiamo snpXplorer, uno stru-
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mento gratuitamente disponibile ai ricercatori per esplorare associazioni
derivanti da studi genetici, per comparare livelli di associazione genetica
in diversi fenotipi o patologie, e per eseguire l’annotazione funzionale di
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